BioMedLib Search Engine
[ goto HOMEPAGE ]
Save time; Find better answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenocarcinoma of pancreas 2005:2010[pubdate] *count=100
3109 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenocarcinoma of pancreas
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 3109
1.
Mizumoto M, Honjo G, Kobashi Y, Nishimura S, Nakamura Y, Yoshimura T, Awane M, Kato Y, Furuyama H, Asao Y, Maeda H, Takakuwa H, Matsusue S:
Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes.
Hepatogastroenterology
; 2008 Mar-Apr;55(82-83):704-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the
pancreas
, especially in relation to dysplastic epithelial changes.
BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms have a better prognosis than ductal adenocarcinomas of the
pancreas
.
The diameters of the tumor, main
pancreatic
duct and mural nodule were measured on the images.
[MeSH-major]
Adenocarcinoma
, Mucinous / pathology. Carcinoma, Papillary / pathology.
Pancreatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18613438.001).
[ISSN]
0172-6390
[Journal-full-title]
Hepato-gastroenterology
[ISO-abbreviation]
Hepatogastroenterology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
2.
Dietrich CF, Jenssen C, Allescher HD, Hocke M, Barreiros AP, Ignee A:
[Differential diagnosis of pancreatic lesions using endoscopic ultrasound].
Z Gastroenterol
; 2008 Jun;46(6):601-17
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Differential
diagnosis
of
pancreatic
lesions using endoscopic ultrasound].
The most common
pancreatic
tumour is the ductal
adenocarcinoma
.
Many other benign and malignant
pancreatic
neoplasms have to be recognised and now account for more than 50 % of
the pancreatic
lesions seen in our daily routine.
An improved differential
diagnosis
is, therefore, mandatory and will be discussed in this review.
[MeSH-major]
Endosonography.
Pancreatic
Neoplasms / ultrasonography
[MeSH-minor]
Biopsy, Fine-Needle. Carcinoma,
Pancreatic
Ductal / pathology. Carcinoma,
Pancreatic
Ductal / ultrasonography. Cell Transformation, Neoplastic / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / ultrasonography. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / ultrasonography. Cystadenoma, Papillary / pathology. Cystadenoma, Papillary / ultrasonography. Cystadenoma, Serous / pathology. Cystadenoma, Serous / ultrasonography.
Diagnosis
, Differential. Humans. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography.
Pancreas
/ pathology.
Pancreas
/ ultrasonography.
Pancreatic
Pseudocyst / pathology.
Pancreatic
Pseudocyst / ultrasonography. Pancreatitis / pathology. Pancreatitis / ultrasonography. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18537088.001).
[ISSN]
0044-2771
[Journal-full-title]
Zeitschrift für Gastroenterologie
[ISO-abbreviation]
Z Gastroenterol
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Number-of-references]
212
3.
Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C:
The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
Int J Oncol
; 2007 Sep;31(3):567-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in
pancreatic
carcinoma cells.
The prognosis of advanced
pancreatic
cancer is poor.
We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of
pancreatic
adenocarcinoma
cells in vitro.
The human
pancreatic
carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M).
Combination of TSA and gemcitabine shows promise for treatment of
pancreatic
cancer in vivo.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Hydroxamic Acids / administration & dosage.
Pancreatic
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17671683.001).
[ISSN]
1019-6439
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
Advertisement
4.
Chang CL, Wu TC, Hung CF:
Control of human mesothelin-expressing tumors by DNA vaccines.
Gene Ther
; 2007 Aug;14(16):1189-98
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and
pancreatic
adenocarcinoma
.
MedlinePlus Health Information.
consumer health - Genes and Gene Therapy
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2000 Feb 15;60(4):1035-42
[
10706121.001
]
[Cites]
Gene Ther. 2007 Jan;14(1):20-9
[
16915291.001
]
[Cites]
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
[
10735013.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7
[
10779556.001
]
[Cites]
Surgery. 2000 Aug;128(2):273-80
[
10923004.001
]
[Cites]
J Leukoc Biol. 2000 Dec;68(6):793-806
[
11129646.001
]
[Cites]
Cancer Res. 2001 Feb 1;61(3):859-63
[
11221870.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50
[
11553767.001
]
[Cites]
Vaccine. 2001 Nov 12;20(3-4):421-9
[
11672905.001
]
[Cites]
Cancer Immunol Immunother. 2001 Sep;50(7):356-60
[
11676395.001
]
[Cites]
Clin Cancer Res. 2001 Dec;7(12):3862-8
[
11751476.001
]
[Cites]
Semin Oncol. 2002 Feb;29(1):41-50
[
11836668.001
]
[Cites]
Semin Oncol. 2002 Feb;29(1):82-96
[
11836673.001
]
[Cites]
Anticancer Res. 2001 Sep-Oct;21(5):3677-84
[
11848542.001
]
[Cites]
Gene Ther. 2002 Feb;9(3):208-13
[
11859424.001
]
[Cites]
Immunology. 2002 Sep;107(1):39-45
[
12225361.001
]
[Cites]
Front Biosci. 2003 Jan 1;8:d55-68
[
12456324.001
]
[Cites]
Nat Med. 2002 Dec;8(12):1369-75
[
12415261.001
]
[Cites]
Nat Med. 2003 Jan;9(1):33-9
[
12496961.001
]
[Cites]
Cancer Res. 2003 Feb 1;63(3):600-7
[
12566302.001
]
[Cites]
J Immunol. 2003 Mar 15;170(6):3162-70
[
12626574.001
]
[Cites]
Curr Opin Mol Ther. 2003 Feb;5(1):20-4
[
12669466.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5
[
12857959.001
]
[Cites]
Int J Cancer. 2003 Dec 20;107(6):976-83
[
14601058.001
]
[Cites]
Lancet. 2003 Nov 15;362(9396):1612-6
[
14630441.001
]
[Cites]
IDrugs. 2003 Dec;6(12):1155-64
[
14666426.001
]
[Cites]
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42
[
15217923.001
]
[Cites]
Nat Med. 2004 Sep;10(9):950-8
[
15334073.001
]
[Cites]
Immunity. 1995 Aug;3(2):165-9
[
7648389.001
]
[Cites]
Annu Rev Immunol. 1997;15:617-48
[
9143702.001
]
[Cites]
J Clin Invest. 1998 Sep 15;102(6):1258-64
[
9739060.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6
[
10500211.001
]
[Cites]
Clin Cancer Res. 2005 May 15;11(10):3814-20
[
15897581.001
]
[Cites]
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31
[
16467095.001
]
[Cites]
Am J Clin Pathol. 2006 Oct;126(4):572-9
[
17019794.001
]
[Cites]
Vaccine. 2007 Jan 2;25(1):127-35
[
16930783.001
]
[Cites]
Int J Cancer. 2000 Apr 1;86(1):89-94
[
10728600.001
]
(PMID = 17581599.001).
[ISSN]
0969-7128
[Journal-full-title]
Gene therapy
[ISO-abbreviation]
Gene Ther.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Vaccines, DNA; 0 / mesothelin
[Other-IDs]
NLM/ NIHMS321551; NLM/ PMC3182456
5.
Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO:
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
Cancer
; 2007 Apr 15;109(8):1561-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of
pancreatic
adenocarcinoma
.
BACKGROUND: Erlotinib, in combination with gemcitabine, has shown clinical benefits in
pancreatic
adenocarcinoma
patients.
The presence of EGFR mutations and increased EGFR copy numbers in
pancreatic
adenocarcinoma
was explored.
METHODS: Sixty-six
pancreatic
cancer patients were included in the analysis.
RESULTS: In the current study the EGFR mutation was harbored in only 1 (1.5%) of the 66 inoperable or metastatic
pancreatic
adenocarcinoma
patients.
There was only 1 patient, who had a highly increased EGFR copy number (> or =6.0 per cell), who died, 2.1 months from the date of
diagnosis
.
The EGFR amplification did not significantly influence survival in
pancreatic
adenocarcinoma
patients (P = .935).
Thirty-two (49%) of the 65
pancreatic
adenocarcinomas examined harbored a point mutation in codons 12 (n = 31) and 61 (n = 1) of the KRAS gene.
The presence of a point mutation in codon 12 adversely influenced survival of
pancreatic
cancer patients (P = .030).
[MeSH-major]
Adenocarcinoma
/ genetics. Genes, ras.
Pancreatic
Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17354229.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 2.7.10.1 / Receptor, Epidermal Growth Factor
6.
Fukamachi K, Tanaka H, Hagiwara Y, Ohara H, Joh T, Iigo M, Alexander DB, Xu J, Long N, Takigahira M, Yanagihara K, Hino O, Saito I, Tsuda H:
An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
Biochem Biophys Res Commun
; 2009 Dec 18;390(3):636-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An animal model of preclinical
diagnosis
of
pancreatic
ductal adenocarcinomas.
Pancreatic
ductal
adenocarcinoma
(PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage.
We believe this is the first report of a
pancreas
tumor animal model in which pre-symptomatic lesions can be diagnosed.
[MeSH-major]
Biomarkers, Tumor / blood. Carcinoma,
Pancreatic
Ductal /
diagnosis
. Membrane Glycoproteins / blood.
Pancreatic
Neoplasms /
diagnosis
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
National BioResource Project.
culture/stock collections - NBRP resources
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19818733.001).
[ISSN]
1090-2104
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
7.
Al-Refaie WB, Choi EA, Tseng JF, Tamm EP, Lee JH, Lee JE, Evans DB, Pisters PW:
Intraductal papillary mucinous neoplasms of the pancreas.
Med Princ Pract
; 2006;15(4):245-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intraductal papillary mucinous neoplasms of the
pancreas
.
The introduction of the exocrine
pancreatic
classification by the World Health Organization and improvements in
pancreatic
imaging have led to an improved understanding of intraductal papillary mucinous neoplasms (IPMNs) of the
pancreas
.
As a result, IPMNs of the
pancreas
are increasingly being recognized as a separate disease entity.
IPMNs are characterized by the cystic dilatation of
the pancreatic
duct and its branches, with papillary projections.
The lymph nodes are involved considerably less frequently than they are in
pancreatic
adenocarcinoma
.
Most patients are symptomatic at
diagnosis
and require a diagnostic workup similar to that for patients with
pancreatic
adenocarcinoma
.
A mural nodule and a main
pancreatic
duct diameter greater than 5 mm have been found to be predictors of malignancy.
[MeSH-major]
Adenocarcinoma
, Mucinous. Carcinoma,
Pancreatic
Ductal.
Pancreatic
Neoplasms
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 S. Karger AG, Basel.
(PMID = 16763389.001).
[ISSN]
1011-7571
[Journal-full-title]
Medical principles and practice : international journal of the Kuwait University, Health Science Centre
[ISO-abbreviation]
Med Princ Pract
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Switzerland
[Number-of-references]
29
8.
Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A:
Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
Pancreatology
; 2010;10(1):66-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant MicroRNA-155 expression is an early event in the multistep progression of
pancreatic
adenocarcinoma
.
BACKGROUND/AIMS:
Pancreatic
intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive
pancreatic
adenocarcinoma
.
METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in
pancreatic
cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR).
CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of
pancreatic
cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Genet. 2008 Jan;40(1):43-50
[
18066065.001
]
[Cites]
Mol Cell Biol. 2008 Nov;28(22):6773-84
[
18794355.001
]
[Cites]
JAMA. 2008 Jan 30;299(4):425-36
[
18230780.001
]
[Cites]
J Mol Diagn. 2008 Mar;10(2):111-22
[
18258927.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Nat Cell Biol. 2008 May;10(5):593-601
[
18376396.001
]
[Cites]
J Biol Chem. 2008 May 30;283(22):14910-4
[
18411277.001
]
[Cites]
PLoS One. 2008;3(7):e2557
[
18596939.001
]
[Cites]
Oncogene. 2008 Jul 17;27(31):4373-9
[
18372920.001
]
[Cites]
J Gastrointest Surg. 2008 Dec;12(12):2171-6
[
18642050.001
]
[Cites]
World J Surg. 2009 Apr;33(4):698-709
[
19030927.001
]
[Cites]
Br J Cancer. 2009 Mar 24;100(6):1002-11
[
19293812.001
]
[Cites]
Cancer Biol Ther. 2009 Feb;8(4):340-6
[
19106647.001
]
[Cites]
Pancreatology. 2009;9(1-2):66-72
[
19077456.001
]
[Cites]
J Cell Mol Med. 2009 Sep;13(9B):3918-28
[
19228262.001
]
[Cites]
Am J Pathol. 2000 May;156(5):1767-71
[
10793087.001
]
[Cites]
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
[
11307091.001
]
[Cites]
Am J Surg Pathol. 2001 May;25(5):579-86
[
11342768.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Am J Pathol. 2002 Nov;161(5):1541-7
[
12414502.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
[
12434020.001
]
[Cites]
Mod Pathol. 2003 Sep;16(9):902-12
[
13679454.001
]
[Cites]
Nat Rev Genet. 2004 Jul;5(7):522-31
[
15211354.001
]
[Cites]
Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21
[
15224285.001
]
[Cites]
Am J Surg Pathol. 2004 Aug;28(8):977-87
[
15252303.001
]
[Cites]
Cancer Res. 1997 Jun 1;57(11):2140-3
[
9187111.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
[
15738415.001
]
[Cites]
Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6
[
15828554.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):839-43
[
15944709.001
]
[Cites]
Mod Pathol. 2005 Jul;18(7):959-63
[
15832197.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7065-70
[
16103053.001
]
[Cites]
J Pathol. 2005 Oct;207(2):243-9
[
16041695.001
]
[Cites]
Cancer Res. 2005 Nov 1;65(21):9628-32
[
16266980.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
[
16461460.001
]
[Cites]
Cancer Cell. 2006 Mar;9(3):189-98
[
16530703.001
]
[Cites]
Cancer Cell. 2006 Jun;9(6):435-43
[
16766263.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665
[
16682259.001
]
[Cites]
Am J Surg Pathol. 2006 Sep;30(9):1067-76
[
16931950.001
]
[Cites]
Dev Biol. 2007 Feb 1;302(1):1-12
[
16989803.001
]
[Cites]
Int J Cancer. 2007 Mar 1;120(5):1046-54
[
17149698.001
]
[Cites]
Cancer Res. 2007 Feb 15;67(4):1419-23
[
17308078.001
]
[Cites]
Leuk Lymphoma. 2007 Feb;48(2):410-2
[
17325905.001
]
[Cites]
Mod Pathol. 2007 May;20(5):570-8
[
17396143.001
]
[Cites]
JAMA. 2007 May 2;297(17):1901-8
[
17473300.001
]
[Cites]
J Hepatobiliary Pancreat Surg. 2007;14(3):224-32
[
17520196.001
]
[Cites]
Mol Cell. 2007 Jun 8;26(5):745-52
[
17540599.001
]
[Cites]
Oncogene. 2007 Jun 28;26(30):4442-52
[
17237814.001
]
[Cites]
Semin Oncol. 2007 Aug;34(4):303-10
[
17674958.001
]
[Cites]
Histopathology. 2007 Oct;51(4):539-46
[
17714470.001
]
[Cites]
Annu Rev Genomics Hum Genet. 2007;8:215-39
[
17506656.001
]
[Cites]
Nature. 2007 Oct 11;449(7163):682-8
[
17898713.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5
[
17911264.001
]
[Cites]
Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi
[
17996793.001
]
[Cites]
Cancer Biol Ther. 2007 Aug;6(8):1284-8
[
17660710.001
]
[Cites]
J Biol Chem. 2008 Jan 11;283(2):1026-33
[
17991735.001
]
(PMID = 20332664.001).
[ISSN]
1424-3911
[Journal-full-title]
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
[ISO-abbreviation]
Pancreatology
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50CA062924
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / MIRN155 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MicroRNAs
[Other-IDs]
NLM/ PMC2865485
9.
Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA:
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Cancer Invest
; 2008 Feb;26(1):47-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory
pancreatic
cancer: results of a phase II study.
BACKGROUND: No therapeutic standard of care exists for patients with advanced
pancreatic
cancer who progress following first-line treatment with a gemcitabine-based regimen.
There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced
pancreatic
cancer.
METHODS: Eligible patients with metastatic
pancreatic
adenocarcinoma
were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based.
CONCLUSIONS: The combination of docetaxel and irinotecan given on a 21-day cycle is associated with excess toxicity in gemcitabine-refractory patients with advanced
pancreatic
cancer.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ secondary. Antineoplastic Combined Chemotherapy Protocols / toxicity.
Pancreatic
Neoplasms / drug therapy.
Pancreatic
Neoplasms / pathology
Genetic Alliance.
consumer health - Pancreatic cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOCETAXEL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18181045.001).
[ISSN]
1532-4192
[Journal-full-title]
Cancer investigation
[ISO-abbreviation]
Cancer Invest.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
10.
Honda K, Fukuhara T, Kojima Y, Tanaka H, Kushihata F, Kobayashi N:
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Gan To Kagaku Ryoho
; 2006 Dec;33(13):2089-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Two cases of advanced
pancreas
cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Two cases of advanced
pancreas
cancer were treated with GTX.
A 62-year-old man with
pancreas
head cancer and 2 liver metastases was treated with GEM 1,000 mg/m(2)/week at weeks 1, 2, and 3, and drug-free week 4 for 3 cycles, but was PD.
A 75-year-old man with
pancreas
head cancer and vascular invasion has been treated with GTX.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy.
Pancreatic
Neoplasms / drug therapy. Vascular Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Liver Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
DOCETAXEL
.
Hazardous Substances Data Bank.
CAPECITABINE
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17197760.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
11.
Vadalà S, Aronica G, Biondi A, Magnano V, Valastro M, Li Volti G, Cordio S, Giannone G:
Distal pancreatectomy with en bloc resection of the celiac axis for pancreatic adenocarcinoma.
Clin Ter
; 2009;160(4):287-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distal pancreatectomy with en bloc resection of the celiac axis for
pancreatic
adenocarcinoma
.
Subsequently, Mayumi et al. and Kimura et al. adopted this approach for locally advanced
adenocarcinoma of
pancreatic
body.
We are here describing this technique in case
of adenocarcinoma
of
pancreatic
body with infiltration of celiac axis achieving also gastric preservation.
CT scan showed a 3 cm mass in the body
of pancreas
infiltrating the origin of celiac axis, causing obstructive atrophy of
pancreatic
tail.
Appleby operation can increase the resectability of locally advanced cancer of the body and tail of the
pancreas
and offers not only a better life quality for patients but also perfect pain relief.
[MeSH-major]
Adenocarcinoma
/ surgery. Pancreatectomy / methods.
Pancreatic
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19795078.001).
[ISSN]
1972-6007
[Journal-full-title]
La Clinica terapeutica
[ISO-abbreviation]
Clin Ter
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
12.
Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P:
Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.
BMC Cancer
; 2009 Feb 25;9:66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable
pancreatic
adenocarcinoma
.
BACKGROUND: Advanced
pancreatic
cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage.
This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I(131) in
pancreatic
cancer (ISRCTN 16857581).
METHODS: Patients with histological/cytological proven inoperable
adenocarcinoma of
the head
of pancreas
were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route.
[MeSH-major]
Adenocarcinoma
/ diagnostic imaging. Carcinoembryonic Antigen / administration & dosage. Immunotoxins / administration & dosage. Iodine Radioisotopes / administration & dosage.
Pancreatic
Neoplasms / radiotherapy. Radioimmunotherapy / methods
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 1999 Oct;5(10 Suppl):3232s-3242s
[
10541369.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Clin Cancer Res. 2000 Feb;6(2):406-14
[
10690517.001
]
[Cites]
Teratog Carcinog Mutagen. 2001;21(1):45-57
[
11135320.001
]
[Cites]
Cancer Res. 2001 Sep 15;61(18):6851-9
[
11559561.001
]
[Cites]
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
[
11602373.001
]
[Cites]
Cancer. 2002 Feb 15;94(4 Suppl):1373-81
[
11877768.001
]
[Cites]
Cancer. 2002 Feb 15;94(4):902-10
[
11920457.001
]
[Cites]
J Clin Oncol. 2002 Aug 1;20(15):3270-5
[
12149301.001
]
[Cites]
Clin Colorectal Cancer. 2002 May;2(1):31-42
[
12453334.001
]
[Cites]
Aliment Pharmacol Ther. 2003 Dec;18(11-12):1049-69
[
14653825.001
]
[Cites]
Int J Cancer. 2004 Apr 20;109(4):618-26
[
14991585.001
]
[Cites]
J Natl Cancer Inst. 1976 Jul;57(1):11-22
[
794493.001
]
[Cites]
Ann N Y Acad Sci. 1983;417:75-85
[
6200051.001
]
[Cites]
Cancer Metastasis Rev. 1987;6(4):559-93
[
3327633.001
]
[Cites]
Cell. 1989 Apr 21;57(2):327-34
[
2702691.001
]
[Cites]
J Surg Oncol. 1991 Jul;47(3):148-54
[
2072697.001
]
[Cites]
J Nucl Med. 1997 Jun;38(6):858-70
[
9189130.001
]
[Cites]
J Clin Oncol. 1997 Jun;15(6):2403-13
[
9196156.001
]
[Cites]
J Nucl Med. 1998 Jan;39(1):34-42
[
9443735.001
]
[Cites]
Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9
[
9756018.001
]
[Cites]
Hybridoma. 1999 Apr;18(2):183-91
[
10380018.001
]
[Cites]
Surgery. 2005 Jun;137(6):597-605
[
15962401.001
]
[Cites]
Nat Biotechnol. 2005 Sep;23(9):1147-57
[
16151408.001
]
[Cites]
Ann Nucl Med. 2005 Jul;19(5):355-65
[
16164191.001
]
[Cites]
J Nucl Med. 2006 Feb;47(2):196-9
[
16455623.001
]
[Cites]
J Nucl Med. 2006 Feb;47(2):247-55
[
16455630.001
]
[Cites]
J Clin Oncol. 2006 Feb 10;24(5):823-34
[
16380412.001
]
[Cites]
J Clin Oncol. 2006 Mar 20;24(9):1395-403
[
16505413.001
]
[Cites]
J Clin Oncol. 2006 Aug 20;24(24):3946-52
[
16921047.001
]
[Cites]
Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64
[
17043623.001
]
[Cites]
Curr Drug Discov Technol. 2006 Dec;3(4):231-43
[
17430101.001
]
[Cites]
J Clin Oncol. 2007 May 20;25(15):1960-6
[
17452677.001
]
[Cites]
J Clin Oncol. 2007 Jun 20;25(18):2607-15
[
17577041.001
]
[Cites]
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
[
10655437.001
]
(PMID = 19243606.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Databank-accession-numbers]
ISRCTN/ ISRCTN16857581
[Grant]
United Kingdom / Medical Research Council / / G9900432; United Kingdom / Cancer Research UK / /
[Publication-type]
Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Immunotoxins; 0 / Iodine Radioisotopes
[Other-IDs]
NLM/ PMC2656541
13.
Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L, Crane CH, Pancreatic Tumor Study Group:
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
Am J Clin Oncol
; 2005 Jun;28(3):227-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiation dose considerations in the palliative treatment of locally advanced
adenocarcinoma of
the
pancreas
.
Treatment of locally advanced
pancreatic
cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate.
From December 1993 through May 2001, 107 patients with locally advanced
adenocarcinoma of
the
pancreas
had been treated with palliative chemoradiation.
Compared with higher doses given over 5 to 6 weeks, chemoradiation (30 Gy in 10 fractions in 2 weeks with concurrent infusional 5-FU) results in a similar median survival, and local disease progression rates in patients with locally advanced
pancreatic
cancer apparently do not substantially improve local disease control or median survival time.
[MeSH-major]
Adenocarcinoma
/ radiotherapy. Palliative Care.
Pancreatic
Neoplasms / radiotherapy. Radiotherapy, High-Energy
MedlinePlus Health Information.
consumer health - Palliative Care
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15923793.001).
[ISSN]
1537-453X
[Journal-full-title]
American journal of clinical oncology
[ISO-abbreviation]
Am. J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA06294; United States / NCI NIH HHS / CA / CA16672
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
14.
Kim T, Grobmyer SR, Dixon LR, Hochwald SN:
Isolated lymphoplasmacytic sclerosing pancreatitis involving the pancreatic tail.
Am Surg
; 2008 Jul;74(7):654-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolated lymphoplasmacytic sclerosing pancreatitis involving
the pancreatic
tail.
CT imaging revealed a hypodense lesion in the tail of the
pancreas
.
Due to concerns of
pancreatic
malignancy, she underwent operation.
We found a dense, inflammatory mass in the tail of the
pancreas
, which was removed via an open distal pancreatectomy with splenectomy.
Histologic analysis revealed a
pancreas
with sclerotic ducts and surrounding lymphoplasmacytic inflammation most consistent with lymphoplasmacytic sclerosing pancreatitis (LPSP).
LPSP, also termed autoimmune pancreatitis, is a benign disease of the
pancreas
, which can mimic
pancreatic
adenocarcinoma
.
It is the most common benign finding diagnosed on pathology after
pancreatic
resection for presumed malignancy.
LPSP most commonly involves the head and, more uncommonly, the tail of the
pancreas
.
[MeSH-major]
Pancreas
/ pathology. Pancreaticoduodenectomy / methods. Pancreatitis / pathology
[MeSH-minor]
Chronic Disease.
Diagnosis
, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Sclerosis
Genetic Alliance.
consumer health - Pancreatitis
.
MedlinePlus Health Information.
consumer health - Pancreatitis
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18646484.001).
[ISSN]
0003-1348
[Journal-full-title]
The American surgeon
[ISO-abbreviation]
Am Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
15.
Ramani VC, Hennings L, Haun RS:
Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer.
BMC Cancer
; 2008;8:373
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Desmoglein 2 is a substrate of kallikrein 7 in
pancreatic
cancer.
BACKGROUND: In a previous report we have demonstrated that the chymotryptic-like serine protease kallikrein 7 (KLK7/hK7) is overexpressed in
pancreatic
cancer.
Thus, the ability of hK7 to degrade desmogleins was assessed and the effect of hK7 expression on desmoglein 2 was examined in cultured
pancreatic
cancer cells.
METHODS: The expression of Dsg1, Dsg2, and Dsg3 in
pancreatic
tissues was examined by immunohistochemistry and their expression in two
pancreatic
cancer cell lines, BxPC-3 and Panc-1, was determined by western blot analysis.
RESULTS: The levels of immunoreactive Dsg1 and Dsg2 were reduced in
pancreatic
adenocarcinomas compared with both normal
pancreatic
and chronic pancreatitis tissues.
CONCLUSION: A reduction in the amount of the cell adhesion components Dsg1 and Dsg2 in
pancreatic
tumors suggests that loss of these desmosomal proteins may play a role in
pancreatic
cancer invasion.
Using in vitro degradation assays, both Dsg1 and Dsg2 could be readily proteolyzed by hK7, which is overexpressed in
pancreatic
adenocarcinomas.
The enforced expression of hK7 in BxPC-3 cells that express significant amounts of Dsg2 resulted in a marked increase in the shedding of soluble Dsg2, which is consistent with the notion that aberrant expression of hK7 in
pancreatic
tumors may result in diminished cell-cell adhesion and facilitate tumor cell invasion.
[MeSH-major]
Adenocarcinoma
/ metabolism. Desmoglein 2 / metabolism. Kallikreins / metabolism.
Pancreatic
Neoplasms / metabolism
[MeSH-minor]
Blotting, Western. Desmoglein 1 / metabolism. Desmoglein 3 / metabolism. Humans. Immunohistochemistry.
Pancreas
/ metabolism.
Pancreas
/ pathology. Pancreatitis / metabolism. RNA, Messenger / metabolism. Recombinant Proteins / metabolism. Tumor Cells, Cultured
Genetic Alliance.
consumer health - Pancreatic cancer
.
Genetic Alliance.
consumer health - Pancreatic cancer 2
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 1999 Nov 15;86(10):2074-82
[
10570434.001
]
[Cites]
J Invest Dermatol. 2004 May;122(5):1235-44
[
15140227.001
]
[Cites]
Trends Endocrinol Metab. 2000 Mar;11(2):54-60
[
10675891.001
]
[Cites]
Nat Rev Mol Cell Biol. 2000 Dec;1(3):208-16
[
11252896.001
]
[Cites]
Pathol Res Pract. 2001;197(2):85-91
[
11261822.001
]
[Cites]
Semin Cancer Biol. 2001 Apr;11(2):143-52
[
11322833.001
]
[Cites]
Biochim Biophys Acta. 2001 Nov 30;1552(1):39-45
[
11781114.001
]
[Cites]
Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61
[
11906548.001
]
[Cites]
Exp Dermatol. 2002 Apr;11(2):115-25
[
11994138.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Jul;34(3):255-68
[
12007186.001
]
[Cites]
Clin Chem. 2002 Aug;48(8):1198-205
[
12142373.001
]
[Cites]
Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58
[
12784999.001
]
[Cites]
Gynecol Oncol. 2004 Aug;94(2):283-8
[
15297163.001
]
[Cites]
Oncol Rep. 2004 Nov;12(5):1001-6
[
15492784.001
]
[Cites]
Br J Urol. 1990 Feb;65(2):176-80
[
2317652.001
]
[Cites]
Annu Rev Cell Biol. 1990;6:461-91
[
2275820.001
]
[Cites]
Arch Dermatol Res. 1991;283(2):108-12
[
1712574.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):353-7
[
1729705.001
]
[Cites]
Breast Cancer Res Treat. 1993;24(3):175-84
[
8435473.001
]
[Cites]
Semin Cancer Biol. 1993 Aug;4(4):219-29
[
8400144.001
]
[Cites]
Semin Cancer Biol. 1993 Aug;4(4):251-8
[
8400147.001
]
[Cites]
Head Neck. 1995 May-Jun;17(3):204-12
[
7540167.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9
[
7543680.001
]
[Cites]
Differentiation. 1996 May;60(2):99-108
[
8641550.001
]
[Cites]
Br J Cancer. 1996 Jun;73(12):1491-7
[
8664118.001
]
[Cites]
Br J Dermatol. 1996 Mar;134(3):460-4
[
8731669.001
]
[Cites]
World J Urol. 1996;14(3):151-6
[
8806193.001
]
[Cites]
J Cell Biol. 1997 Jul 14;138(1):193-201
[
9214392.001
]
[Cites]
J Cell Sci. 1998 Feb;111 ( Pt 4):495-509
[
9443898.001
]
[Cites]
Int Rev Cytol. 1999;185:237-302
[
9750269.001
]
[Cites]
Nat Rev Cancer. 2004 Nov;4(11):876-90
[
15516960.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Apr 22;329(4):1260-6
[
15766562.001
]
[Cites]
J Pathol. 2005 Oct;207(2):199-206
[
16025435.001
]
[Cites]
J Invest Dermatol. 2006 Jul;126(7):1622-32
[
16628198.001
]
[Cites]
Eur J Cancer. 2006 Sep;42(14):2397-403
[
16890424.001
]
[Cites]
J Biol Chem. 2007 Feb 9;282(6):3640-52
[
17158887.001
]
[Cites]
Cancer. 2007 May 1;109(9):1811-20
[
17354228.001
]
[Cites]
Br J Cancer. 2007 Jun 18;96(12):1783-7
[
17519903.001
]
[Cites]
Am J Pathol. 2007 Sep;171(3):906-16
[
17640963.001
]
[Cites]
Biochem Biophys Res Commun. 2008 May 16;369(4):1169-73
[
18343220.001
]
[Cites]
Virchows Arch. 2003 Jul;443(1):51-6
[
12759751.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
(PMID = 19091121.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DSG1 protein, human; 0 / DSG2 protein, human; 0 / DSG3 protein, human; 0 / Desmoglein 1; 0 / Desmoglein 2; 0 / Desmoglein 3; 0 / RNA, Messenger; 0 / Recombinant Proteins; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
[Other-IDs]
NLM/ PMC2628383
16.
Gulluoglu MG, Karayigit E, Ozden I, Kapran Y, Dizdaroglu F:
Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?
Pathology
; 2008 Jan;40(1):35-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Does HepPar-1 immunoexpression have a role in differential
diagnosis
of periampullary cancer?
We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential
diagnosis
of this group of cancers.
The expression of antibodies was also measured in ductal
adenocarcinoma of
the pancreatic
head (DAPH).
METHODS: Sixty-five patients with PAC and DAPH who underwent
pancreatic
Whipple resection constituted the study cohort.
In addition to CDX2 and MUC2 antibodies, HepPar-1 immunoexpression seems to have a potential role in differential
diagnosis
of PACs.
[MeSH-major]
Adenocarcinoma
/
diagnosis
.
Adenocarcinoma
/ metabolism. Antibodies, Monoclonal / metabolism. Carcinoma,
Pancreatic
Ductal /
diagnosis
. Carcinoma,
Pancreatic
Ductal / metabolism. Common Bile Duct Neoplasms /
diagnosis
. Common Bile Duct Neoplasms / metabolism
[MeSH-minor]
Adult. Aged. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct / metabolism. Common Bile Duct / pathology.
Diagnosis
, Differential. Female. Homeodomain Proteins / immunology. Homeodomain Proteins / metabolism. Humans. Male. Middle Aged. Mucin-2. Mucins / immunology. Mucins / metabolism.
Pancreatic
Ducts / metabolism.
Pancreatic
Ducts / pathology. Retrospective Studies. Sensitivity and Specificity
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18038313.001).
[ISSN]
0031-3025
[Journal-full-title]
Pathology
[ISO-abbreviation]
Pathology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
17.
Ricketts R, Tamboli P, Czerniak B, Guo CC:
Tumor-to-tumor metastasis: report of 2 cases of metastatic carcinoma to angiomyolipoma of the kidney.
Arch Pathol Lab Med
; 2008 Jun;132(6):1016-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In one case, the donor tumor originated from neuroendocrine carcinoma of the
pancreas
, and in the other case the donor tumor was from
adenocarcinoma of
the lung.
An awareness of this phenomenon is important to avoid an incorrect
diagnosis
when encountering unusual morphologic features in renal angiomyolipoma.
[MeSH-minor]
Adenocarcinoma
/ pathology. Aged. Carcinoma, Neuroendocrine / pathology. Humans. Immunohistochemistry. Lung Neoplasms / pathology. Male. Middle Aged.
Pancreatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18517262.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
18.
Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL:
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.
Invest New Drugs
; 2006 Nov;24(6):515-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced
pancreas
cancer: a Southwest Oncology Group study.
PURPOSE: The purpose of this Phase II multi-institutional study was to define the efficacy and toxicity of ixabepilone in patients with advance
pancreatic
adenocarcinoma
.
PATIENTS AND METHODS: Patients were required to have
pancreatic
adenocarcinoma
and metastatic or recurrent disease that was not amenable to curative resection.
CONCLUSION: Ixabepilone shows encouraging activity in patients with advanced
pancreatic
cancer and should be investigated further in this disease.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Epothilones / therapeutic use.
Pancreatic
Neoplasms / drug therapy. Tubulin Modulators / therapeutic use
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
Ixabepilone
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2004 Sep 15;22(18):3776-83
[
15365074.001
]
[Cites]
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
[
10655437.001
]
[Cites]
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
[
14974761.001
]
[Cites]
Invest New Drugs. 2005 Oct;23 (5):485-7
[
16133800.001
]
[Cites]
Clin Cancer Res. 2004 Feb 15;10(4):1289-98
[
14977827.001
]
[Cites]
J Clin Oncol. 1997 Jun;15(6):2414-9
[
9196157.001
]
[Cites]
J Clin Oncol. 2004 Jul 1;22(13):2610-6
[
15226328.001
]
[Cites]
Invest New Drugs. 1994;12(1):29-34
[
7960602.001
]
[Cites]
Clin Cancer Res. 2001 May;7(5):1429-37
[
11350914.001
]
[Cites]
Cancer. 1999 Mar 15;85(6):1261-8
[
10189130.001
]
[Cites]
J Clin Oncol. 1997 Jun;15(6):2403-13
[
9196156.001
]
[Cites]
Br J Cancer. 1996 Jan;73(1):101-5
[
8554969.001
]
[Cites]
Invest New Drugs. 2006 Nov;24(6):515-20
[
16699973.001
]
(PMID = 16699973.001).
[ISSN]
0167-6997
[Journal-full-title]
Investigational new drugs
[ISO-abbreviation]
Invest New Drugs
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA27575; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA76447
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Epothilones; 0 / Tubulin Modulators; K27005NP0A / ixabepilone
19.
Søreide K, Immervoll H, Molven A:
[Precursors to pancreatic cancer].
Tidsskr Nor Laegeforen
; 2006 Mar 23;126(7):905-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Precursors to
pancreatic
cancer].
BACKGROUND:
Pancreatic
adenocarcinoma
is a relatively frequent cancer with an extremely poor prognosis.
Until recently, the natural history of
pancreatic
adenocarcinoma
has not been possible to study, but the identification of precursor lesions (
pancreatic
intraepithelial neoplasia, PanIN) has lead to a better understanding of the stepwise morphological and genetic alterations involved in the development of invasive
adenocarcinoma
.
MATERIAL AND METHODS: Relevant literature from the period of 1996-2005 was found by searching the Medline database, combining the terms "
pancreas
", "cancer", "PanIN" and "neoplasia".
RESULTS AND INTERPRETATION: PanINs are established as designation of histological precursor lesions to
pancreatic
adenocarcinoma
.
PanIN grade I to III represent stepwise morphological alterations in
the pancreatic
ductal epithelium, from early neoplasia (PanIN I and II), via carcinoma in situ (PanIN III) to the development of invasive ductal
adenocarcinoma
.
Increased knowledge about
pancreatic
carcinogenesis may pave the way for prevention strategies, early detection, and new treatment options, thus ultimately improving the prognosis of the patients.
[MeSH-major]
Adenocarcinoma
/ pathology. Carcinoma,
Pancreatic
Ductal / pathology.
Pancreatic
Neoplasms / pathology. Precancerous Conditions / pathology
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16554881.001).
[ISSN]
0807-7096
[Journal-full-title]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
[ISO-abbreviation]
Tidsskr. Nor. Laegeforen.
[Language]
nor
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Norway
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
36
20.
O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B:
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
Oncologist
; 2010;15(12):1310-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic
pancreatic
adenocarcinoma
(CALGB 80603).
BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic
pancreas adenocarcinoma
following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).
PATIENTS AND METHODS: Patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and with progressive
pancreas adenocarcinoma
following treatment with gemcitabine were eligible.
CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory
pancreas adenocarcinoma
patients.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use.
Pancreatic
Neoplasms / drug therapy. Pyrroles / therapeutic use. Salvage Therapy
Genetic Alliance.
consumer health - Pancreatic cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2000 May 15;88(10):2239-45
[
10820344.001
]
[Cites]
J Clin Oncol. 2009 Jan 10;27(2):193-8
[
19047305.001
]
[Cites]
Cancer. 2004 Jul 1;101(1):133-8
[
15221998.001
]
[Cites]
J Clin Oncol. 1997 Jun;15(6):2403-13
[
9196156.001
]
[Cites]
Eur J Cancer. 1998 Aug;34(9):1439-47
[
9849429.001
]
[Cites]
Clin Cancer Res. 2009 Mar 15;15(6):1873-82
[
19276273.001
]
[Cites]
Oncology. 2009;76(4):254-61
[
19246950.001
]
[Cites]
J Clin Oncol. 2009 May 1;27(13):2231-7
[
19307500.001
]
[Cites]
Science. 2009 Jun 12;324(5933):1457-61
[
19460966.001
]
[Cites]
Curr Drug Metab. 2009 Jun;10(5):470-81
[
19689244.001
]
[Cites]
J Gastrointest Cancer. 2009;40(1-2):1-9
[
19513861.001
]
[Cites]
Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85
[
19828009.001
]
[Cites]
Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97
[
19828010.001
]
[Cites]
J Clin Oncol. 2010 Aug 1;28(22):3617-22
[
20606091.001
]
[Cites]
Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7
[
20130876.001
]
[Cites]
Ann Oncol. 1999;10 Suppl 4:69-73
[
10436789.001
]
[Cites]
Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39
[
15648955.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3509-16
[
15908661.001
]
[Cites]
Invest New Drugs. 2005 Aug;23(4):369-75
[
16012797.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):8033-40
[
16258101.001
]
[Cites]
Jpn J Clin Oncol. 2007 Feb;37(2):114-20
[
17272317.001
]
[Cites]
J Clin Oncol. 2007 May 20;25(15):1960-6
[
17452677.001
]
[Cites]
Gut. 2007 Aug;56(8):1134-52
[
17625148.001
]
[Cites]
J Clin Oncol. 2007 Oct 20;25(30):4787-92
[
17947726.001
]
[Cites]
J Clin Oncol. 2008 Jan 20;26(3):463-7
[
18202421.001
]
[Cites]
BMC Cancer. 2008;8:82
[
18373843.001
]
[Cites]
Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8
[
18172650.001
]
[Cites]
Cancer. 2008 Oct 15;113(8):2046-52
[
18756532.001
]
[Cites]
J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166
[
11992800.001
]
(PMID = 21148613.001).
[ISSN]
1549-490X
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00397787
[Grant]
United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
[Other-IDs]
NLM/ PMC3227926
21.
Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M:
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Transl Oncol
; 2010 Dec 01;3(6):373-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected
pancreatic
cancer.
BACKGROUND: Erlotinib is approved for the treatment of advanced
pancreas
cancer.
We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected
pancreatic
cancer patients.
METHODS: Patients with resected
pancreatic
adenocarcinoma
received erlotinib and capecitabine concurrently with IMRT delivered at 1.8 Gy daily in 28 fractions (total = 50.4 Gy).
CONCLUSIONS: When administered concurrently with IMRT, erlotinib 100 mg daily and capecitabine 800 mg/m(2) twice daily (Monday to Friday) can be administered safely in resected
pancreas
cancer patients, and is the recommended regimen for efficacy studies using this regimen.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21151476.001).
[ISSN]
1936-5233
[Journal-full-title]
Translational oncology
[ISO-abbreviation]
Transl Oncol
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA104900
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3000462
22.
Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S:
Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT.
Radiology
; 2008 Sep;248(3):876-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intraductal papillary mucinous neoplasm of the
pancreas
: assessment of the likelihood of invasiveness with multisection CT.
RESULTS: The following findings showed significant differences among the three groups: maximum diameter of the main
pancreatic
duct (MPD), size (length of major axis) of the largest mural nodule in the MPD or in any associated cystic lesion, abnormal attenuating area in the surrounding parenchyma, calcification in the lesion, protrusion of the MPD into the ampulla of Vater, and bile duct dilatation.
[MeSH-major]
Adenocarcinoma
, Mucinous / radiography. Adenoma / radiography.
Pancreatic
Neoplasms / radiography. Papilloma, Intraductal / radiography. Radiographic Image Enhancement / methods. Tomography, X-Ray Computed / methods
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
RSNA, 2008
(PMID = 18632526.001).
[ISSN]
1527-1315
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
23.
Cienfuegos JA, Baixauli J, Zozaya G, Bueno A, Arredondo J, Regueira FM, Angós R, Hernández-Lizoáin JL, Idoate MA:
Peutz-Jeghers syndrome and duodeno-jejunal adenocarcinoma--therapeutic implications.
Rev Esp Enferm Dig
; 2009 Dec;101(12):875-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Peutz-Jeghers syndrome and duodeno-jejunal
adenocarcinoma
--therapeutic implications.
Hemminki in 1997 described the presence of LKB-1 mutation tumor-suppressor gen.The patients with PJS develop a higher cumulative incidence of gastrointestinal,
pancreas
and extraintestinal tumors, being occasion of a renew interest on hamartomatous polyposis syndromes regarding the clinical care, cancer surveillance treatment and long term follow-up.We report the case of a 38 years old male, diagnosed of PJS who developed a multiple
adenocarcinoma
in duodenum and yeyunum.
[MeSH-major]
Adenocarcinoma
. Duodenal Neoplasms. Jejunal Neoplasms. Neoplasms, Multiple Primary. Peutz-Jeghers Syndrome / complications
Genetic Alliance.
consumer health - Peutz Jeghers syndrome
.
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20082550.001).
[ISSN]
1130-0108
[Journal-full-title]
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
[ISO-abbreviation]
Rev Esp Enferm Dig
[Language]
eng
[Publication-type]
Case Reports; Comparative Study; Journal Article
[Publication-country]
Spain
24.
Kaifi JT, Cataldegirmen G, Wachowiak R, Schurr PG, Kleinhans H, Kosti G, Yekebas EF, Mann O, Kutup A, Kalinin V, Strate T, Izbicki JR:
Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.
Anticancer Res
; 2007 Jan-Feb;27(1A):69-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in
pancreatic
carcinoma and chronic pancreatitis.
Kazal-type genes are associated with cancer and
pancreatic
disease.
The aim of the present study was to examine whether ECRG2 STR polymorphisms are associated with
pancreatic
carcinoma and chronic pancreatitis.
MATERIALS AND METHODS: A total of 209 surgically treated patients were analyzed, 92 with
pancreatic
adenocarcinoma
and 117 with chronic pancreatitis.
RESULTS: ECRG2 STR of highest incidence was TCA3/TCA3 [47 (51%) in
pancreatic
carcinoma; 59 (50%) in pancreatitis patients], followed by the TCA3/TCA4 [37 (40%); 54 (46%)] and TCA4/TCA4 [8 (9%); 4 (4%)] genotypes.
No correlation in frequency of STRs comparing chronic pancreatitis and
pancreatic
cancer was determined using the Chi-squared test (p = 0.23).
CONCLUSION: The data show that ECRG2 STR polymorphism TCA3/TCA3 in exon 4 is the most prevalent polymorphism found in
pancreatic
adenocarcinoma
and chronic pancreatitis detected in peripheral blood.
None of the polymorphisms was associated with poor clinical outcome in
pancreatic
cancer patients.
[MeSH-major]
Adenocarcinoma
/ genetics. Microsatellite Repeats.
Pancreatic
Neoplasms / genetics. Pancreatitis, Chronic / genetics. Tumor Suppressor Proteins / genetics
Genetic Alliance.
consumer health - Pancreatitis
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17352218.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human; 0 / Tumor Suppressor Proteins
25.
Liau SS, Rocha F, Matros E, Redston M, Whang E:
High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
Cancer
; 2008 Jul 15;113(2):302-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in
pancreatic
adenocarcinoma
.
BACKGROUND: High mobility group AT-hook 1 (HMGA1) proteins are architectural transcription factors that are overexpressed by
pancreatic
adenocarcinomas.
The authors hypothesized that tumor HMGA1 status represents a novel prognostic marker in
pancreatic
adenocarcinoma
.
METHODS: Tumor HMGA1 expression was examined by immunohistochemical analysis of tissues from 89 consecutive patients who underwent resection for
pancreatic
adenocarcinoma
.
Short-hairpin RNA (shRNA)-mediated RNA interference was used to silence HMGA1 expression in MiaPaCa2 and PANC1
pancreatic
cancer cells.
RESULTS: Tumor HMGA1 expression was detected in 93% of patients with
pancreatic
adenocarcinoma
.
CONCLUSIONS: The current findings suggested that HMGA1 is an independent predictor of poor postoperative survival in patients with
pancreatic
adenocarcinoma
.
HMGA1 warrants further evaluation as a prognostic marker and therapeutic target in
pancreatic
cancer.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 1990 May 25;265(15):8573-82
[
1692833.001
]
[Cites]
Br J Cancer. 2007 Mar 26;96(6):993-1000
[
17342093.001
]
[Cites]
J Cell Biol. 1994 Feb;124(4):619-26
[
8106557.001
]
[Cites]
Mol Cell Biol. 1995 Mar;15(3):1786-96
[
7862168.001
]
[Cites]
Cell. 1995 Dec 29;83(7):1091-100
[
8548797.001
]
[Cites]
Oncogene. 1997 Jun 19;14(24):2971-7
[
9205104.001
]
[Cites]
Oncogene. 1998 May;16(20):2681-6
[
9632144.001
]
[Cites]
Clin Cancer Res. 2004 Nov 15;10(22):7637-44
[
15569996.001
]
[Cites]
Cancer Res. 2000 Jun 15;60(12):3117-22
[
10866296.001
]
[Cites]
Mol Cell Biol. 2001 Jan;21(2):575-94
[
11134344.001
]
[Cites]
Pancreas. 2002 Jan;24(1):42-6
[
11741181.001
]
[Cites]
Oncogene. 2004 Jan 22;23(3):777-85
[
14737112.001
]
[Cites]
Langenbecks Arch Surg. 2004 Jun;389(3):193-7
[
15107999.001
]
[Cites]
Nature. 2004 Aug 26;430(7003):1034-9
[
15329723.001
]
[Cites]
Cancer Res. 1989 Dec 1;49(23):6543-6
[
2819710.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Sep 30;335(3):949-56
[
16105664.001
]
[Cites]
Dig Dis Sci. 2005 Oct;50(10):1764-70
[
16187170.001
]
[Cites]
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
[
16514137.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):2980-9
[
16540646.001
]
[Cites]
J Pathol. 2006 Jun;209(2):206-12
[
16521118.001
]
[Cites]
Diabetes. 2006 Sep;55(9):2470-8
[
16936195.001
]
[Cites]
J Gastrointest Surg. 2006 Nov;10(9):1254-62; discussion 1263
[
17114012.001
]
[Cites]
Cancer Res. 2006 Dec 15;66(24):11613-22
[
17178855.001
]
[Cites]
Exp Cell Res. 2007 Jan 1;313(1):77-87
[
17045586.001
]
[Cites]
J Clin Invest. 2007 Mar;117(3):693-702
[
17290307.001
]
[Cites]
Nucleic Acids Res. 1993 Sep 11;21(18):4259-67
[
8414980.001
]
(PMID = 18473350.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA114103-04; United States / NCI NIH HHS / CA / R01 CA114103; United States / NCI NIH HHS / CA / R01 CA114103-04
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
124544-67-8 / HMGA1a Protein; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
[Other-IDs]
NLM/ NIHMS253257; NLM/ PMC2997611
26.
Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Büchler MW, Friess H:
The neurotrophic factor artemin promotes pancreatic cancer invasion.
Ann Surg
; 2006 Aug;244(2):274-81
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The neurotrophic factor artemin promotes
pancreatic
cancer invasion.
OBJECTIVE: To analyze the role of Artemin in
pancreatic
ductal
adenocarcinoma
(PDAC) in terms of expression, influence on cancer cell behavior, and pain correlation.
METHODS: Artemin and its receptors (GFRalpha3/RET) were studied in PDAC tissues and normal
pancreas
by Western blot analysis and immunohistochemistry.
RNA expression was analyzed in
pancreatic
tissues (normal, cancer) and
pancreatic
cancer cell lines by QRT-PCR.
RESULTS: Artemin and GFRalpha3/RET were both detected at enhanced levels in PDAC compared with normal
pancreas
, localizing predominantly in hypertrophic nerves and arterial walls, as well as in cancer cells of primary and metastatic lesions.
However, Artemin promoted
pancreatic
cancer cell invasion up to 5-fold, without affecting cancer cell proliferation.
However by increasing cancer cell invasion, Artemin seems to influence neural invasion and thereby contribute to cancer cell spreading along
pancreatic
nerves.
[MeSH-major]
Adenocarcinoma
/ pathology. Nerve Growth Factors / physiology. Nerve Tissue Proteins / physiology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Blotting, Western. Cell Line, Tumor. Cell Proliferation. Coloring Agents. Glial Cell Line-Derived Neurotrophic Factor Receptors / physiology. Humans. Hypertrophy. Immunohistochemistry. Neoplasm Invasiveness. Nerve Regeneration / physiology. Neurons / pathology. Pain / physiopathology.
Pancreas
/ innervation.
Pancreas
/ pathology. Polymerase Chain Reaction. Prospective Studies. Tetrazolium Salts. Thiazoles
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
METHYLTHIAZOLETETRAZOLIUM
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Pancreas. 2003 Aug;27(2):190-6
[
12883269.001
]
[Cites]
Ann Surg. 2005 Jan;241(1):144-51
[
15622002.001
]
[Cites]
Nat Med. 2003 Nov;9(11):1383-9
[
14528299.001
]
[Cites]
Oncogene. 2004 Jan 8;23(1):71-81
[
14712212.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5291-300
[
15289335.001
]
[Cites]
Cancer. 1987 Nov 1;60(9):2284-303
[
3326653.001
]
[Cites]
Ann Surg. 1989 Feb;209(2):181-7
[
2464969.001
]
[Cites]
Gastroenterology. 1991 Feb;100(2):529-36
[
1985049.001
]
[Cites]
N Engl J Med. 1992 Feb 13;326(7):455-65
[
1732772.001
]
[Cites]
Science. 1993 May 21;260(5111):1130-2
[
8493557.001
]
[Cites]
Gastroenterology. 1994 Jul;107(1):219-30
[
8020665.001
]
[Cites]
Nature. 1996 Dec 5;384(6608):467-70
[
8945474.001
]
[Cites]
J Biol Chem. 1998 Feb 6;273(6):3502-8
[
9452475.001
]
[Cites]
J Neurosci. 1999 Nov 1;19(21):9322-31
[
10531437.001
]
[Cites]
J Biol Chem. 2000 Feb 4;275(5):3412-20
[
10652334.001
]
[Cites]
Development. 2000 Oct;127(20):4335-44
[
11003834.001
]
[Cites]
Pancreas. 2001 Apr;22(3):279-84
[
11291930.001
]
[Cites]
Eur J Neurosci. 2001 Jun;13(11):2177-82
[
11422460.001
]
[Cites]
Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73
[
11544105.001
]
[Cites]
Development. 2001 Oct;128(19):3685-95
[
11585795.001
]
[Cites]
Development. 2001 Oct;128(20):3963-74
[
11641220.001
]
[Cites]
Pancreas. 2002 Jan;24(1):15-25
[
11741178.001
]
[Cites]
J Biol Chem. 2002 Jan 18;277(3):1991-9
[
11713247.001
]
[Cites]
Neuron. 2002 Jul 18;35(2):267-82
[
12160745.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
Nat Med. 2003 May;9(5):589-95
[
12669033.001
]
[Cites]
Neuron. 1998 Feb;20(2):245-53
[
9491986.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5801-6
[
9576965.001
]
[Cites]
J Am Coll Surg. 1998 Jun;186(6):675-82
[
9632157.001
]
[Cites]
J Neurol. 1998 Nov;245(11 Suppl 3):P35-42
[
9808338.001
]
[Cites]
Neuron. 1998 Dec;21(6):1291-302
[
9883723.001
]
[Cites]
Int J Cancer. 1999 Mar 31;81(1):67-73
[
10077155.001
]
[Cites]
Surgery. 2003 Aug;134(2):293-9
[
12947332.001
]
(PMID = 16858191.001).
[ISSN]
0003-4932
[Journal-full-title]
Annals of surgery
[ISO-abbreviation]
Ann. Surg.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / ARTN protein, human; 0 / Coloring Agents; 0 / Glial Cell Line-Derived Neurotrophic Factor Receptors; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
[Other-IDs]
NLM/ PMC1602177
27.
Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG:
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
Gastroenterology
; 2010 Jul;139(1):292-303
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dasatinib inhibits the development of metastases in a mouse model of
pancreatic
ductal
adenocarcinoma
.
BACKGROUND & AIMS:
Pancreatic
ductal
adenocarcinoma
(PDAC) is a highly invasive and metastatic disease for which conventional treatments are of limited efficacy.
Targeting expression of Trp53(R172H) and Kras(G12D) to the mouse
pancreas
results in the formation of invasive and metastatic PDAC.
[MeSH-major]
Carcinoma,
Pancreatic
Ductal / drug therapy.
Pancreatic
Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. src-Family Kinases / antagonists & inhibitors
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
(PMID = 20303350.001).
[ISSN]
1528-0012
[Journal-full-title]
Gastroenterology
[ISO-abbreviation]
Gastroenterology
[Language]
eng
[Grant]
United Kingdom / Chief Scientist Office / / CAF/06/24; United Kingdom / Cancer Research UK / / C157/A9148; United Kingdom / Chief Scientist Office / / ; United Kingdom / Cancer Research UK / / C2193/A7603
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / src-Family Kinases; RBZ1571X5H / Dasatinib
28.
Nuernberg D, Ignee A, Dietrich CF:
[Ultrasound in gastroenterology. Biliopancreatic system].
Med Klin (Munich)
; 2007 Feb 15;102(2):112-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
GALLBLADDER: Ultrasound has become widely accepted for
the diagnosis
of gallbladder disease.
PANCREAS
: In diagnostic imaging of the
pancreas
ultrasound stands at the beginning of a diagnostic cascade.
Ductal
adenocarcinoma
seems to be less vascularized in comparison to the surrounding tissue, while endocrine tumors and macro- and microcystic adenoma are rather hypervascularized.
[MeSH-major]
Biliary Tract Diseases / ultrasonography.
Pancreatic
Diseases / ultrasonography
[MeSH-minor]
Adenoma / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic / ultrasonography. Carcinoma / ultrasonography. Cholangiocarcinoma / ultrasonography. Cholangitis, Sclerosing / ultrasonography. Cholecystitis / ultrasonography. Choledocholithiasis / ultrasonography. Contrast Media.
Diagnosis
, Differential. Endosonography. Gallbladder Neoplasms / ultrasonography. Humans. Middle Aged.
Pancreatic
Neoplasms / ultrasonography. Pancreatitis / ultrasonography. Polyps / ultrasonography. Sensitivity and Specificity. Ultrasonography, Doppler, Color / methods
MedlinePlus Health Information.
consumer health - Pancreatic Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17323018.001).
[ISSN]
0723-5003
[Journal-full-title]
Medizinische Klinik (Munich, Germany : 1983)
[ISO-abbreviation]
Med. Klin. (Munich)
[Language]
ger
[Publication-type]
Comparative Study; English Abstract; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Contrast Media
[Number-of-references]
228
29.
Sceusi EL, Wray CJ:
Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.
World J Surg Oncol
; 2009;7:98
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
adenocarcinoma
in a patient with situs inversus: a case report of this rare coincidence.
BACKGROUND: Situs inversus (SI) is a relatively rare occurrence in patients with
pancreatic
adenocarcinoma
.
Pancreatic
resection in these patients has rarely been described.
CT scan imaging is a principle modality for detecting
pancreatic
cancer and its use in SI patients is seldom reported.
CASE PRESENTATION: We report a 48 year old woman with SI who, despite normal CT scan 8 months earlier, presented with obstructive jaundice and a
pancreatic
head mass requiring a pancreaticoduodenectomy.
The surgical pathology report demonstrated
pancreatic
adenocarcinoma
.
CONCLUSION: SI is a rare condition with concurrent
pancreatic
cancer being even rarer.
Additionally, radiographic imaging has significantly improved detection of early
pancreatic
cancer; however, there continues to be a need for improved detection of small neoplasms.
[MeSH-major]
Adenocarcinoma
/ complications.
Pancreatic
Neoplasms / complications. Situs Inversus / complications
Genetic Alliance.
consumer health - Situs inversus
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur Radiol. 2009 Oct;19(10):2448-55
[
19415290.001
]
[Cites]
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
[
19474385.001
]
[Cites]
Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8
[
18948228.001
]
[Cites]
Transplant Proc. 2008 Jun;40(5):1792-5
[
18589199.001
]
[Cites]
Eur J Surg Oncol. 2007 May;33(4):524-7
[
17081721.001
]
[Cites]
Wiad Lek. 2006;59(9-10):707-9
[
17338134.001
]
[Cites]
Curr Opin Gastroenterol. 2006 Sep;22(5):512-9
[
16891882.001
]
[Cites]
AJR Am J Roentgenol. 1998 May;170(5):1315-22
[
9574609.001
]
[Cites]
Semin Cell Dev Biol. 1998 Feb;9(1):89-99
[
9572118.001
]
[Cites]
J Clin Gastroenterol. 1997 Mar;24(2):92-6
[
9077725.001
]
[Cites]
AJR Am J Roentgenol. 2004 Apr;182(4):897-903
[
15039161.001
]
[Cites]
AJR Am J Roentgenol. 2004 Mar;182(3):619-23
[
14975959.001
]
[Cites]
Am J Surg. 2003 Jun;185(6):606-7
[
12781900.001
]
[Cites]
Radiol Clin North Am. 2002 Dec;40(6):1263-72
[
12479710.001
]
[Cites]
Radiology. 2002 Sep;224(3):764-8
[
12202711.001
]
[Cites]
Am J Med Genet. 2001 Jul 15;101(4):345-55
[
11471158.001
]
[Cites]
Surg Radiol Anat. 2000;22(5-6):293-7
[
11236325.001
]
[Cites]
Radiographics. 2002 Nov-Dec;22(6):1439-56
[
12432114.001
]
(PMID = 20021643.001).
[ISSN]
1477-7819
[Journal-full-title]
World journal of surgical oncology
[ISO-abbreviation]
World J Surg Oncol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2803176
30.
Chang SM, Yan ST, Wei CK, Lin CW, Tseng CE:
Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas.
World J Gastroenterol
; 2010 Jun 7;16(21):2692-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Solitary concomitant endocrine tumor and ductal
adenocarcinoma of pancreas
.
Pancreatic
tumors with combined exocrine and endocrine features are rare.
Most reported cases are classified as mixed exocrine and endocrine carcinoma of the
pancreas
.
We report the first case of solitary concomitant endocrine tumor and ductal
adenocarcinoma of
the
pancreas
.
The tumor was fortuitously discovered in
the pancreatic
tail after a tumor survey panel.
The exocrine part showed a poorly-differentiated
adenocarcinoma
.
We reviewed the literature on
pancreatic
tumors with combined exocrine and endocrine features.
[MeSH-major]
Adenocarcinoma
/ pathology. Carcinoma,
Pancreatic
Ductal / pathology. Endocrine Gland Neoplasms / pathology.
Pancreatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
GLUCAGON
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
West J Med. 1986 Jun;144(6):746-9
[
3014756.001
]
[Cites]
Cancer. 1984 Nov 1;54(9):1766-70
[
6089999.001
]
[Cites]
J Gastroenterol. 1997 Aug;32(4):562-5
[
9250909.001
]
[Cites]
Int J Pancreatol. 1999 Apr;25(2):77-87
[
10360219.001
]
[Cites]
Virchows Arch. 2004 Sep;445(3):231-5
[
15517367.001
]
[Cites]
Pancreas. 2005 Jul;31(1):79-83
[
15968252.001
]
[Cites]
JOP. 2005 Sep;6(5):449-54
[
16186667.001
]
[Cites]
Pancreatology. 2006;6(6):520-6
[
17124434.001
]
[Cites]
Gastroenterology. 2008 Apr;134(4):981-7
[
18395079.001
]
[Cites]
Arch Pathol Lab Med. 2000 Feb;124(2):284-6
[
10656740.001
]
[Cites]
Int J Pancreatol. 2000 Jun;27(3):249-57
[
10952408.001
]
[Cites]
Surg Today. 2001;31(2):177-9
[
11291717.001
]
[Cites]
Histopathology. 2002 Aug;41(2):122-6
[
12147089.001
]
[Cites]
Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):473-5
[
15313692.001
]
[Cites]
Hum Pathol. 1982 Mar;13(3):263-71
[
7076209.001
]
[Cites]
J Korean Med Sci. 1996 Apr;11(2):188-92
[
8835769.001
]
(PMID = 20518094.001).
[ISSN]
2219-2840
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Hypoglycemic Agents; 0 / Synaptophysin; 9007-92-5 / Glucagon
[Other-IDs]
NLM/ PMC2880785
31.
McCluggage WG, Hurrell DP, Kennedy K:
Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
Am J Surg Pathol
; 2010 May;34(5):735-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastatic carcinomas in the cervix mimicking primary cervical
adenocarcinoma
and
adenocarcinoma
in situ: report of a series of cases.
A variety of other neoplasms rarely metastasize to the cervix and, in most cases,
the diagnosis
is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
We describe 6 cases of metastatic
adenocarcinoma
involving the cervix with superficial "mucosal" involvement mimicking primary cervical
adenocarcinoma
or
adenocarcinoma
in situ.
In 5 cases, the primary
adenocarcinoma
was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
In the other case, the primary neoplasm was in the
pancreas
and this was initially interpreted as a primary cervical
adenocarcinoma
.
It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous
diagnosis
of a primary cervical
adenocarcinoma
or
adenocarcinoma
in situ.
[MeSH-major]
Carcinoma in Situ /
diagnosis
. Cystadenocarcinoma, Serous /
diagnosis
. Ovarian Neoplasms /
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
. Peritoneal Neoplasms /
diagnosis
. Uterine Cervical Neoplasms /
diagnosis
[MeSH-minor]
Adult. Aged. Biomarkers, Tumor / metabolism.
Diagnosis
, Differential. Female. Humans. Middle Aged
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - A practical manual on visual screening for cervical neoplasia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20414103.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
32.
Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E:
Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.
Neoplasma
; 2009;56(1):56-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in
pancreatic
adenocarcinoma
.
The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in
pancreatic
adenocarcinoma
(PA) and chronic pancreatitis (CP) as regards to healthy volunteers.
We studied 41 patients with
pancreatic
adenocarcinoma
, 56 with chronic pancreatitis and 50 healthy volunteers.
-308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in
pancreatic
diseases.
Key words:
pancreatic
adenocarcinoma
, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.
[MeSH-major]
Adenocarcinoma
/ genetics. Interferon-gamma / genetics.
Pancreatic
Neoplasms / genetics. Tumor Necrosis Factor-alpha / genetics
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19152246.001).
[ISSN]
0028-2685
[Journal-full-title]
Neoplasma
[ISO-abbreviation]
Neoplasma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Slovakia
[Chemical-registry-number]
0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
33.
Mané JM, Sancho A, Muñoz A, Rubio I, Fernández R, Carrera S, Fuente N, Ballesteros D, Casas R, Marrodán I, Mielgo X, López-Vivanco G:
Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
Tumori
; 2010 May-Jun;96(3):405-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fixed-dose-rate gemcitabine infusion in patients with advanced
pancreatic
or biliary tree
adenocarcinoma
.
AIMS AND BACKGROUND: Gemcitabine is an effective agent in
pancreatic
adenocarcinoma
.
We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with
pancreatic
or biliary tree
adenocarcinoma
.
METHODS: Eligible patients with locally advanced or metastatic
pancreatic
or biliary tree
adenocarcinoma
received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives.
Pancreatic
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20845800.001).
[ISSN]
0300-8916
[Journal-full-title]
Tumori
[ISO-abbreviation]
Tumori
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
34.
Lang ZQ, Qu GM, Yao WD, Jiang L:
Microadenocarcinoma in the head of the pancreas.
Chin Med J (Engl)
; 2007 Oct 20;120(20):1853-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microadenocarcinoma in the head of the
pancreas
.
[MeSH-major]
Adenocarcinoma
/ pathology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Aged. Carcinoma, Neuroendocrine /
diagnosis
.
Diagnosis
, Differential. Humans. Male
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18028787.001).
[ISSN]
0366-6999
[Journal-full-title]
Chinese medical journal
[ISO-abbreviation]
Chin. Med. J.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
China
35.
Keleg S, Kayed H, Jiang X, Penzel R, Giese T, Büchler MW, Friess H, Kleeff J:
Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion.
Int J Cancer
; 2007 Jul 1;121(1):21-32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adrenomedullin is induced by hypoxia and enhances
pancreatic
cancer cell invasion.
In this study, the expression and functional role of ADM and its signaling components were investigated in
pancreatic
adenocarcinoma
(PDAC).
By QRT-PCR, median mRNA levels of ADM and CRLR were 1.5- and 2.4-fold higher, respectively, in PDAC tissues compared to normal
pancreatic
tissues.
By immunohistochemistry, ADM, CRLR, RAMP1 and RAMP2, but not RAMP3, were expressed in
pancreatic
cancer cells.
All 5 evaluated
pancreatic
cancer cells lines expressed ADM, CRLR, RAMP1 and RAMP2, whereas RAMP3 was expressed in only 1/5
pancreatic
cancer cell lines.
ADM was strongly induced by hypoxia and significantly increased invasiveness in 3/5 human
pancreatic
cancer cells.
Blocking of CRLR decreased invasiveness in 4/5 human
pancreatic
cancer cells.
Furthermore, ADM increases invasiveness of some
pancreatic
cancer cells and might influence angiogenesis, suggesting that blocking this pathway might have a therapeutic potential.
[MeSH-major]
Adrenomedullin / metabolism. Cell Hypoxia. Cell Movement.
Pancreatic
Neoplasms / metabolism.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Calcitonin Receptor-Like Protein. Cell Line. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Intracellular Signaling Peptides and Proteins / genetics. Membrane Proteins / genetics. Middle Aged. Neoplasm Invasiveness / pathology.
Pancreas
/ metabolism. RNA, Messenger / genetics. Receptor Activity-Modifying Protein 1. Receptor Activity-Modifying Protein 2. Receptor Activity-Modifying Protein 3. Receptor Activity-Modifying Proteins. Receptors, Calcitonin / genetics. Signal Transduction. Transforming Growth Factor beta1 / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17290391.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / CALCRL protein, human; 0 / Calcitonin Receptor-Like Protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RAMP1 protein, human; 0 / RAMP2 protein, human; 0 / RAMP3 protein, human; 0 / RNA, Messenger; 0 / Receptor Activity-Modifying Protein 1; 0 / Receptor Activity-Modifying Protein 2; 0 / Receptor Activity-Modifying Protein 3; 0 / Receptor Activity-Modifying Proteins; 0 / Receptors, Calcitonin; 0 / Transforming Growth Factor beta1; 0 / Vascular Endothelial Growth Factor A; 148498-78-6 / Adrenomedullin
36.
Balci NC, Perman WH, Saglam S, Akisik F, Fattahi R, Bilgin M:
Diffusion-weighted magnetic resonance imaging of the pancreas.
Top Magn Reson Imaging
; 2009 Feb;20(1):43-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diffusion-weighted magnetic resonance imaging of the
pancreas
.
The technique is more frequently used in body imaging, and recent investigations showed its use in
pancreatic
imaging.
Diffusion-weighted imaging can be helpful as a complementary imaging method in the differentiation between mass-forming focal pancreatitis and
pancreatic
adenocarcinoma
.
The apparent diffusion coefficient (ADC) values derived from DWI can distinguish between simple
pancreatic
cyst, inflammatory cysts, and cystic neoplasms of the
pancreas
.
In this paper, we reviewed the technical aspects of DWI and its use in
pancreatic
imaging.
[MeSH-major]
Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods.
Pancreas
/ pathology.
Pancreatic
Diseases /
diagnosis
MedlinePlus Health Information.
consumer health - Pancreatic Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19687725.001).
[ISSN]
1536-1004
[Journal-full-title]
Topics in magnetic resonance imaging : TMRI
[ISO-abbreviation]
Top Magn Reson Imaging
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
28
37.
Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A:
Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.
Pathol Int
; 2005 Feb;55(2):63-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the
pancreas
.
The expression of claudin-4 was investigated in human
pancreas
,
pancreatic
ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the
pancreas
(IPMT), and compared with that of claudin-1.
In human adult
pancreatic
specimens, both claudin-1 and claudin-4 were immunohistochemically found in main and branching
pancreatic
ducts, terminal ductules and acinic cells, with the exception of endocrine cells.
Of 12 cases of
pancreatic
ductal
adenocarcinoma
, 11 (92%) had positive immunostaining for claudin-4, and seven (58%) for claudin-1.
[MeSH-major]
Adenocarcinoma
, Mucinous / metabolism.
Adenocarcinoma
, Papillary / metabolism. Carcinoma,
Pancreatic
Ductal / metabolism. Membrane Proteins / metabolism.
Pancreatic
Neoplasms / metabolism
[MeSH-minor]
Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Claudin-1. Claudin-4. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged.
Pancreas
/ metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15693851.001).
[ISSN]
1320-5463
[Journal-full-title]
Pathology international
[ISO-abbreviation]
Pathol. Int.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
38.
Hruban RH, Maitra A, Goggins M:
Update on pancreatic intraepithelial neoplasia.
Int J Clin Exp Pathol
; 2008;1(4):306-16
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Update on
pancreatic
intraepithelial neoplasia.
Pancreatic
intraepithelial neoplasia (PanIN) is a histologically well-defined precursor to invasive ductal
adenocarcinoma of
the
pancreas
.
Molecular studies have helped establish the progression of PanIN to invasive cancer, and recently genetically engineered mouse models have been generated that recapitulate the entire spectrum of lesions from precursor to invasive
pancreatic
cancer.
Some PanIN lesions produce lobulocentric atrophy of
the pancreatic
parenchyma, and, when multifocal, this lobulocentric atrophy may be detectable using currently available imaging techniques such as endoscopic ultrasound.
COS Scholar Universe.
author profiles
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Cell. 2005 Sep;8(3):185-95
[
16169464.001
]
[Cites]
Cancer Cell. 2005 May;7(5):469-83
[
15894267.001
]
[Cites]
Nat Methods. 2004 Nov;1(2):141-7
[
15782177.001
]
[Cites]
Am J Surg Pathol. 2003 Dec;27(12):1495-501
[
14657708.001
]
[Cites]
Mod Pathol. 2003 Oct;16(10):996-1006
[
14559982.001
]
[Cites]
J Natl Cancer Inst. 2003 Apr 16;95(8):622-5
[
12697855.001
]
[Cites]
Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83
[
12673124.001
]
[Cites]
Pancreas. 2003 Apr;26(3):e48-54
[
12657964.001
]
[Cites]
Cancer Biol Ther. 2002 May-Jun;1(3):293-6
[
12432281.001
]
[Cites]
Am J Pathol. 2002 Nov;161(5):1541-7
[
12414502.001
]
[Cites]
Mod Pathol. 2002 Oct;15(10):1087-95
[
12379756.001
]
[Cites]
Gastroenterology. 2002 Oct;123(4):1052-60
[
12360467.001
]
[Cites]
Am J Clin Pathol. 2002 Aug;118(2):194-201
[
12162677.001
]
[Cites]
Am J Pathol. 2002 May;160(5):1573-81
[
12000709.001
]
[Cites]
Mol Cell Biol. 2002 Jan;22(2):635-43
[
11756558.001
]
[Cites]
Am J Surg Pathol. 2001 Aug;25(8):1047-53
[
11474289.001
]
[Cites]
Am J Pathol. 2001 May;158(5):1677-83
[
11337365.001
]
[Cites]
Cancer Cell. 2003 Dec;4(6):437-50
[
14706336.001
]
[Cites]
Mod Pathol. 2003 Sep;16(9):902-12
[
13679454.001
]
[Cites]
Cancer Res. 2003 Jul 1;63(13):3735-42
[
12839967.001
]
[Cites]
Cancer Res. 2003 May 1;63(9):2005-9
[
12727809.001
]
[Cites]
Am J Clin Pathol. 2002 May;117(5):791-6
[
12090430.001
]
[Cites]
Am J Surg Pathol. 2001 May;25(5):579-86
[
11342768.001
]
[Cites]
Clin Cancer Res. 2000 Aug;6(8):2969-72
[
10955772.001
]
[Cites]
JAMA. 2000 Oct 18;284(15):1954-61
[
11035892.001
]
[Cites]
Am J Pathol. 2000 Jul;157(1):83-92
[
10880379.001
]
[Cites]
Am J Pathol. 2000 Jun;156(6):2123-33
[
10854233.001
]
[Cites]
Am J Pathol. 2000 May;156(5):1767-71
[
10793087.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):2002-6
[
10766191.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):1835-9
[
10766168.001
]
[Cites]
Cancer Res. 2005 Mar 1;65(5):1619-26
[
15753353.001
]
[Cites]
Neoplasia. 2005 Jan;7(1):17-23
[
15720814.001
]
[Cites]
Cancer. 1999 Apr 15;85(8):1703-10
[
10223563.001
]
[Cites]
Ann Intern Med. 1999 Aug 17;131(4):247-55
[
10454945.001
]
[Cites]
Ann Diagn Pathol. 1998 Oct;2(5):286-92
[
9845751.001
]
[Cites]
Cancer Res. 1998 Oct 15;58(20):4740-4
[
9788631.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21
[
9641496.001
]
[Cites]
Am J Surg Pathol. 1998 Feb;22(2):163-9
[
9500216.001
]
[Cites]
Cancer Res. 1997 Aug 1;57(15):3126-30
[
9242437.001
]
[Cites]
Cancer Res. 1997 Jun 1;57(11):2140-3
[
9187111.001
]
[Cites]
J Natl Cancer Inst. 1997 Mar 19;89(6):442-6
[
9091646.001
]
[Cites]
Science. 1996 Jan 19;271(5247):350-3
[
8553070.001
]
[Cites]
Gastroenterology. 1996 Jan;110(1):227-31
[
8536861.001
]
[Cites]
Nat Genet. 1994 Sep;8(1):27-32
[
7726912.001
]
[Cites]
Cancer Res. 1994 Jul 1;54(13):3568-73
[
8012983.001
]
[Cites]
Cancer Res. 1993 Mar 1;53(5):953-6
[
8439969.001
]
[Cites]
Cancer. 1979 Apr;43(4):1418-28
[
445339.001
]
[Cites]
Cancer Res. 1976 Jul;36(7 PT 2):2690-8
[
1277176.001
]
[Cites]
Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21
[
15224285.001
]
[Cites]
Am J Surg Pathol. 2004 Aug;28(8):977-87
[
15252303.001
]
[Cites]
Gastroenterology. 2004 Jun;126(7):1674-80
[
15188160.001
]
[Cites]
Cancer Res. 2004 Apr 1;64(7):2634-8
[
15059921.001
]
[Cites]
Genes Dev. 2003 Dec 15;17(24):3112-26
[
14681207.001
]
[Cites]
Mol Imaging. 2007 Mar-Apr;6(2):131-9
[
17445507.001
]
[Cites]
Cancer Res. 2007 Aug 1;67(15):7068-71
[
17652141.001
]
[Cites]
Am J Pathol. 2007 Jul;171(1):263-73
[
17591971.001
]
[Cites]
J Hepatobiliary Pancreat Surg. 2007;14(3):243-54
[
17520199.001
]
[Cites]
Am J Surg Pathol. 2007 Apr;31(4):645-6
[
17414117.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42
[
17360542.001
]
[Cites]
Cancer Cell. 2007 Mar;11(3):291-302
[
17349585.001
]
[Cites]
Cancer Cell. 2007 Mar;11(3):229-43
[
17349581.001
]
[Cites]
Cancer Cell. 2007 Mar;11(3):211-3
[
17349578.001
]
[Cites]
Cancer Res. 2007 Jan 15;67(2):433-6
[
17234748.001
]
[Cites]
Gastroenterology. 2006 Dec;131(6):1844-55
[
17087933.001
]
[Cites]
Genes Dev. 2006 Nov 15;20(22):3130-46
[
17114584.001
]
[Cites]
Clin Cancer Res. 2006 Sep 15;12(18):5417-22
[
17000675.001
]
[Cites]
Clin Cancer Res. 2006 Sep 15;12(18):5411-6
[
17000674.001
]
[Cites]
Am J Surg Pathol. 2006 Sep;30(9):1067-76
[
16931950.001
]
[Cites]
J Hepatobiliary Pancreat Surg. 2006;13(4):286-95
[
16858539.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665
[
16682259.001
]
[Cites]
Am J Surg Pathol. 2006 Jun;30(6):754-9
[
16723855.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):1208-17
[
16424060.001
]
[Cites]
Cancer Res. 2006 Jan 1;66(1):242-7
[
16397237.001
]
[Cites]
Cancer Res. 2006 Jan 1;66(1):95-106
[
16397221.001
]
[Cites]
Virchows Arch. 2005 Nov;447(5):800-5
[
16021508.001
]
[Cites]
Int J Cancer. 2006 Jan 15;118(2):405-11
[
16052519.001
]
[Cites]
N Engl J Med. 2005 Oct 27;353(17):1784-92
[
16251534.001
]
(PMID = 18787611.001).
[ISSN]
1936-2625
[Journal-full-title]
International journal of clinical and experimental pathology
[ISO-abbreviation]
Int J Clin Exp Pathol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2480542
[Keywords]
NOTNLM ; Pancreatic cancer / epigenetics / genetics / intraepithelial neoplasm / metaplasia
39.
Kurisu Y, Shibayama Y, Tsuji M, Kurokawa A, Akutagawa H, Egashira Y, Matsuo T, Itabashi T:
A case of primary ductal adenocarcinoma of the lacrimal gland: histopathological and immunohistochemical study.
Pathol Res Pract
; 2005;201(1):49-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A case of primary ductal
adenocarcinoma of
the lacrimal gland: histopathological and immunohistochemical study.
We encountered primary ductal
adenocarcinoma of
the lacrimal gland in a 67-year-old Japanese man.
To the best of our knowledge, only three cases of primary ductal
adenocarcinoma of
the lacrimal gland have been reported in the literature.
The mass was resected, and primary ductal
adenocarcinoma of
the lacrimal gland was diagnosed histopathologically.
He died from recurrence at the primary site and metastasis to the brain, lungs, liver, common bile duct, and
pancreas
2 years and 10 months after surgery although adjunctive orbital radiotherapy was given.
It was not clear whether the ductal
adenocarcinoma
originated from the ductal or acinar epithelium of the lacrimal gland, because the immunohistochemical features of both epithelia were identical.
MedlinePlus Health Information.
consumer health - Eye Cancer
.
MedlinePlus Health Information.
consumer health - Tears
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15807311.001).
[ISSN]
0344-0338
[Journal-full-title]
Pathology, research and practice
[ISO-abbreviation]
Pathol. Res. Pract.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
68238-35-7 / Keratins
[Number-of-references]
14
40.
Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC:
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.
J Transl Med
; 2009 Dec 11;7:105
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of
pancreatic
cancer
diagnosis
.
BACKGROUND:
Pancreatic
cancer continues to prove difficult to clinically diagnose.
Multiple simultaneous measurements of plasma biomarkers can increase sensitivity and selectivity of
diagnosis
.
METHODS: We examined the plasma levels of 21 biomarkers in a clinically defined cohort of 52 locally advanced (Stage II/III)
pancreatic
ductal
adenocarcinoma
cases and 43 age-matched controls using a multiplex proximity ligation assay.
The optimal biomarker panel for
diagnosis
was computed using a combination of the PAM algorithm and logistic regression modeling.
RESULTS: Three markers, CA19-9, OPN and CHI3L1, measured in multiplex were found to have superior sensitivity for
pancreatic
cancer vs. CA19-9 alone (93% vs. 80%).
In addition, we identified two markers, CEA and CA125, that when measured simultaneously have prognostic significance for survival for this clinical stage of
pancreatic
cancer (p < 0.003).
CONCLUSIONS: A multiplex panel assaying CA19-9, OPN and CHI3L1 in plasma improves accuracy of
pancreatic
cancer
diagnosis
.
A panel assaying CEA and CA125 in plasma can predict survival for this clinical cohort of
pancreatic
cancer patients.
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2006 Nov 20;24(33):5291-7
[
17114663.001
]
[Cites]
Cancer Biomark. 2005;1(6):259-69
[
17192050.001
]
[Cites]
Expert Opin Ther Targets. 2007 Feb;11(2):219-34
[
17227236.001
]
[Cites]
Nat Methods. 2007 Apr;4(4):327-9
[
17369836.001
]
[Cites]
Clin Chem. 2008 Mar;54(3):582-9
[
18171715.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Cancer Metastasis Rev. 2008 Sep;27(3):351-62
[
18483785.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81
[
18843033.001
]
[Cites]
J Clin Oncol. 2008 Oct 10;26(29):4771-6
[
18779603.001
]
[Cites]
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45
[
18952487.001
]
[Cites]
J Clin Oncol. 2009 Feb 1;27(4):572-8
[
19075264.001
]
[Cites]
Nat Biotechnol. 2002 May;20(5):473-7
[
11981560.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
[
12011421.001
]
[Cites]
Oncogene. 2009 Sep 24;28(38):3412-22
[
19597469.001
]
[Cites]
BMC Cancer. 2009;9:8
[
19134206.001
]
[Cites]
Clin Cancer Res. 2003 Jan;9(1):59-67
[
12538452.001
]
[Cites]
Acta Obstet Gynecol Scand. 2003 Mar;82(3):287-93
[
12694127.001
]
[Cites]
Breast Cancer Res Treat. 2003 Jul;80(1):15-21
[
12889595.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91
[
15006928.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8420-4
[
15155907.001
]
[Cites]
Cancer Res. 1983 Nov;43(11):5489-92
[
6193872.001
]
[Cites]
Cancer. 1988 Dec 1;62(11):2287-90
[
3179943.001
]
[Cites]
Pancreas. 1994 Nov;9(6):735-40
[
7846017.001
]
[Cites]
Eur J Cancer. 1995;31A(9):1437-42
[
7577068.001
]
[Cites]
Clin Chem. 1997 Sep;43(9):1749-56
[
9299971.001
]
[Cites]
Br J Cancer. 1999 Mar;79(9-10):1494-9
[
10188896.001
]
[Cites]
Eur J Surg Oncol. 2005 Mar;31(2):164-9
[
15698733.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18
[
15734951.001
]
[Cites]
J Clin Oncol. 2005 Jul 10;23(20):4524-31
[
16002843.001
]
[Cites]
J Clin Oncol. 2006 Nov 20;24(33):5313-27
[
17060676.001
]
(PMID = 20003342.001).
[ISSN]
1479-5876
[Journal-full-title]
Journal of translational medicine
[ISO-abbreviation]
J Transl Med
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA67166
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Other-IDs]
NLM/ PMC2796647
41.
Yeh TS, Tseng JH, Chiu CT, Liu NJ, Chen TC, Jan YY, Chen MF:
Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts.
Ann Surg
; 2006 Aug;244(2):248-53
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Adenocarcinoma
, Mucinous / classification. Bile Duct Neoplasms / classification. Bile Ducts, Intrahepatic / radiography. Cholangiography / methods. Precancerous Conditions / classification
MedlinePlus Health Information.
consumer health - Bile Duct Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Pancreas. 2005 Apr;30(3):233-8
[
15782100.001
]
[Cites]
Br J Surg. 1998 Sep;85(9):1206-9
[
9752860.001
]
[Cites]
Hepatology. 2000 Jan;31(1):12-7
[
10613721.001
]
[Cites]
Dig Dis Sci. 2000 Feb;45(2):312-6
[
10711444.001
]
[Cites]
Ann Surg. 2000 Aug;232(2):166-74
[
10903592.001
]
[Cites]
AJR Am J Roentgenol. 2000 Sep;175(3):721-5
[
10954456.001
]
[Cites]
AJR Am J Roentgenol. 2000 Oct;175(4):1135-9
[
11000178.001
]
[Cites]
Hepatology. 2001 Oct;34(4 Pt 1):651-8
[
11584359.001
]
[Cites]
Gut. 2002 Nov;51 Suppl 6:VI1-9
[
12376491.001
]
[Cites]
Br J Surg. 2004 Jan;91(1):99-104
[
14716802.001
]
[Cites]
Radiographics. 2004 Jan-Feb;24(1):53-66; discussion 66-7
[
14730036.001
]
[Cites]
Am J Surg Pathol. 2004 Mar;28(3):327-38
[
15104295.001
]
[Cites]
Cancer. 1993 Apr 15;71(8):2461-5
[
8384069.001
]
[Cites]
Surgery. 1996 Sep;120(3):509-14
[
8784405.001
]
[Cites]
Ann Surg. 1998 Jan;227(1):63-9
[
9445112.001
]
[Cites]
Gastroenterology. 2005 May;128(6):1655-67
[
15887157.001
]
(PMID = 16858187.001).
[ISSN]
0003-4932
[Journal-full-title]
Annals of surgery
[ISO-abbreviation]
Ann. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1602176
42.
Freitas D, Fernandes Gdos S, Hoff PM, Cunha JE:
Medical management of pancreatic adenocarcinoma.
Pancreatology
; 2009;9(3):223-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Medical management of
pancreatic
adenocarcinoma
.
Pancreatic
cancer is the fourth leading cause of cancer death in the United States.
In 2008, an estimated 34,290 people died from
pancreatic
cancer and 37,680 new cases were diagnosed.
Despite modern treatment, 90% of patients die within 1 year of
diagnosis
.
In the present paper the English-language literature addressing the medical management in
pancreatic
cancer was reviewed.
Based on these data we will discuss the role of currently used chemotherapy and target therapy in
pancreatic
cancer, as well as perspectives of the emerging strategies that are arising in order to improve the outcomes of this complex disease.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antineoplastic Agents / therapeutic use.
Pancreatic
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
CAPECITABINE
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 S. Karger AG, Basel.
(PMID = 19420981.001).
[ISSN]
1424-3911
[Journal-full-title]
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
[ISO-abbreviation]
Pancreatology
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
[Number-of-references]
112
43.
Ionescu M, Dumitraşcu T, Stroescu C, Ciurea S, Popescu I:
[Resection of the celiac axis increase resectability rate in locally advanced pancreatic body and gastric tumor].
Chirurgia (Bucur)
; 2006 May-Jun;101(3):297-305
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Resection of the celiac axis increase resectability rate in locally advanced
pancreatic
body and gastric tumor].
[Transliterated title]
Rezectia
de
trunchi celiac--factor
de
creştere a rezecabilităţii in neoplasmele pancreatice si gastrice local avansate.
Carcinoma of the body and tail of the
pancreas
is often diagnosed at an advanced stage or metastatic stage.
[MeSH-major]
Adenocarcinoma
/ surgery. Celiac Artery / surgery.
Pancreatic
Neoplasms / surgery. Stomach Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16927919.001).
[ISSN]
1221-9118
[Journal-full-title]
Chirurgia (Bucharest, Romania : 1990)
[ISO-abbreviation]
Chirurgia (Bucur)
[Language]
rum
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Romania
44.
Donadelli M, Dalla Pozza E, Costanzo C, Scupoli MT, Scarpa A, Palmieri M:
Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
J Cell Biochem
; 2008 May 1;104(1):202-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Zinc depletion efficiently inhibits
pancreatic
cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
We investigated the ability of the zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to reduce
pancreatic
cancer cell viability.
TPEN was much more efficient to inhibit
pancreatic
adenocarcinoma
cell growth than a panel of anti-cancer drugs, including 5-fluorouracil, irinotecan, cisplatin, edelfosine, trichostatin A, mitomycin C, and gemcitabine, the gold standard chemotherapeutic agent for
pancreatic
cancer.
Moreover, TPEN showed a dose- and time-dependent anti-proliferative effect significantly higher on
pancreatic
cancer cells than on normal primary fibroblasts.
This effect may be explained by a significantly higher zinc depletion by TPEN in
pancreatic
cancer cells as compared to fibroblasts.
In this study, we suggest that zinc depletion may be an efficient strategy in the treatment of
pancreatic
cancer because of its reduced antiproliferative effect on normal cells.
[MeSH-major]
Cell Proliferation / drug effects. Ethylenediamines / pharmacology. Gene Expression Regulation, Neoplastic.
Pancreatic
Neoplasms / therapy. Zinc / deficiency
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
ZINC, ELEMENTAL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17979179.001).
[ISSN]
1097-4644
[Journal-full-title]
Journal of cellular biochemistry
[ISO-abbreviation]
J. Cell. Biochem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Chelating Agents; 0 / Ethylenediamines; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; J41CSQ7QDS / Zinc
45.
Benedix F, Lippert H, Meyer F:
[Acute inguinal swelling--unusual presentation of postoperative necrotising pancreatitis].
Zentralbl Chir
; 2009 Apr;134(2):186-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We report on a 61-year-old male who underwent explorative laparotomy for
pancreatic
tumour.
Intraoperatively,
the diagnosis
of a locally advanced carcinoma of the head of the
pancreas
was confirmed histologically.
[MeSH-major]
Adenocarcinoma
/ surgery. Edema / surgery. Inguinal Canal / surgery.
Pancreatic
Neoplasms / surgery. Pancreatitis, Acute Necrotizing / surgery. Postoperative Complications / surgery
[MeSH-minor]
Abdominal Abscess /
diagnosis
. Abdominal Abscess / pathology. Abdominal Abscess / surgery.
Diagnosis
, Differential. Hernia, Inguinal /
diagnosis
. Humans. Male. Middle Aged. Neoplasm Invasiveness. Reoperation
Genetic Alliance.
consumer health - Pancreatitis
.
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Edema
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19382054.001).
[ISSN]
0044-409X
[Journal-full-title]
Zentralblatt für Chirurgie
[ISO-abbreviation]
Zentralbl Chir
[Language]
ger
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Germany
46.
Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD:
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
J Clin Oncol
; 2010 Aug 01;28(22):3605-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced
pancreatic
adenocarcinoma
: Southwest Oncology Group-directed intergroup trial S0205.
PURPOSE: Patients with advanced
pancreas
cancer present with disease that is poorly responsive to conventional therapies.
Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients with
pancreas
cancer.
PATIENTS AND METHODS: Patients with unresectable locally advanced or metastatic
pancreatic
adenocarcinoma
were randomly assigned to receive gemcitabine alone or gemcitabine plus cetuximab.
CONCLUSION: In patients with advanced
pancreas
cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives.
Pancreatic
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CETUXIMAB
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
[
10655437.001
]
[Cites]
Cancer Res. 2000 Jun 1;60(11):2926-35
[
10850439.001
]
[Cites]
Cancer. 2000 Jul 1;89(1):74-82
[
10897003.001
]
[Cites]
Cancer Invest. 2003;21(1):73-86
[
12643012.001
]
[Cites]
Pancreas. 2004 Jul;29(1):e1-8
[
15211117.001
]
[Cites]
J Clin Oncol. 2004 Jul 1;22(13):2610-6
[
15226328.001
]
[Cites]
N Engl J Med. 2004 Jul 22;351(4):337-45
[
15269313.001
]
[Cites]
Anticancer Res. 1993 May-Jun;13(3):565-9
[
8317885.001
]
[Cites]
J Clin Oncol. 1997 Jun;15(6):2403-13
[
9196156.001
]
[Cites]
Cancer. 2006 Aug 15;107(4):676-85
[
16847885.001
]
[Cites]
J Clin Oncol. 2007 May 20;25(15):1960-6
[
17452677.001
]
[Cites]
Lancet Oncol. 2008 Jan;9(1):39-44
[
18077217.001
]
[Cites]
Lancet Oncol. 2008 Jan;9(1):7-8
[
18177814.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Cell Mol Life Sci. 2008 May;65(10):1566-84
[
18259690.001
]
[Cites]
Br J Cancer. 2008 Jul 8;99(1):1-5
[
18506149.001
]
[CommentIn]
J Clin Oncol. 2011 Jan 20;29(3):e70-1; author reply e72-3
[
21149660.001
]
(PMID = 20606093.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00075686
[Grant]
United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / U10 CA077202; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / U10 CA091105; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA095860; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA067663; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA058861; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
[Publication-type]
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab
[Other-IDs]
NLM/ PMC2917315
47.
Fukukura Y, Hamada H, Kamiyama T, Yoneyama T, Takumi K, Nakajo M:
Pancreatic adenocarcinoma: analysis of the effect of various concentrations of contrast material.
Radiat Med
; 2008 Jul;26(6):355-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
adenocarcinoma
: analysis of the effect of various concentrations of contrast material.
PURPOSE: The aim of this study was to compare the efficacy of two contrast materials with moderate and high iodine concentrations for the depiction of
pancreatic
adenocarcinoma
.
MATERIALS AND METHODS: A series of 107 patients with histologically proven
pancreatic
adenocarcinoma
underwent helical computed tomography.
We evaluated enhancement of the aorta, portal vein, hepatic parenchyma,
pancreatic
parenchyma, and
pancreatic
adenocarcinoma
during each phase.
RESULTS: During all phases, both aortic and
pancreatic
enhancement were significantly greater in group B than in group A (P<0.01).
Tumor-to-
pancreas
contrast was significantly greater in group B than in group A at both 30 s (P<0.01) and 70 s (P<0.05).
CONCLUSION: Administration of contrast material with a high iodine concentration is more effective for depicting
pancreatic
adenocarcinomas.
[MeSH-major]
Adenocarcinoma
/ diagnostic imaging. Contrast Media / administration & dosage. Iopamidol / administration & dosage.
Pancreatic
Neoplasms / diagnostic imaging
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiology. 2003 Oct;229(1):81-90
[
14519871.001
]
[Cites]
Radiat Med. 2003 Mar-Apr;21(2):74-9
[
12816354.001
]
[Cites]
AJR Am J Roentgenol. 1994 Jun;162(6):1425-9
[
8192012.001
]
[Cites]
AJR Am J Roentgenol. 2006 Feb;186(2):406-15
[
16423946.001
]
[Cites]
Radiology. 1995 Oct;197(1):89-93
[
7568860.001
]
[Cites]
Radiology. 1999 Jan;210(1):97-101
[
9885593.001
]
[Cites]
Radiology. 1995 Apr;195(1):1-8
[
7892446.001
]
[Cites]
Radiology. 1992 May;183(2):297-303
[
1561324.001
]
[Cites]
AJR Am J Roentgenol. 2006 Feb;186(2):379-85
[
16423942.001
]
[Cites]
Radiology. 1999 Aug;212(2):445-52
[
10429702.001
]
[Cites]
AJR Am J Roentgenol. 1996 Jul;167(1):49-55
[
8659419.001
]
[Cites]
Br J Surg. 1995 Jan;82(1):111-5
[
7881926.001
]
[Cites]
Cancer. 1995 Nov 1;76(9):1671-7
[
8635074.001
]
[Cites]
AJR Am J Roentgenol. 2002 Apr;178(4):821-6
[
11906855.001
]
[Cites]
Radiology. 1998 Feb;206(2):373-8
[
9457188.001
]
[Cites]
Radiology. 2000 Sep;216(3):718-23
[
10966700.001
]
[Cites]
Radiology. 1998 Feb;206(2):455-64
[
9457200.001
]
[Cites]
Radiology. 2000 Aug;216(2):403-9
[
10924561.001
]
[Cites]
J Am Coll Surg. 1999 Jul;189(1):1-7
[
10401733.001
]
[Cites]
AJR Am J Roentgenol. 2005 May;184(5):1535-40
[
15855112.001
]
[Cites]
J Comput Assist Tomogr. 2005 Sep-Oct;29(5):582-7
[
16163023.001
]
[Cites]
Radiology. 1997 Mar;202(3):655-62
[
9051012.001
]
[Cites]
Radiology. 1995 May;195(2):353-7
[
7724752.001
]
[Cites]
Br J Radiol. 2004 Oct;77(922):821-30
[
15482993.001
]
[Cites]
Radiology. 1999 Jul;212(1):219-25
[
10405745.001
]
[Cites]
Radiology. 1995 Nov;197(2):381-5
[
7480681.001
]
[Cites]
Radiology. 2001 Jul;220(1):97-102
[
11425979.001
]
(PMID = 18677610.001).
[ISSN]
0288-2043
[Journal-full-title]
Radiation medicine
[ISO-abbreviation]
Radiat Med
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Contrast Media; JR13W81H44 / Iopamidol
48.
Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP:
Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
Neoplasia
; 2006 Apr;8(4):279-89
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant Wnt/beta-catenin signaling in
pancreatic
adenocarcinoma
.
The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced
pancreatic
adenocarcinoma
(n = 31).
Thus, Wnt/beta-catenin activation was observed in 65% of
pancreatic
adenocarcinomas, independently of beta-catenin gene mutations in most tumors.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Digestion. 1999 Nov-Dec;60(6):544-8
[
10545724.001
]
[Cites]
Gastroenterology. 2005 Jul;129(1):285-302
[
16012954.001
]
[Cites]
Bioessays. 1999 Dec;21(12):1021-30
[
10580987.001
]
[Cites]
Oncogene. 1999 Nov 18;18(48):6776-84
[
10597286.001
]
[Cites]
Science. 2000 Mar 3;287(5458):1606-9
[
10733430.001
]
[Cites]
J Med Invest. 2000 Feb;47(1-2):47-55
[
10740979.001
]
[Cites]
Development. 2001 Mar;128(6):871-81
[
11222142.001
]
[Cites]
Cancer Res. 2001 Apr 15;61(8):3245-9
[
11309273.001
]
[Cites]
Hepatology. 2001 May;33(5):1098-109
[
11343237.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):37-52
[
11467451.001
]
[Cites]
Mol Cell Biol. 2001 Sep;21(17):5857-68
[
11486025.001
]
[Cites]
Development. 2005 Nov;132(21):4663-74
[
16192304.001
]
[Cites]
Curr Opin Cell Biol. 2005 Oct;17(5):459-65
[
16099633.001
]
[Cites]
Cancer Lett. 2006 Feb 28;233(2):328-37
[
15893416.001
]
[Cites]
J Neurochem. 2001 Sep;78(6):1219-32
[
11579131.001
]
[Cites]
Am J Pathol. 2001 Nov;159(5):1619-27
[
11696422.001
]
[Cites]
Anticancer Res. 2001 Nov-Dec;21(6A):4127-34
[
11911306.001
]
[Cites]
Cancer Res. 2002 Apr 1;62(7):2064-71
[
11929826.001
]
[Cites]
Science. 2002 May 31;296(5573):1644-6
[
12040179.001
]
[Cites]
Anticancer Res. 2002 Jul-Aug;22(4):2015-27
[
12174879.001
]
[Cites]
J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32
[
12384795.001
]
[Cites]
Dev Dyn. 2002 Nov;225(3):260-70
[
12412008.001
]
[Cites]
Oncogene. 2002 Nov 28;21(54):8293-301
[
12447692.001
]
[Cites]
J Gastrointest Surg. 2002 Nov-Dec;6(6):838-43; discussion 844
[
12504222.001
]
[Cites]
Gastroenterology. 2003 Jan;124(1):202-16
[
12512043.001
]
[Cites]
J Pathol. 2003 Feb;199(2):185-90
[
12533831.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2003;43:199-231
[
12195027.001
]
[Cites]
Cancer Res. 2003 Feb 1;63(3):586-92
[
12566300.001
]
[Cites]
Cancer Biol Ther. 2002 Nov-Dec;1(6):621-5
[
12642683.001
]
[Cites]
Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11
[
12644979.001
]
[Cites]
Hepatology. 2003 Apr;37(4):824-32
[
12668975.001
]
[Cites]
Ann Surg Oncol. 2003 Apr;10(3):284-90
[
12679314.001
]
[Cites]
Cancer Lett. 2003 Apr 25;193(2):161-70
[
12706873.001
]
[Cites]
J Clin Invest. 2003 May;111(9):1287-95
[
12727920.001
]
[Cites]
J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221
[
12707770.001
]
[Cites]
Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24
[
12781368.001
]
[Cites]
Trends Cell Biol. 2003 Jun;13(6):328-35
[
12791299.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97
[
12849999.001
]
[Cites]
World J Surg. 2003 Oct;27(10):1075-84
[
12925907.001
]
[Cites]
Gene Expr. 2003;11(3-4):141-7
[
14686787.001
]
[Cites]
Gastroenterology. 2004 Apr;126(4):1134-46
[
15057752.001
]
[Cites]
J Cell Biol. 1993 Feb;120(3):757-66
[
8425900.001
]
[Cites]
Trends Genet. 1993 Sep;9(9):317-21
[
8236461.001
]
[Cites]
Oncogene. 1995 Jan 5;10(1):177-84
[
7824270.001
]
[Cites]
Development. 1995 Nov;121(11):3529-37
[
8582267.001
]
[Cites]
EMBO J. 1997 Jul 1;16(13):3797-804
[
9233789.001
]
[Cites]
Genes Dev. 1997 Dec 15;11(24):3286-305
[
9407023.001
]
[Cites]
Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8
[
9647782.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51
[
9671767.001
]
[Cites]
Science. 1998 Sep 4;281(5382):1509-12
[
9727977.001
]
[Cites]
Am J Pathol. 1999 Feb;154(2):325-9
[
10027390.001
]
[Cites]
Nature. 1999 Apr 1;398(6726):431-6
[
10201374.001
]
[Cites]
Int J Cancer. 1999 Aug 12;82(4):504-11
[
10404062.001
]
[Cites]
Semin Liver Dis. 1999;19(3):235-42
[
10518303.001
]
[Cites]
Oncol Rep. 1999 Nov-Dec;6(6):1253-6
[
10523691.001
]
[Cites]
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
[
15661684.001
]
[Cites]
J Hepatol. 2005 Jul;43(1):132-41
[
15893845.001
]
[Cites]
Adv Cancer Res. 2000;77:1-24
[
10549354.001
]
(PMID = 16756720.001).
[ISSN]
1476-5586
[Journal-full-title]
Neoplasia (New York, N.Y.)
[ISO-abbreviation]
Neoplasia
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NIDDK NIH HHS / DK / 1R01DK62277
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Wnt Proteins; 0 / beta Catenin
[Other-IDs]
NLM/ PMC1600679
49.
Koizumi K, Fujii T, Matsumoto A, Sugiyama R, Suzuki S, Sukegawa R, Ozawa K, Orii F, Taruishi M, Saitoh Y, Sotokawa M, Takada A:
[Synchronous double invasive ductal carcinomas of the pancreas with multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas].
Nihon Shokakibyo Gakkai Zasshi
; 2009 Jan;106(1):98-105
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Synchronous double invasive ductal carcinomas of the
pancreas
with multifocal branch duct intraductal papillary mucinous neoplasms of the
pancreas
].
CT scan revealed double tumors in
the pancreatic
head and body concomitant with multicystic lesions of the
pancreas
.
Final histological
diagnosis
was double invasive ductal carcinomas of the
pancreas
head and tail with multifocal branch duct intraductal papillary mucinous adenomas of the
pancreas
.
The present case suggests that entire
pancreas
might have malignant potential in patients with intraductal papillary mucinous neoplasms.
[MeSH-major]
Adenocarcinoma
, Mucinous / surgery. Carcinoma,
Pancreatic
Ductal / surgery. Carcinoma, Papillary / surgery. Neoplasms, Multiple Primary.
Pancreatic
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19122428.001).
[ISSN]
0446-6586
[Journal-full-title]
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
[ISO-abbreviation]
Nihon Shokakibyo Gakkai Zasshi
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
50.
Yango J, Pieters T, Coche E, Lambert M:
[Increased serum CA 19.9 in bronchiectasis].
Rev Mal Respir
; 2008 Jan;25(1):78-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Elévation
du
CA 19.9 sérique et bronchectasies.
INTRODUCTION: CA 19.9 is considered the most specific and sensitive serological marker of
pancreatic
adenocarcinoma
.
Exhaustive investigation and clinical evolution excluded a neoplastic digestive
disorder
but positron emission tomography revealed a distinct hypermetabolic focus in the area of the hilum of the right lung.
[MeSH-major]
Bronchiectasis /
diagnosis
. CA-19-9 Antigen / blood
[MeSH-minor]
Aged. Biomarkers / blood. Female. Haemophilus Infections /
diagnosis
. Haemophilus Infections / immunology. Haemophilus influenzae / immunology. Haemophilus influenzae / isolation & purification. Humans
Genetic Alliance.
consumer health - Bronchiectasis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18288056.001).
[ISSN]
0761-8425
[Journal-full-title]
Revue des maladies respiratoires
[ISO-abbreviation]
Rev Mal Respir
[Language]
fre
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
France
[Chemical-registry-number]
0 / Biomarkers; 0 / CA-19-9 Antigen
51.
Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP:
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Cancer Lett
; 2006 Feb 28;233(2):328-37
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The tyrosine kinase inhibitor imatinib fails to inhibit
pancreatic
cancer progression.
Pancreatic
cancers express KIT and PDGFRs.
Therefore, 26 patients with unresectable
pancreatic
cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily.
Pancreatic
adenocarcinoma
was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens.
In this small series of
pancreatic
cancer patients, treatment with imatinib was not associated with a significant control of cancer progression.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Pancreatic
Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
[MeSH-minor]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ secondary. Adult. Aged. Benzamides. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Quality of Life. Receptors, Platelet-Derived Growth Factor / metabolism. Surveys and Questionnaires. Survival Rate
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15893416.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
52.
Nichols MT, Russ PD, Chen YK:
Pancreatic imaging: current and emerging technologies.
Pancreas
; 2006 Oct;33(3):211-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
imaging: current and emerging technologies.
This review discusses the current imaging modalities for
the diagnosis
and staging of solid and cystic
pancreatic
lesions and for the assessment of acute and chronic pancreatitis, and the future role of emerging technologies in the management of
pancreatic
diseases.
Multidetector row spiral computed tomography is superior to conventional single-detector row spiral computed tomography in the detection and staging of
pancreatic
adenocarcinoma
.
Positron emission tomography-computed tomography fusion may improve the staging accuracy for
pancreatic
cancer.
Echo-enhanced ultrasound may have an emerging role in evaluating
pancreatic
masses.
Endoscopic ultrasound with fine needle aspiration for cytology is the single best method for
diagnosis
and staging of nonmetastatic
pancreatic
cancer with a high accuracy for determining tumor resectability.
Secretin-stimulated imaging techniques may eventually provide a noninvasive method of reliably assessing
pancreatic
exocrine function.
[MeSH-major]
Pancreatic
Diseases /
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
[MeSH-minor]
Acute Disease. Biopsy, Fine-Needle. Chronic Disease. Humans. Pancreatitis /
diagnosis
. Pancreatitis / pathology. Pancreatitis / radiography. Pancreatitis / ultrasonography. Positron-Emission Tomography. Tomography, X-Ray Computed / methods
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Diseases
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17003640.001).
[ISSN]
1536-4828
[Journal-full-title]
Pancreas
[ISO-abbreviation]
Pancreas
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
105
53.
Xu J, Liang Z, Hao S, Zhu L, Ashish M, Jin C, Fu D, Ni Q:
Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging.
Abdom Imaging
; 2009 Nov;34(6):759-66
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
adenocarcinoma
: dynamic 64-slice helical CT with perfusion imaging.
Thus, in lesions of the tissues of the
pancreas
, this offers to increase the accuracy of CT
diagnosis
.
In this study, our aim was to explore the perfusion characteristics of normal
pancreas
and
pancreatic
adenocarcinoma
.
METHODS: Dynamic 64-slice helical CT was conducted in 36 patients with non-
pancreatic
disease and in 40 patients with histopathologically proven
pancreatic
adenocarcinoma
.
RESULTS: There was no significant difference noted between the distribution of BF, BV, and PS values in different regions of the
pancreas
, namely the head, neck, body, and tail (P > 0.05).
The BF, BV, and PS of normal
pancreas
were recorded as 135.24 +/- 48.36 ml min(-1) 100 g(-1), 200.55 +/- 54.96 ml 100 g(-1), and 49.75 +/- 24.27 ml min(-1) 100 g(-1), respectively.
BF, BV, and PS values of the tumor tissue of
pancreatic
adenocarcinoma
decreased significantly compared to normal
pancreas
(P < 0.05).
CONCLUSIONS: Normal
pancreas
appears homogenous on perfusion CT.
A significant decrease of BF, BV, and PS was observed in
pancreatic
adenocarcinoma
.
Dynamic 64-slice helical CT with perfusion imaging should be considered a potential modality to increase the accuracy of CT
diagnosis
for
pancreatic
adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
/ radiography.
Pancreatic
Neoplasms / radiography. Tomography, Spiral Computed / methods
[MeSH-minor]
Case-Control Studies. Contrast Media. Female. Humans. Iohexol. Male. Middle Aged.
Pancreas
/ blood supply.
Pancreas
/ radiography. Pancreaticoduodenectomy. Prospective Studies
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19672566.001).
[ISSN]
1432-0509
[Journal-full-title]
Abdominal imaging
[ISO-abbreviation]
Abdom Imaging
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Contrast Media; 4419T9MX03 / Iohexol
54.
Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA:
Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
Clin Cancer Res
; 2010 Dec 1;16(23):5712-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Noninvasive radiofrequency field destruction of
pancreatic
adenocarcinoma
xenografts treated with targeted gold nanoparticles.
PURPOSE:
Pancreatic
carcinoma is one of the deadliest cancers with few effective treatments.
We used the astounding heating rates of AuNPs in nonionizing radiofrequency (RF) radiation to investigate human
pancreatic
xenograft destruction in a murine model.
EXPERIMENTAL DESIGN: Weekly, Panc-1 and Capan-1 human
pancreatic
carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody-conjugated AuNPs, respectively.
Cetuximab- and PAM4-conjugated AuNPs demonstrated RF field-induced destruction of Panc-1 and Capan-1
pancreatic
carcinoma xenografts after 6 weeks of weekly treatment (P = 0.004 and P = 0.035, respectively).
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CETUXIMAB
.
Hazardous Substances Data Bank.
GOLD, ELEMENTAL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
©2010 AACR.
[Cites]
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S
[
14506191.001
]
[Cites]
J Biomed Opt. 2000 Oct;5(4):383-90
[
11092426.001
]
[Cites]
Cancer Res. 1979 Jun;39(6 Pt 2):2245-51
[
445424.001
]
[Cites]
Ann Clin Lab Sci. 1981 Sep-Oct;11(5):386-91
[
7036839.001
]
[Cites]
J Urol. 1989 Nov;142(5):1364-8
[
2810532.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9
[
2106751.001
]
[Cites]
Am J Pathol. 1996 Oct;149(4):1271-86
[
8863675.001
]
[Cites]
J Invest Dermatol. 1998 May;110(5):746-51
[
9579539.001
]
[Cites]
Lasers Surg Med. 1998;23(4):194-203
[
9829430.001
]
[Cites]
Langmuir. 2005 Nov 8;21(23):10644-54
[
16262332.001
]
[Cites]
Hepatology. 2006 Feb;43(2 Suppl 1):S45-53
[
16447274.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6
[
17135351.001
]
[Cites]
J Clin Oncol. 2007 Nov 20;25(33):5225-32
[
18024868.001
]
[Cites]
Cancer. 2007 Dec 15;110(12):2654-65
[
17960610.001
]
[Cites]
Clin Cancer Res. 2007 Dec 15;13(24):7380-7
[
18094420.001
]
[Cites]
Nat Protoc. 2008;3(2):314-20
[
18274533.001
]
[Cites]
Biophys J. 2008 May 15;94(10):3790-7
[
18234813.001
]
[Cites]
Cancer Res. 2008 Jun 15;68(12):4819-26
[
18559529.001
]
[Cites]
Surgery. 2008 Aug;144(2):125-32
[
18656617.001
]
[Cites]
J Exp Ther Oncol. 2008;7(4):313-26
[
19227011.001
]
[Cites]
Ann Surg Oncol. 2009 Apr;16(4):836-47
[
19194760.001
]
[Cites]
World J Gastroenterol. 2009 Jun 28;15(24):2995-3002
[
19554652.001
]
[Cites]
Small. 2009 Jul;5(13):1553-61
[
19326357.001
]
[Cites]
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
[
19474385.001
]
[Cites]
Int J Radiat Biol. 2009 Dec;85(12):1114-25
[
19995237.001
]
[Cites]
Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45
[
19909777.001
]
[Cites]
J Surg Oncol. 2010 Mar 15;101(4):315-20
[
20187063.001
]
[Cites]
Toxicol Appl Pharmacol. 2010 May 15;245(1):116-23
[
20193702.001
]
[Cites]
Cancer. 2010 Jul 1;116(13):3285-93
[
20564640.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54
[
14597719.001
]
(PMID = 21138869.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA151668-02; United States / NCI NIH HHS / CA / T32 CA09599; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / U54 CA151668; United States / NCI NIH HHS / CA / T32 CA009599-21; United States / NCI NIH HHS / CA / U54 CA143837; United States / NCI NIH HHS / CA / U54CA143837; United States / NCI NIH HHS / CA / U54 CA151668-02; United States / NCI NIH HHS / CA / T32 CA009599
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 7440-57-5 / Gold; PQX0D8J21J / Cetuximab
[Other-IDs]
NLM/ NIHMS245136; NLM/ PMC3057504
55.
Chen B, Hu S, Wang L, Wachtel MS, Frezza EE:
Extended pancreatectomy with en bloc resection of the celiac axis for locally advanced cancer of pancreatic body and tail.
Hepatogastroenterology
; 2008 Nov-Dec;55(88):2252-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extended pancreatectomy with en bloc resection of the celiac axis for locally advanced cancer of
pancreatic
body and tail.
At present, most surgeons will not resect the
pancreas
if there is involvement of celiac axis.
We present the case of a 67 yo male with
pancreatic
body and tail cancer invading the celiac axis treated by extended pancreatectomy, splenectomy, partial resection of proximal portion of jejunum and transverse colon, and left adrenalectomy with en bloc resection of celiac axis.
The case demonstrates that a procedure that may offer cure of locally advanced
pancreas
cancer may also completely resolve abdominal pain.
[MeSH-major]
Adenocarcinoma
/ pathology. Pancreatectomy / methods.
Pancreatic
Neoplasms / surgery
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19260516.001).
[ISSN]
0172-6390
[Journal-full-title]
Hepato-gastroenterology
[ISO-abbreviation]
Hepatogastroenterology
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Greece
56.
Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Drebber U, Hoelscher AH, Schneider PM:
Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.
World J Gastroenterol
; 2006 Jan 21;12(3):437-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the
pancreas
compared with cancer of the papilla of Vater.
AIM: We examined quantitative mRNA expression of growth factor receptors (c-erbB-1, c-erbB-2) and the anti-apoptosis gene survivin known to be regulated in
pancreatic
adenocarcinomas and compared the expression pattern with that in carcinomas of the papilla of Vater.
METHODS: Quantitative real-time reverse transcriptase-PCR (QRT-PCR, Taqman) was performed to analyze mRNA expression levels of c-erbB-1, c-erbB-2 and survivin in normal and corresponding tumor samples of 31
pancreatic
adenocarcinomas and 8 cancers of the papilla of Vater.
RESULTS: The overall median mRNA expression of survivin was significantly increased in both
adenocarcinoma of
the
pancreas
(P<0.01) and papilla of Vater (P<0.008) compared with uninvolved normal control tissue.
In
pancreatic
cancer, expression of c-erbB-1 was significantly decreased compared with the normal
pancreatic
tissue (P<0.03), whereas in the cancer of the papilla of Vater expression of c-erbB-2 was significantly downregulated (P<0.05) compared with the paired normal samples.
CONCLUSION: The common anti-apoptosis gene survivin is overexpressed both in the cancer of the papilla of Vater and
pancreas
.
In contrast, the growth factor receptor genes c-erbB-1 and c-erbB-2 are differentially regulated in both tumor entities adding further evidence that
pancreatic
cancer is biologically different from the cancer of papilla of Vater.
[MeSH-major]
Adenocarcinoma
/ metabolism. Ampulla of Vater. Common Bile Duct Neoplasms / metabolism.
Pancreatic
Neoplasms / metabolism. RNA, Messenger / genetics. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 1999 Dec;230(6):767-74; discussion 774-5
[
10615931.001
]
[Cites]
Oncol Rep. 2005 Jun;13(6):1241-6
[
15870949.001
]
[Cites]
Am J Pathol. 2000 Feb;156(2):393-8
[
10666367.001
]
[Cites]
Gut. 2000 May;46(5):645-50
[
10764707.001
]
[Cites]
Int J Oncol. 2000 Jul;17(1):103-6
[
10853025.001
]
[Cites]
Int J Cancer. 2000 Nov 20;89(6):469-74
[
11102889.001
]
[Cites]
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
[
11307091.001
]
[Cites]
Lab Invest. 1999 Nov;79(11):1327-33
[
10576203.001
]
[Cites]
J Clin Oncol. 2001 May 1;19(9):2422-32
[
11331321.001
]
[Cites]
Ann Surg Oncol. 2001 May;8(4):305-10
[
11352303.001
]
[Cites]
Mod Pathol. 2001 Jul;14(7):677-85
[
11455000.001
]
[Cites]
Cancer. 2001 Jul 15;92(2):271-8
[
11466679.001
]
[Cites]
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
[
11577478.001
]
[Cites]
Am J Clin Oncol. 2001 Oct;24(5):496-9
[
11586103.001
]
[Cites]
Surg Oncol. 2001 Jul-Aug;10(1-2):1-23
[
11719025.001
]
[Cites]
Ann Surg. 2001 Dec;234(6):758-68
[
11729382.001
]
[Cites]
Br J Cancer. 2002 Mar 18;86(6):886-92
[
11953819.001
]
[Cites]
Med Electron Microsc. 2001 Dec;34(4):207-12
[
11956993.001
]
[Cites]
J Hepatobiliary Pancreat Surg. 2002;9(1):1-11
[
12021893.001
]
[Cites]
Stat Methods Med Res. 2002 Jun;11(3):247-74
[
12094758.001
]
[Cites]
Anticancer Res. 2002 May-Jun;22(3):1593-7
[
12168842.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
Oncogene. 2003 Nov 24;22(53):8581-9
[
14634620.001
]
[Cites]
Pediatr Dev Pathol. 2003 Sep-Oct;6(5):392-7
[
14708732.001
]
[Cites]
J Immunol. 2004 Mar 15;172(6):3922-9
[
15004200.001
]
[Cites]
Hepatogastroenterology. 2004 Mar-Apr;51(56):334-7
[
15086152.001
]
[Cites]
Pancreas. 2004 Jul;29(1):e1-8
[
15211117.001
]
[Cites]
Surgery. 2004 Aug;136(2):443-8
[
15300213.001
]
[Cites]
World J Gastroenterol. 2004 Sep 15;10(18):2759-61
[
15309737.001
]
[Cites]
Cancer Chemother Rep. 1966 Mar;50(3):163-70
[
5910392.001
]
[Cites]
Radiology. 1973 Nov;109(2):297-303
[
4742316.001
]
[Cites]
Ann R Coll Surg Engl. 1985 May;67(3):139-43
[
2988399.001
]
[Cites]
Science. 1986 Jun 27;232(4758):1644-6
[
3012781.001
]
[Cites]
Br J Surg. 1987 Oct;74(10):957-61
[
3664230.001
]
[Cites]
Cell. 1990 Apr 20;61(2):203-12
[
2158859.001
]
[Cites]
Mol Cell Biol. 1990 Jun;10(6):2973-82
[
2342466.001
]
[Cites]
J Pathol. 1990 Jul;161(3):195-200
[
2202801.001
]
[Cites]
J Pathol. 1991 Feb;163(2):111-6
[
1707959.001
]
[Cites]
Prog Growth Factor Res. 1992;4(1):1-24
[
1355372.001
]
[Cites]
Surg Gynecol Obstet. 1993 Jan;176(1):33-8
[
8093983.001
]
[Cites]
Anticancer Res. 1993 May-Jun;13(3):565-9
[
8317885.001
]
[Cites]
Oncology. 1993 Nov-Dec;50(6):418-25
[
7901825.001
]
[Cites]
Int J Cancer. 1994 Jun 15;57(6):786-92
[
8206673.001
]
[Cites]
Cell. 1994 Jul 15;78(1):5-8
[
8033211.001
]
[Cites]
Br J Surg. 1995 Jan;82(1):111-5
[
7881926.001
]
[Cites]
Oncology. 1995 Sep-Oct;52(5):392-6
[
7637957.001
]
[Cites]
Int J Pancreatol. 1995 Feb;17(1):15-21
[
8568330.001
]
[Cites]
J Urol. 1996 Jan;155(1):321-6
[
7490879.001
]
[Cites]
Genome Res. 1996 Oct;6(10):986-94
[
8908518.001
]
[Cites]
Genome Res. 1996 Oct;6(10):995-1001
[
8908519.001
]
[Cites]
Eur J Surg Oncol. 1997 Feb;23(1):30-5
[
9066744.001
]
[Cites]
Nat Med. 1997 Aug;3(8):917-21
[
9256286.001
]
[Cites]
Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60
[
9339931.001
]
[Cites]
Anticancer Res. 1997 Sep-Oct;17(5B):3841-7
[
9427790.001
]
[Cites]
Nature. 1998 Dec 10;396(6711):580-4
[
9859993.001
]
[Cites]
J Am Coll Surg. 1999 Jul;189(1):1-7
[
10401733.001
]
[Cites]
Am J Gastroenterol. 2000 Jan;95(1):17-31
[
10638554.001
]
(PMID = 16489645.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
[Other-IDs]
NLM/ PMC4066064
57.
Wada K, Takada T, Amano H, Yoshida M, Miura F, Toyota N, Kato K, Isaka T, Nagashima I:
[Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe].
Nihon Geka Gakkai Zasshi
; 2006 Jul;107(4):187-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Trend in the management of
pancreatic
adenocarcinoma
--Japan vs. US and Europe].
Pancreatic
adenocarcinoma
remains to have poor prognosis.
Current rationale for the treatment of
pancreatic
adenocarcinoma
in the US and European countries consists of the following formula:.
The efficacy of "Japanese" radical resection including vascular resection or
pancreatic
nerve plexus resection should be evaluated, although the devise of novel diagnostic modalities and more effective adjuvant or neoadjuvant therapy are crucial to improve prognosis of this disease.
[MeSH-major]
Adenocarcinoma
/ therapy.
Pancreatic
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16878412.001).
[ISSN]
0301-4894
[Journal-full-title]
Nihon Geka Gakkai zasshi
[ISO-abbreviation]
Nihon Geka Gakkai Zasshi
[Language]
jpn
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Japan
[Number-of-references]
21
58.
Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM:
Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.
J Surg Oncol
; 2009 Jul 1;100(1):8-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pancreatic
adenocarcinoma
in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.
BACKGROUND: There is a dearth of data in a younger population of patients with
pancreatic
ductal
adenocarcinoma
(PAC) regarding epidemiology, genetics, prognosis, and outcome.
RESULTS: One hundred thirty-six cases of PAC, age <or=45 years at
diagnosis
, were identified.
[MeSH-major]
Adenocarcinoma
/ mortality.
Pancreatic
Neoplasms / mortality
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 Wiley-Liss, Inc.
(PMID = 19384918.001).
[ISSN]
1096-9098
[Journal-full-title]
Journal of surgical oncology
[ISO-abbreviation]
J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
59.
Furukawa H, Uesaka K, Boku N:
Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography.
Arch Surg
; 2008 Mar;143(3):275-80; discussion 281
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment decision making in
pancreatic
adenocarcinoma
: multidisciplinary team discussion with multidetector-row computed tomography.
HYPOTHESIS: Multidetector-row computed tomography reduces the frequency of use of other imaging methods in patients with
pancreatic
carcinoma.
PATIENTS: Two hundred thirteen patients with
pancreatic
carcinoma.
MAIN OUTCOME MEASURE: Multidetector-row computed tomography was initially performed in patients with newly diagnosed
pancreatic
carcinoma.
RESULTS: Of the 213
pancreatic
carcinomas, 79 (37%) were classified as probably resectable, 127 (60%) as certainly unresectable, and 7 (3%) as probably unresectable.
CONCLUSIONS: Multidetector-row computed tomography provides reliable information for staging
pancreatic
carcinoma.
Multidisciplinary team discussion along with use of this noninvasive technique simplifies the diagnostic strategy for
pancreatic
carcinoma and decreases the need for invasive staging methods.
[MeSH-major]
Carcinoma,
Pancreatic
Ductal / radiography. Decision Making.
Pancreatic
Neoplasms / radiography.
Pancreatic
Neoplasms / surgery. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18347275.001).
[ISSN]
1538-3644
[Journal-full-title]
Archives of surgery (Chicago, Ill. : 1960)
[ISO-abbreviation]
Arch Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
60.
Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD:
Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells.
PLoS One
; 2007 Apr 25;2(4):e392
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human
pancreatic
cancer cells.
Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including
pancreatic
adenocarcinoma
.
PRINCIPLE FINDINGS: Both Sulf proteins were upregulated in human
pancreatic
adenocarcinoma
tumors and were broadly expressed in human
pancreatic
adenocarcinoma
cell lines.
Three of four
pancreatic
adenocarcinoma
cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling.
Exposure of these
pancreatic
adenocarcinoma
cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth.
CONCLUSIONS/SIGNIFICANCE: We have identified the Sulfs as potentiators of autocrine Wnt signaling in
pancreatic
cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells.
Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of
pancreatic
cancer.
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2001 Oct 15;61(20):7388-93
[
11606367.001
]
[Cites]
Oncogene. 2004 Feb 19;23(7):1439-47
[
14973553.001
]
[Cites]
Genes Cells. 2002 Feb;7(2):173-85
[
11895481.001
]
[Cites]
J Biol Chem. 2002 Dec 20;277(51):49175-85
[
12368295.001
]
[Cites]
Am J Pathol. 2003 Apr;162(4):1151-62
[
12651607.001
]
[Cites]
Ann Surg Oncol. 2003 Apr;10(3):284-90
[
12679314.001
]
[Cites]
J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34
[
12775774.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7
[
15067127.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5
[
15240889.001
]
[Cites]
Cancer Res. 2004 Jul 15;64(14):4717-20
[
15256437.001
]
[Cites]
Oncogene. 2004 Aug 12;23(36):6170-4
[
15208662.001
]
[Cites]
J Neurosci Res. 2004 Sep 1;77(5):653-61
[
15352211.001
]
[Cites]
Cell. 1982 Nov;31(1):99-109
[
6297757.001
]
[Cites]
Cancer Cell. 2004 Nov;6(5):497-506
[
15542433.001
]
[Cites]
Development. 2004 Dec;131(24):6009-21
[
15563523.001
]
[Cites]
Cancer Res. 2005 Feb 1;65(3):743-8
[
15705870.001
]
[Cites]
Nature. 2005 Apr 14;434(7035):843-50
[
15829953.001
]
[Cites]
Mol Ther. 2005 May;11(5):724-33
[
15851011.001
]
[Cites]
Mol Cancer. 2005;4(1):14
[
15817123.001
]
[Cites]
Cancer Cell. 2005 May;7(5):469-83
[
15894267.001
]
[Cites]
Nat Rev Cancer. 2005 Jun;5(6):459-67
[
15905855.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6245-54
[
16024626.001
]
[Cites]
J Biol Chem. 2005 Dec 2;280(48):40066-73
[
16192265.001
]
[Cites]
Neoplasia. 2005 Nov;7(11):1001-10
[
16331886.001
]
[Cites]
Dev Dyn. 2006 Mar;235(3):681-90
[
16425220.001
]
[Cites]
J Biol Chem. 2006 Feb 24;281(8):4969-76
[
16377625.001
]
[Cites]
BMC Biochem. 2006;7:2
[
16417632.001
]
[Cites]
Neoplasia. 2006 Apr;8(4):279-89
[
16756720.001
]
[Cites]
Gastroenterology. 2006 Jun;130(7):2130-44
[
16762634.001
]
[Cites]
Cancer Res. 2006 Jun 15;66(12):6025-32
[
16778174.001
]
[Cites]
Biochem J. 2006 Nov 15;400(1):63-73
[
16901266.001
]
[Cites]
Mol Cell Biol. 2007 Jan;27(2):678-88
[
17116694.001
]
[Cites]
Breast Cancer Res. 2006;8(5):R56
[
17014703.001
]
[Cites]
Nat Genet. 2000 Jul;25(3):329-32
[
10888884.001
]
[Cites]
J Clin Invest. 2001 Jul;108(2):169-73
[
11457867.001
]
[Cites]
J Clin Invest. 2001 Aug;108(3):357-61
[
11489926.001
]
[Cites]
J Biol Chem. 2001 Aug 17;276(33):30744-52
[
11406624.001
]
[Cites]
Science. 2001 Aug 31;293(5535):1663-6
[
11533491.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jun 20;306(1):293-7
[
12788103.001
]
[Cites]
J Biol Chem. 2003 Jun 20;278(25):23107-17
[
12686563.001
]
[Cites]
J Cell Biol. 2003 Jul 21;162(2):341-51
[
12860968.001
]
[Cites]
J Virol. 2003 Aug;77(16):8957-61
[
12885912.001
]
[Cites]
Nature. 2003 Oct 23;425(6960):846-51
[
14520411.001
]
[Cites]
Nature. 2003 Oct 23;425(6960):851-6
[
14520413.001
]
[Cites]
Gene Expr. 2003;11(3-4):141-7
[
14686787.001
]
[Cites]
Gastroenterology. 2004 Jan;126(1):231-48
[
14699503.001
]
[Cites]
Nat Rev Cancer. 2003 Dec;3(12):903-11
[
14737121.001
]
[Cites]
J Biol Chem. 2004 Feb 13;279(7):5604-11
[
14645250.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
[
11707567.001
]
(PMID = 17460759.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / R01 HL075602; United States / NIGMS NIH HHS / GM / GM57411; United States / NIGMS NIH HHS / GM / R01 GM057411; United States / NCI NIH HHS / CA / R21 CA122025; United States / NCI NIH HHS / CA / R01 CA112537; United States / NHLBI NIH HHS / HL / HL075602; United States / NCI NIH HHS / CA / CA122025; United States / NCI NIH HHS / CA / CA112537
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Wnt Proteins; EC 3.1.6.- / Sulfatases
[Other-IDs]
NLM/ PMC1849966
[General-notes]
NLM/ Original DateCompleted: 20070803
61.
Buchholz M, Braun M, Heidenblut A, Kestler HA, Klöppel G, Schmiegel W, Hahn SA, Lüttges J, Gress TM:
Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions.
Oncogene
; 2005 Oct 6;24(44):6626-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transcriptome analysis of microdissected
pancreatic
intraepithelial neoplastic lesions.
Pancreatic
ductal
adenocarcinoma
(PDAC) carries the most dismal prognosis of all solid tumours.
Putative precursor lesions, termed
pancreatic
intraepithelial neoplasia (PanIN), are classified into three different grades (PanIN-1 through -3) based on the degree of cellular atypia they display.
We have conducted large-scale expression profiling analyses of microdissected cells from normal
pancreatic
ducts, PanINs of different grades and PDACs using whole-genome oligonucleotide microarrays.
Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early
diagnosis
of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the
pancreas
.
[MeSH-major]
Carcinoma in Situ / genetics.
Pancreatic
Neoplasms / genetics. RNA, Messenger / genetics
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16103885.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA Primers; 0 / RNA, Messenger
62.
Angst E, Sibold S, Tiffon C, Weimann R, Gloor B, Candinas D, Stroka D:
Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer.
Br J Cancer
; 2006 Aug 7;95(3):307-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in
pancreatic
cancer.
Pancreatic
ductal
adenocarcinoma
, called
pancreatic
cancer, is a highly aggressive cancer that is characterised by its avascular structure, which results in a severe hypoxic environment.
In this study, we investigated whether NDRG1 is upregulated in these tumours, thus providing a novel marker for malignant cells in the
pancreas
.
By immunohistochemistry, we observed that NDRG1 was highly expressed in well-differentiated cells of
pancreatic
cancer, whereas the poorly differentiated tumour cells were negative.
In addition, hyperplastic islets and ducts of nonquiescent
pancreatic
tissue were positive.
To further explore its selective expression in tumours, two well-established
pancreatic
cancer cell lines of unequal differentiation status were exposed to 2% oxygen.
Taken together, our data suggest that NDRG1 will not serve as a reliable marker of tumour cells in the
pancreas
, but may serve as a marker of differentiation.
[MeSH-major]
Carcinoma,
Pancreatic
Ductal / genetics. Cell Cycle Proteins / genetics. Cell Differentiation. Cell Hypoxia. Gene Expression Regulation, Neoplastic / genetics. Intracellular Signaling Peptides and Proteins / genetics.
Pancreatic
Neoplasms / genetics
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lab Invest. 1997 Jul;77(1):85-92
[
9251681.001
]
[Cites]
J Cell Biochem. 2006 Apr 1;97(5):1025-35
[
16288478.001
]
[Cites]
Cancer Res. 1998 May 15;58(10):2182-9
[
9605764.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92
[
9653127.001
]
[Cites]
Cancer Res. 1998 Oct 1;58(19):4439-44
[
9766676.001
]
[Cites]
Biochim Biophys Acta. 1999 Jul 8;1450(3):364-73
[
10395947.001
]
[Cites]
Cancer Res. 2004 Nov 1;64(21):7655-60
[
15520163.001
]
[Cites]
Surgery. 2005 Feb;137(2):192-9
[
15674201.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2768-73
[
15814659.001
]
[Cites]
Clin Cancer Res. 1999 Nov;5(11):3711-21
[
10589791.001
]
[Cites]
Cancer Res. 2000 Jan 1;60(1):38-41
[
10646848.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):749-55
[
10676663.001
]
[Cites]
Biochem Biophys Res Commun. 2000 Sep 16;276(1):321-8
[
11006124.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22
[
11072146.001
]
[Cites]
Science. 2001 Apr 20;292(5516):464-8
[
11292862.001
]
[Cites]
FASEB J. 2001 May;15(7):1312-4
[
11344124.001
]
[Cites]
Surg Oncol. 2000 Nov;9(3):95-101
[
11356337.001
]
[Cites]
Clin Cancer Res. 2001 Jul;7(7):2145-51
[
11448934.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Nov 9;288(4):882-6
[
11688991.001
]
[Cites]
Mol Carcinog. 2001 Oct;32(2):100-9
[
11746822.001
]
[Cites]
Mol Cell Biol. 2002 Mar;22(6):1734-41
[
11865053.001
]
[Cites]
Med Oncol. 2001;18(4):243-59
[
11918451.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-6
[
12011461.001
]
[Cites]
Cell Biol Toxicol. 2002;18(2):87-96
[
12046693.001
]
[Cites]
Br J Cancer. 2002 Jun 17;86(12):1914-9
[
12085186.001
]
[Cites]
Environ Health Perspect. 2002 Oct;110 Suppl 5:783-8
[
12429530.001
]
[Cites]
Histochem Cell Biol. 2002 Nov;118(5):399-408
[
12432451.001
]
[Cites]
Pancreas. 2003 Jan;26(1):56-64
[
12499918.001
]
[Cites]
Cancer Res. 2003 Apr 1;63(7):1441-4
[
12670886.001
]
[Cites]
Cancer Res. 2003 Apr 15;63(8):1731-6
[
12702552.001
]
[Cites]
Oncogene. 2003 May 22;22(21):3213-20
[
12761491.001
]
[Cites]
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):222-7
[
14734473.001
]
[Cites]
Anticancer Res. 2003 Nov-Dec;23(6C):4721-7
[
14981919.001
]
[Cites]
J Surg Res. 2004 Aug;120(2):295-303
[
15234226.001
]
[Cites]
Mol Cancer. 2003 Jan 22;2:12
[
12605718.001
]
[Cites]
Oncogene. 2004 Jul 22;23(33):5675-81
[
15184886.001
]
[Cites]
Cancer Res. 2004 Aug 15;64(16):5876-81
[
15313932.001
]
[Cites]
Aerosp Med. 1973 Jun;44(6):636-8
[
4708612.001
]
[Cites]
Am J Surg. 1983 Jun;145(6):813-8
[
6305226.001
]
[Cites]
J Biol Chem. 1993 Oct 15;268(29):21513-8
[
8408001.001
]
[Cites]
Blood. 1993 Dec 15;82(12):3610-5
[
8260699.001
]
[Cites]
Cancer Res. 1996 Oct 1;56(19):4509-15
[
8813149.001
]
[Cites]
J Biol Chem. 1996 Nov 22;271(47):29659-65
[
8939898.001
]
[Cites]
Cancer Res. 1996 Dec 15;56(24):5754-7
[
8971187.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3296-302
[
15867226.001
]
[Cites]
Clin Cancer Res. 2005 Oct 15;11(20):7220-5
[
16243791.001
]
[Cites]
J Biol Chem. 1997 Sep 5;272(36):22642-7
[
9278421.001
]
(PMID = 16832411.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / RNA, Messenger
[Other-IDs]
NLM/ PMC2360652
63.
Song SJ, Lee JM, Kim YJ, Kim SH, Lee JY, Han JK, Choi BI:
Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis.
J Magn Reson Imaging
; 2007 Jul;26(1):86-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differentiation of intraductal papillary mucinous neoplasms from other
pancreatic
cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis.
PURPOSE: To compare the diagnostic performance of multirow-detector computed tomography (MDCT) and magnetic resonance imaging (MRI) in the differentiation of intraductal papillary mucinous neoplasms (IPMNs) from other
pancreatic
cystic masses.
MATERIALS AND METHODS: A total of 53 patients with pathologically proven
pancreatic
cystic lesions who had undergone MDCT and MRI were included in this study.
CONCLUSION:
Pancreatic
MRI shows better diagnostic performance than MDCT for differentiating IPMNs from other cystic lesions of the
pancreas
.
[MeSH-major]
Adenocarcinoma
, Mucinous /
diagnosis
.
Adenocarcinoma
, Papillary /
diagnosis
. Magnetic Resonance Imaging / methods.
Pancreatic
Cyst /
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
. Tomography, X-Ray Computed / methods
[MeSH-minor]
Aged.
Diagnosis
, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. ROC Curve
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2007 Wiley-Liss, Inc.
(PMID = 17659551.001).
[ISSN]
1053-1807
[Journal-full-title]
Journal of magnetic resonance imaging : JMRI
[ISO-abbreviation]
J Magn Reson Imaging
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
64.
Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M:
MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.
Ann Surg Oncol
; 2010 Dec;17(12):3120-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MicroRNA-203 expression as a new prognostic marker of
pancreatic
adenocarcinoma
.
BACKGROUND: Detection of aberrant microRNA (miR) expression may contribute to
diagnosis
and prognosis of various cancers.
The aim of this study is to evaluate the correlation between miR-203 expression and prognosis of patients with
pancreatic
adenocarcinoma
after curative resection.
METHODS: A total of 113 formalin-fixed paraffin-embedded tissue samples of
pancreatic
adenocarcinoma
, 20 samples of chronic pancreatitis, and 8 samples of normal
pancreas
were obtained.
RESULTS: miR-203 was overexpressed in
pancreatic
adenocarcinoma
samples compared with chronic pancreatitis (P < 0.001) and normal
pancreas
(P = 0.001) samples.
An association between miR-203 expression and clinicopathological factors of
pancreatic
adenocarcinoma
was not observed.
CONCLUSIONS: miR-203 expression is a new prognostic marker in
pancreatic
adenocarcinoma
patients.
[MeSH-major]
Adenocarcinoma
/ genetics. Biomarkers, Tumor / genetics. MicroRNAs / genetics.
Pancreatic
Neoplasms / genetics. Pancreatitis, Chronic / genetics
[MeSH-minor]
Adenocarcinoma
, Mucinous / genetics.
Adenocarcinoma
, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma,
Pancreatic
Ductal / genetics. Carcinoma,
Pancreatic
Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging.
Pancreas
/ metabolism.
Pancreas
/ pathology. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20652642.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MIRN203 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger
65.
Sanchez SE, Trevino JG:
Current adjuvant and targeted therapies for pancreatic adenocarcinoma.
Curr Med Chem
; 2008;15(17):1674-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Current adjuvant and targeted therapies for
pancreatic
adenocarcinoma
.
Pancreatic
cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year.
Gemcitabine is currently considered to be the standard of care for the treatment of advanced
pancreatic
cancer.
In this paper we present an overview of the current treatment options for the different presenting stages of
pancreatic
cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Adjuvants, Pharmaceutic / therapeutic use.
Pancreatic
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18673217.001).
[ISSN]
0929-8673
[Journal-full-title]
Current medicinal chemistry
[ISO-abbreviation]
Curr. Med. Chem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Adjuvants, Pharmaceutic
[Number-of-references]
76
66.
Wong JC, Lu DS:
Staging of pancreatic adenocarcinoma by imaging studies.
Clin Gastroenterol Hepatol
; 2008 Dec;6(12):1301-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Staging of
pancreatic
adenocarcinoma
by imaging studies.
Imaging studies play a crucial role in
the diagnosis
and management of patients with
pancreatic
adenocarcinoma
.
Computed tomography (CT) is the most widely available and best-validated modality for imaging patients with
pancreatic
adenocarcinoma
.
To maximize the diagnostic efficacy of CT, use of a
pancreas
protocol is mandatory.
The sensitivity of CT for
diagnosis
of
pancreatic
adenocarcinoma
(89%-97%) and its positive predictive value for predicting unresectability (89%-100%) are high.
Magnetic resonance imaging has not been shown to perform better than CT for
the diagnosis
and staging of
pancreatic
adenocarcinoma
, but can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that cannot be fully characterized by CT.
Ultrasound is often the first study obtained in patients with obstructive jaundice or unexplained abdominal pain, but its utility for
diagnosis
and staging of patients with
pancreatic
adenocarcinoma
is limited.
Positron emission tomography/CT combines the functional information provided by positron emission tomography with the anatomic information provided by CT and is a promising modality for imaging of patients with
pancreatic
adenocarcinoma
, but its utility has not been established.
Endoscopic ultrasound is generally considered superior to CT for
the diagnosis
and local staging of
pancreatic
cancer, but is limited by availability and inability to assess for distant metastases.
[MeSH-major]
Adenocarcinoma
/
diagnosis
.
Adenocarcinoma
/ pathology.
Pancreas
/ radiography.
Pancreas
/ ultrasonography.
Pancreatic
Neoplasms /
diagnosis
.
Pancreatic
Neoplasms / pathology. Severity of Illness Index
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18948228.001).
[ISSN]
1542-7714
[Journal-full-title]
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
[ISO-abbreviation]
Clin. Gastroenterol. Hepatol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
42
67.
Naito Y, Kinoshita H, Okabe Y, Arikawa S, Higaki K, Morimitsu Y, Yamasaki F, Suda K, Yasumoto M, Kusano H, Nakashima O, Yano H:
Pathomorphologic study of undifferentiated carcinoma in seven cases: relationship between tumor and pancreatic duct epithelium.
J Hepatobiliary Pancreat Surg
; 2009;16(4):478-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pathomorphologic study of undifferentiated carcinoma in seven cases: relationship between tumor and
pancreatic
duct epithelium.
BACKGROUND/PURPOSE: By the time undifferentiated carcinoma is detected, it has formed a large mass, and it is reportedly difficult to pathologically observe its relationship with
the pancreatic
duct.
In this study, we examined
the pancreatic
ducts of seven patients of surgical samples, and pathomorphologically investigated the relationship between the adenocarcinomatous and sarcomatous components and the pattern of tumor extension.
In addition, we evaluated the usefulness of
pancreatic
juice cytology by comparison with the findings of the main
pancreatic
duct (MPD).
METHODS: Seven primary undifferentiated carcinomas of the
pancreas
(from three male and four female patients with a mean age of 59 years) were analyzed.
Pancreatic
juice cytology was performed and evaluated in two patients.
In one of these three, the tumor presented intraductal growth in the MPD, and preoperative
pancreatic
juice cytology revealed atypical cells with osteoclast-like giant cells.
(1) invasion and expansive growth during the sarcomatous transformation
of adenocarcinoma
, and (2) intraductal extension.
Of note, postoperative
pancreatic
juice cytology may be useful for
the diagnosis
.
[MeSH-major]
Adenocarcinoma
/ pathology.
Pancreatic
Ducts / pathology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Abdominal Pain / etiology. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness.
Pancreatic
Juice / cytology
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19367361.001).
[ISSN]
1436-0691
[Journal-full-title]
Journal of hepato-biliary-pancreatic surgery
[ISO-abbreviation]
J Hepatobiliary Pancreat Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
68.
Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra SK:
MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
Mol Cancer Res
; 2007 Apr;5(4):309-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MUC4 mucin potentiates
pancreatic
tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
MUC4, a transmembrane mucin, is aberrantly expressed in
pancreatic
adenocarcinomas while remaining undetectable in the normal
pancreas
.
Recent studies have shown that the expression of MUC4 is associated with the progression of
pancreatic
cancer and is inversely correlated with the prognosis of
pancreatic
cancer patients.
In the present study, we have examined the phenotypic and molecular consequences of MUC4 silencing with an aim of establishing the mechanistic basis for its observed role in the pathogenesis of
pancreatic
cancer.
The silencing of MUC4 expression was achieved by stable expression of a MUC4-specific short hairpin RNA in CD18/HPAF, a highly metastatic
pancreatic
adenocarcinoma
cell line.
Consistent with our previous observation, inhibition of MUC4 expression restrained
the pancreatic
tumor cell growth and metastasis as shown in an orthotopic mouse model.
In conclusion, our study provides experimental evidence that supports the functional significance of MUC4 in
pancreatic
cancer progression and indicates a novel role for MUC4 in cancer cell signaling.
[MeSH-major]
Extracellular Matrix Proteins / metabolism. Gene Expression Regulation, Neoplastic. Mucins / physiology.
Pancreatic
Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17406026.001).
[ISSN]
1541-7786
[Journal-full-title]
Molecular cancer research : MCR
[ISO-abbreviation]
Mol. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA 78590
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Actins; 0 / Antigens, CD18; 0 / Extracellular Matrix Proteins; 0 / Integrins; 0 / MUC4 protein, human; 0 / Muc4 protein, mouse; 0 / Mucin-4; 0 / Mucins
69.
Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y:
Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
J Cancer Res Clin Oncol
; 2008 Apr;134(4):481-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant Pim-3 expression is involved in gastric adenoma-
adenocarcinoma
sequence and cancer progression.
PURPOSE: Pim-3, a member of the proto-oncogene Pim family with serine/threonine kinase activity was aberrantly expressed in cancerous lesions of endoderm-derived organs such as liver,
pancreas
, and colon.
CONCLUSIONS: Aberrant Pim-3 expression was involved in gastric adenoma-
adenocarcinoma
sequence and subsequent invasion and metastasis process in gastric cancer.
[MeSH-major]
Adenocarcinoma
/ chemistry. Adenoma / chemistry. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins / analysis. Stomach Neoplasms / chemistry
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3
[
14571786.001
]
[Cites]
J Surg Oncol. 2007 Aug 1;96(2):95-101
[
17443727.001
]
[Cites]
Int J Cancer. 2005 Mar 20;114(2):209-18
[
15540201.001
]
[Cites]
Int J Cancer. 2005 Nov 10;117(3):376-80
[
15900596.001
]
[Cites]
Mod Pathol. 2004 Sep;17(9):1141-9
[
15167936.001
]
[Cites]
Carcinogenesis. 2002 Jan;23(1):201-5
[
11756242.001
]
[Cites]
Neoplasia. 2005 Mar;7(3):241-52
[
15799824.001
]
[Cites]
Lung Cancer. 2006 Feb;51(2):181-91
[
16324768.001
]
[Cites]
Breast Cancer Res Treat. 1995;36(2):169-80
[
8534865.001
]
[Cites]
Anticancer Res. 2006 Sep-Oct;26(5A):3579-83
[
17094486.001
]
[Cites]
Gastroenterol Clin North Am. 2002 Jun;31(2):499-516
[
12134615.001
]
[Cites]
Mol Cell Biol. 2003 Jun;23(11):3897-908
[
12748291.001
]
[Cites]
Blood. 2004 Jun 15;103(12):4536-44
[
14982870.001
]
[Cites]
Int J Cancer. 2005 Mar 20;114(2):242-8
[
15543611.001
]
[Cites]
J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23
[
16807756.001
]
[Cites]
Lancet. 2004 Mar 27;363(9414):1049-57
[
15051286.001
]
[Cites]
Cancer Sci. 2007 Mar;98(3):321-8
[
17270021.001
]
[Cites]
Pathol Int. 2003 Oct;53(10 ):659-66
[
14516315.001
]
[Cites]
Eur J Cancer. 1999 Apr;35(4):647-51
[
10492641.001
]
[Cites]
Brain Pathol. 2003 Oct;13(4):507-18
[
14655756.001
]
[Cites]
Am J Gastroenterol. 2001 Jan;96(1):16-26
[
11197247.001
]
[Cites]
J Biol Chem. 1998 Jun 26;273(26):16535-43
[
9632723.001
]
[Cites]
Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40
[
18091387.001
]
[Cites]
EMBO J. 1999 Jun 15;18(12):3359-69
[
10369676.001
]
[Cites]
Cell Oncol. 2005;27(4):215-23
[
16308470.001
]
[Cites]
J Clin Invest. 2005 Oct;115(10):2618-24
[
16200194.001
]
[Cites]
J Clin Pathol. 2007 Mar;60(3):273-7
[
16714395.001
]
[Cites]
Cancer Res. 2006 Jul 1;66(13):6741-7
[
16818649.001
]
[Cites]
Croat Med J. 2007 Apr;48(2):207-17
[
17436385.001
]
[Cites]
Br J Cancer. 2006 Nov 20;95(10):1371-8
[
17088917.001
]
[Cites]
Hepatogastroenterology. 2006 Jul-Aug;53(70):484-90
[
16995446.001
]
(PMID = 17876606.001).
[ISSN]
0171-5216
[Journal-full-title]
Journal of cancer research and clinical oncology
[ISO-abbreviation]
J. Cancer Res. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antigens, CD34; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
70.
Hamacher R, Schmid RM, Saur D, Schneider G:
Apoptotic pathways in pancreatic ductal adenocarcinoma.
Mol Cancer
; 2008;7:64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Apoptotic pathways in
pancreatic
ductal
adenocarcinoma
.
Pancreatic
ductal
adenocarcinoma
(PDAC) is one of the most common causes of cancer related death.
Despite the advances in understanding of the molecular pathogenesis,
pancreatic
cancer remains a major unsolved health problem.
[MeSH-major]
Apoptosis / physiology. Carcinoma,
Pancreatic
Ductal / metabolism.
Pancreatic
Neoplasms / metabolism. Signal Transduction
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2007 Aug 3;282(31):22551-62
[
17553788.001
]
[Cites]
J Clin Pathol. 2007 Aug;60(8):885-95
[
16775116.001
]
[Cites]
Oncol Rep. 2007 Sep;18(3):695-701
[
17671722.001
]
[Cites]
Curr Mol Med. 2007 Aug;7(5):504-21
[
17691965.001
]
[Cites]
Br J Cancer. 2007 Aug 20;97(4):523-30
[
17622249.001
]
[Cites]
J Surg Res. 2007 Oct;142(2):281-6
[
17640673.001
]
[Cites]
Expert Rev Anticancer Ther. 2007 Sep;7(9):1255-64
[
17892425.001
]
[Cites]
Curr Opin Immunol. 2007 Oct;19(5):488-96
[
17629468.001
]
[Cites]
Oncogene. 2007 Oct 25;26(49):7006-16
[
17471230.001
]
[Cites]
Recent Results Cancer Res. 2008;177:151-64
[
18084957.001
]
[Cites]
Nat Rev Cancer. 2008 Jan;8(1):61-70
[
18075512.001
]
[Cites]
Ann Surg Oncol. 2008 Feb;15(2):609-17
[
18026799.001
]
[Cites]
Clin Cancer Res. 2008 Mar 1;14(5):1470-7
[
18316571.001
]
[Cites]
Annu Rev Pathol. 2008;3:157-88
[
18039136.001
]
[Cites]
Science. 1997 Oct 24;278(5338):687-9
[
9381178.001
]
[Cites]
Ann N Y Acad Sci. 1999;887:150-63
[
10668471.001
]
[Cites]
Ann Surg. 2000 Mar;231(3):368-79
[
10714630.001
]
[Cites]
Exp Cell Res. 2000 Apr 10;256(1):58-66
[
10739652.001
]
[Cites]
Oncogene. 2006 Oct 30;25(51):6817-30
[
17072330.001
]
[Cites]
Anticancer Res. 2006 Sep-Oct;26(5A):3265-73
[
17094439.001
]
[Cites]
Oncogene. 2000 Nov 16;19(48):5477-86
[
11114725.001
]
[Cites]
Int J Oncol. 2001 Feb;18(2):311-6
[
11172597.001
]
[Cites]
Nat Rev Cancer. 2002 Apr;2(4):301-10
[
12001991.001
]
[Cites]
J Gastrointest Surg. 2001 Nov-Dec;5(6):603-12; discussion 612-3
[
12086898.001
]
[Cites]
Pancreatology. 2001;1(3):254-62
[
12120204.001
]
[Cites]
Semin Oncol. 2002 Jun;29(3 Suppl 11):71-6
[
12138400.001
]
[Cites]
Surgery. 2002 Aug;132(2):127-34
[
12219002.001
]
[Cites]
Gastroenterology. 2002 Dec;123(6):2052-63
[
12454861.001
]
[Cites]
Mol Cancer Ther. 2002 Oct;1(12):989-97
[
12481421.001
]
[Cites]
Int J Cancer. 2003 Apr 20;104(4):469-76
[
12584745.001
]
[Cites]
Oncogene. 2003 Mar 6;22(9):1365-70
[
12618762.001
]
[Cites]
Int J Gastrointest Cancer. 2002;31(1-3):71-8
[
12622417.001
]
[Cites]
Oncogene. 2003 May 22;22(21):3243-51
[
12761494.001
]
[Cites]
Int J Cancer. 2003 Jul 20;105(6):735-46
[
12767057.001
]
[Cites]
Cancer Sci. 2003 May;94(5):467-72
[
12824895.001
]
[Cites]
Br J Cancer. 2003 Jul 21;89(2):391-7
[
12865934.001
]
[Cites]
Int J Gastrointest Cancer. 2003;33(1):15-26
[
12909735.001
]
[Cites]
Pancreas. 2003 Oct;27(3):e57-62
[
14508142.001
]
[Cites]
Br J Cancer. 2003 Nov 3;89(9):1714-21
[
14583775.001
]
[Cites]
Oncogene. 2003 Nov 24;22(53):8543-67
[
14634618.001
]
[Cites]
Br J Cancer. 2003 Dec 1;89(11):2110-5
[
14647146.001
]
[Cites]
Semin Oncol. 2004 Feb;31(1):90-119
[
14970941.001
]
[Cites]
Biochim Biophys Acta. 2004 Mar 1;1644(2-3):125-32
[
14996497.001
]
[Cites]
Pancreas. 2008 Apr;36(3):225-35
[
18362834.001
]
[Cites]
Cancer Res. 2008 Apr 15;68(8):2944-51
[
18413764.001
]
[Cites]
Biochim Biophys Acta. 2008 May;1783(5):941-52
[
18191642.001
]
[Cites]
Cell Death Differ. 2008 Jun;15(6):977-87
[
18369371.001
]
[Cites]
J Exp Med. 2000 May 15;191(10):1721-34
[
10811865.001
]
[Cites]
Cancer Res. 2000 Jun 15;60(12):3117-22
[
10866296.001
]
[Cites]
J Cell Biochem. 2000 Sep 7;79(3):355-69
[
10972974.001
]
[Cites]
Cancer Res. 2000 Oct 1;60(19):5451-5
[
11034087.001
]
[Cites]
Oncogene. 2001 Jul 12;20(31):4258-69
[
11464292.001
]
[Cites]
Cancer. 2001 Jul 15;92(2):271-8
[
11466679.001
]
[Cites]
J Pathol. 2001 Aug;194(4):444-50
[
11523052.001
]
[Cites]
Clin Cancer Res. 2001 Oct;7(10):3269-75
[
11595724.001
]
[Cites]
Pancreas. 2001 Oct;23(3):251-8
[
11590320.001
]
[Cites]
J Cell Sci. 2001 Aug;114(Pt 15):2735-46
[
11683408.001
]
[Cites]
Br J Cancer. 2002 Mar 18;86(6):886-92
[
11953819.001
]
[Cites]
Br J Cancer. 2002 Mar 18;86(6):893-8
[
11953820.001
]
[Cites]
Nat Rev Cancer. 2002 Apr;2(4):277-88
[
12001989.001
]
[Cites]
Cancer Res. 1998 Apr 15;58(8):1741-9
[
9563493.001
]
[Cites]
Science. 1998 Nov 13;282(5392):1318-21
[
9812896.001
]
[Cites]
Oncology. 1999;56(1):73-82
[
9885381.001
]
[Cites]
Clin Cancer Res. 1999 Jan;5(1):119-27
[
9918209.001
]
[Cites]
Cancer. 2004 Nov 15;101(10):2351-62
[
15476283.001
]
[Cites]
Oncogene. 2004 Nov 11;23(53):8571-80
[
15467756.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):307-15
[
15549092.001
]
[Cites]
Pancreatology. 2004;4(6):567-86
[
15550766.001
]
[Cites]
FASEB J. 2005 Apr;19(6):620-2
[
15670977.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Apr;6(4):287-97
[
15803136.001
]
[Cites]
Gastroenterology. 2005 May;128(6):1606-25
[
15887154.001
]
[Cites]
Cancer Res. 2005 Oct 15;65(20):9164-8
[
16230374.001
]
[Cites]
Anticancer Res. 2005 Nov-Dec;25(6B):3967-72
[
16309185.001
]
[Cites]
Nat Rev Cancer. 2005 Dec;5(12):921-9
[
16341083.001
]
[Cites]
J Cell Biochem. 2006 Jan 1;97(1):98-108
[
16173075.001
]
[Cites]
Curr Dir Autoimmun. 2006;9:1-17
[
16394652.001
]
[Cites]
Cancer Res. 2006 Mar 1;66(5):2778-84
[
16510599.001
]
[Cites]
Mol Cancer Ther. 2006 Mar;5(3):483-93
[
16546962.001
]
[Cites]
Cancer Treat Res. 2006;130:141-65
[
16610707.001
]
[Cites]
Pancreas. 2006 Apr;32(3):288-96
[
16628085.001
]
[Cites]
Genes Dev. 2006 May 15;20(10):1218-49
[
16702400.001
]
[Cites]
World J Gastroenterol. 2006 May 14;12(18):2901-7
[
16718816.001
]
[Cites]
Am J Surg Pathol. 2006 Jun;30(6):754-9
[
16723855.001
]
[Cites]
Oncogene. 2006 Aug 7;25(34):4798-811
[
16892092.001
]
[Cites]
EMBO J. 2006 Aug 23;25(16):3801-12
[
16902410.001
]
[Cites]
Oncogene. 2006 Oct 30;25(51):6685-705
[
17072322.001
]
[Cites]
Ann N Y Acad Sci. 2003 Dec;1010:510-3
[
15033781.001
]
[Cites]
J Am Coll Surg. 2004 Apr;198(4):591-9
[
15051014.001
]
[Cites]
Oncogene. 2004 Apr 12;23(16):2861-74
[
15077149.001
]
[Cites]
Oncogene. 2004 Apr 12;23(16):2950-66
[
15077156.001
]
[Cites]
Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71
[
15166955.001
]
[Cites]
Mol Cancer. 2003 Jan 7;2:6
[
12605713.001
]
[Cites]
Mol Cancer. 2003 Jan 22;2:15
[
12605716.001
]
[Cites]
Nat Rev Cancer. 2004 Aug;4(8):592-603
[
15286739.001
]
[Cites]
Surgery. 2004 Aug;136(2):443-8
[
15300213.001
]
[Cites]
World J Gastroenterol. 2004 Sep 15;10(18):2759-61
[
15309737.001
]
[Cites]
J Med Chem. 2004 Aug 26;47(18):4417-26
[
15317454.001
]
[Cites]
Cancer Gene Ther. 2004 Sep;11(9):633-41
[
15272314.001
]
[Cites]
Genes Dev. 2004 Sep 15;18(18):2195-224
[
15371334.001
]
[Cites]
Cell. 1997 Oct 17;91(2):231-41
[
9346240.001
]
[Cites]
Oncogene. 2001 Feb 15;20(7):859-68
[
11314019.001
]
[Cites]
Cancer Cell. 2006 Nov;10(5):389-99
[
17097561.001
]
[Cites]
Cancer Res. 2006 Dec 15;66(24):11613-22
[
17178855.001
]
[Cites]
Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62
[
17183360.001
]
[Cites]
Oncogene. 2007 Jan 11;26(2):248-57
[
16832350.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Mol Cancer Ther. 2007 Mar;6(3):957-66
[
17339366.001
]
[Cites]
Br J Cancer. 2007 Mar 26;96(6):993-1000
[
17342093.001
]
[Cites]
Int J Cancer. 2007 Jun 1;120(11):2344-52
[
17311258.001
]
[Cites]
Int J Cancer. 2007 Jul 1;121(1):66-75
[
17304504.001
]
[Cites]
Cancer Res. 2007 May 15;67(10):4679-86
[
17510394.001
]
(PMID = 18652674.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Inhibitor of Apoptosis Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Oncogene Protein v-akt
[Number-of-references]
112
[Other-IDs]
NLM/ PMC2515336
71.
Alldinger I, Dittert D, Peiper M, Fusco A, Chiappetta G, Staub E, Lohr M, Jesnowski R, Baretton G, Ockert D, Saeger HD, Grützmann R, Pilarsky C:
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer.
Pancreatology
; 2005;5(4-5):370-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene expression analysis of
pancreatic
cell lines reveals genes overexpressed in
pancreatic
cancer.
BACKGROUND:
Pancreatic
cancer is one of the leading causes of cancer-related death.
Using DNA gene expression analysis based on a custom made Affymetrix cancer array, we investigated the expression pattern of both primary and established
pancreatic
carcinoma cell lines.
METHODS: We analyzed the gene expression of 5 established
pancreatic
cancer cell lines (AsPC-1, BxPC-3, Capan-1, Capan-2 and HPAF II) and 5 primary isolates, 1 of them derived from benign
pancreatic
duct cells.
Several of the upregulated genes (like Prefoldin 5, ADAM9 and E-cadherin) have been associated with
pancreatic
cancer before.
The other differentially regulated genes, however, play a so far unknown role in the course of human
pancreatic
carcinoma.
By means of immunohistochemistry we could show that thymosin beta-10 (TMSB10), upregulated in tumor cell lines, is expressed in human
pancreatic
carcinoma, but not in non-neoplastic
pancreatic
tissue, suggesting a role for TMSB10 in the carcinogenesis of
pancreatic
carcinoma.
CONCLUSION: Using gene expression profiling of
pancreatic
cell lines we were able to identify genes differentially expressed in
pancreatic
adenocarcinoma
, which might contribute to
pancreatic
cancer development.
[MeSH-major]
Carcinoma,
Pancreatic
Ductal / genetics. Down-Regulation. Gene Expression Profiling.
Pancreatic
Neoplasms / genetics. Up-Regulation
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Male. Middle Aged.
Pancreas
/ metabolism. Thymosin / genetics. Thymosin / metabolism
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 S. Karger AG, Basel.
(PMID = 15983444.001).
[ISSN]
1424-3903
[Journal-full-title]
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
[ISO-abbreviation]
Pancreatology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Switzerland
[Chemical-registry-number]
61512-21-8 / Thymosin; 87397-91-9 / thymosin beta(10)
72.
Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS:
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
J Am Coll Surg
; 2007 Oct;205(4):558-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Application of
the pancreatic
adenocarcinoma
staging system to
pancreatic
neuroendocrine tumors.
BACKGROUND: The American Joint Committee on Cancer (AJCC) 6(th) edition staging system for
pancreatic
adenocarcinoma
specifically excludes
pancreatic
neuroendocrine tumors (PNETs), and a widely accepted staging classification does not exist.
Our objective was to evaluate the feasibility of applying the AJCC
pancreatic
adenocarcinoma
staging system to PNETs.
When comparing outcomes to those of patients with
pancreatic
adenocarcinoma
, the estimated median survival was significantly better for resected patients with PNETs (60 versus 13 months, p < 0.0001).
CONCLUSIONS: When applied to PNETs, the AJCC staging system for
pancreatic
adenocarcinoma
provides survival discrimination by stage for surgical and nonsurgical patients.
Survival rates are better for PNETs than for
pancreatic
adenocarcinoma
, but the staging system can effectively stratify patients with PNETs.
[MeSH-major]
Neoplasm Staging. Neuroendocrine Tumors / pathology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Adenocarcinoma
/ pathology. Adolescent. Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17903729.001).
[ISSN]
1879-1190
[Journal-full-title]
Journal of the American College of Surgeons
[ISO-abbreviation]
J. Am. Coll. Surg.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
73.
O'Connor JK, Sause WT, Hazard LJ, Belnap LP, Noyes RD:
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.
Int J Radiat Oncol Biol Phys
; 2005 Nov 15;63(4):1060-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival after attempted surgical resection and intraoperative radiation therapy for
pancreatic
and periampullary
adenocarcinoma
.
PURPOSE: To evaluate a single institution's experience with intraoperative radiation therapy (IORT) in combination with attempted surgical resection for
pancreatic
and periampullary
adenocarcinoma
.
METHODS AND MATERIALS: From May 1986 until June 2001, 77 patients at LDS Hospital underwent attempted surgical resection and IORT for
pancreatic
or periampullary
adenocarcinoma
.
Forty-four patients with tumors located in the
pancreas
and 9 patients with periampullary tumors underwent potentially curative surgical resection and IORT.
Twenty-four patients had
pancreatic
tumors deemed unresectable and underwent surgical bypass and IORT.
RESULTS: Patients undergoing a potentially curative resection and IORT for periampullary
adenocarcinoma
had a median survival of 167 months and a 56% 5-year actuarial survival, compared with a median survival of 16 months and a 19% 5-year actuarial survival for patients undergoing the same treatment for
pancreatic
adenocarcinoma
(p = 0.03).
CONCLUSIONS: Intraoperative radiation therapy is well tolerated and does not increase the morbidity or mortality of potentially curative surgical resection for
pancreatic
or periampullary
adenocarcinoma
.
Patients with periampullary
adenocarcinoma
have a better prognosis than those with
pancreatic
adenocarcinoma
, and patients with unresectable
pancreatic
disease fared worse.
[MeSH-major]
Adenocarcinoma
/ mortality. Ampulla of Vater. Common Bile Duct Neoplasms / mortality.
Pancreatic
Neoplasms / mortality
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15978737.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
U3P01618RT / Fluorouracil
74.
Goitia-Durán MB, Linhares MM, Artigiani Neto R, Apodaca-Torrez FR, Lobo EJ, Goldenberg A:
Expression of p53, p16 and Ki67 proteins in ductal adenocarcinoma of the pancreatic head and their relation with survival and cell differentiation.
Einstein (Sao Paulo)
; 2010 Dec;8(4):444-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of p53, p16 and Ki67 proteins in ductal
adenocarcinoma of
the pancreatic
head and their relation with survival and cell differentiation.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 26760327.001).
[ISSN]
1679-4508
[Journal-full-title]
Einstein (São Paulo, Brazil)
[ISO-abbreviation]
Einstein (Sao Paulo)
[Language]
eng; por
[Publication-type]
Journal Article
[Publication-country]
Brazil
75.
Hara H, Suda K:
Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
Am J Clin Pathol
; 2008 Jan;129(1):115-29
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Review of the cytologic features of noninvasive ductal carcinomas of the
pancreas
: differences from invasive ductal carcinoma.
Invasive ductal
adenocarcinoma
(IDA) of the
pancreas
(IDAP) originating from the ductal gland has a poor prognosis.
Noninvasive carcinomas are principally intraductal papillary mucinous carcinomas (IPMCs) and
pancreatic
intraepithelial neoplasms 3 (PanIN-3).
[MeSH-major]
Carcinoma,
Pancreatic
Ductal / pathology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Adenocarcinoma
, Mucinous / metabolism.
Adenocarcinoma
, Mucinous / pathology.
Adenocarcinoma
, Papillary / metabolism.
Adenocarcinoma
, Papillary / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Nucleus / pathology.
Diagnosis
, Differential. Humans. Hyperplasia / pathology. Mucins / metabolism. Neoplasm Invasiveness / pathology
Genetic Alliance.
consumer health - invasive ductal carcinoma
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18089497.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Mucins
76.
Soman AD, Collins JM, DePetris G, Decker GA, Silva A, Moss A, Greer W, Ashman J, Callister M, Borad MJ:
Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature.
JOP
; 2010;11(6):604-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolated supraclavicular lymph node metastasis in
pancreatic
adenocarcinoma
: a report of three cases and review of the literature.
CONTEXT: Supraclavicular lymph nodes represent a rare site of metastasis in
pancreatic
cancer.
We report three cases of
pancreatic
adenocarcinoma
with metastases to supraclavicular lymph nodes.
CASE REPORT: A 51-year-old male was diagnosed with locally advanced
pancreatic
adenocarcinoma
on computed tomography (CT) scan.
The patient received systemic chemotherapy for metastatic
pancreatic
adenocarcinoma
.
The second patient, a 66-year-old female with
pancreatic
adenocarcinoma
, underwent pancreaticoduodenectomy and was found to have peripancreatic lymph node involvement.
PET/CT scan and biopsy revealed supraclavicular lymph node metastasis from a
pancreatic
adenocarcinoma
primary.
Staging evaluations revealed a
pancreatic
mass for which he underwent subtotal pancreatectomy and splenectomy.
Histopathology revealed grade 3
pancreatic
adenocarcinoma
.
Excisional biopsy of a supraclavicular lymph node showed metastatic
pancreatic
adenocarcinoma
.
CONCLUSION: In patients with
pancreatic
adenocarcinoma
, supraclavicular lymph node metastasis represents an uncommon, but clinically significant finding that can lead to changes in treatment planning.
[MeSH-major]
Adenocarcinoma
/
diagnosis
.
Adenocarcinoma
/ pathology.
Pancreatic
Neoplasms /
diagnosis
.
Pancreatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
JOP. 2011 Jan;12(1):66-7; author reply 70
[
21206107.001
]
(PMID = 21068495.001).
[ISSN]
1590-8577
[Journal-full-title]
JOP : Journal of the pancreas
[ISO-abbreviation]
JOP
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Italy
77.
Wolfson D, Barkin JS, Chari ST, Clain JE, Bell RH Jr, Alexakis N, Neoptolemos JP:
Management of pancreatic masses.
Pancreas
; 2005 Oct;31(3):203-17
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of
pancreatic
masses.
[MeSH-major]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ surgery.
Pancreatic
Neoplasms / pathology.
Pancreatic
Neoplasms / surgery. Preoperative Care
[MeSH-minor]
Diagnosis
, Differential. Humans. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16163050.001).
[ISSN]
1536-4828
[Journal-full-title]
Pancreas
[ISO-abbreviation]
Pancreas
[Language]
eng
[Publication-type]
Consensus Development Conference; Journal Article
[Publication-country]
United States
[Number-of-references]
105
78.
Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ:
Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.
HPB (Oxford)
; 2009 Nov;11(7):606-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Validation of a prediction rule to maximize curative (R0) resection of early-stage
pancreatic
adenocarcinoma
.
BACKGROUND: The surgeon's contribution to patients with localized
pancreatic
adenocarcinoma
(PAC) is a margin negative (R0) resection.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20495714.001).
[ISSN]
1477-2574
[Journal-full-title]
HPB : the official journal of the International Hepato Pancreato Biliary Association
[ISO-abbreviation]
HPB (Oxford)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2785957
79.
Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O:
Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses.
Ultraschall Med
; 2010 Dec;31(6):571-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid
pancreatic
masses.
PURPOSE: Contrast-enhanced harmonic endoscopic ultrasonography (CEH-EUS) for the assessment of microcirculation and the delineation of
pancreatic
tumors in order to characterize and stage them has only recently become available for commercial use, and few reports have been published.
The purpose of the study was the qualitative and quantitative digital image analysis of
pancreatic
adenocarcinomas using conventional endoscopic ultrasonography (EUS) and CEH-EUS and the evaluation of whether contrast medium injection modified
adenocarcinoma
staging and patient management.
MATERIALS AND METHODS: In each of 30 prospectively examined patients with suspected
pancreatic
solid lesions, CEH-EUS was performed using the same quantity of the contrast agent SonoVue and a low mechanical index (0.3 - 0.4), followed by EUS-FNA.
The histology, based on EUS-FNA or surgery and 9 months of follow-up, was:
pancreatic
adenocarcinoma
(n = 15), pseudotumoral chronic pancreatitis (n = 12), neuroendocrine tumor (n = 1), common bile duct tumor (n = 1), lymph node metastases of gastric cancer (n = 1).
RESULTS: CEH-EUS showed a hypoenhanced pattern in 14 cases
of adenocarcinoma
and in 10 cases of chronic pancreatitis.
The index of the contrast uptake ratio was significantly lower in
adenocarcinoma
than in mass-forming chronic pancreatitis.
A cut-off uptake ratio index value of 0.17 for diagnosing
adenocarcinoma
corresponded to an AUC (CI 95%) of 0.86 (0.67 - 1.00) with a sensitivity of 80%, a specificity of 91.7%, a positive predictive value of 92.8%, and a negative predictive value of 78%.
The size of
the pancreatic
mass was assessed significantly more effectively by CEH-EUS but
adenocarcinoma
staging was not modified.
CONCLUSION: The majority of cases of both
pancreatic
adenocarcinoma
and chronic pancreatitis were hypoenhanced and visual discrimination was not possible.
[MeSH-major]
Adenocarcinoma
/ ultrasonography. Endosonography / methods. Image Enhancement / methods. Image Processing, Computer-Assisted / methods.
Pancreatic
Neoplasms / ultrasonography. Tumor Burden / physiology
[MeSH-minor]
Aged. Aged, 80 and over. Biopsy. Contrast Media / administration & dosage.
Diagnosis
, Differential. Female. Humans. Male. Microvessels / ultrasonography. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Phospholipids. Prospective Studies. Sulfur Hexafluoride
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
SULFUR HEXAFLUORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© Georg Thieme Verlag KG Stuttgart · New York.
(PMID = 21080306.001).
[ISSN]
1438-8782
[Journal-full-title]
Ultraschall in der Medizin (Stuttgart, Germany : 1980)
[ISO-abbreviation]
Ultraschall Med
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
80.
Eltoum IA, Eloubeidi MA, Chhieng DC, Tamhane A, Crowe R, Jhala D, St John KD, Wilcox CM, Siegal GP, Vickers S, Jhala NC:
Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma.
Am J Clin Pathol
; 2005 Nov;124(5):697-707
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytologic grade independently predicts survival of patients with
pancreatic
adenocarcinoma
.
Our objectives were to devise a cytologic grading system and determine whether it would predict survival of patients with solid-type
pancreatic
adenocarcinoma
.
We devised a grading system that independently predicted survival in patients with
pancreatic
adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
/ pathology.
Pancreatic
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16203289.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Azure Stains; 0 / Romanowsky-Giemsa stain; TDQ283MPCW / Eosine Yellowish-(YS)
81.
Muroni M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, Pilozzi E, Ramacciato G:
Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
Hepatobiliary Pancreat Dis Int
; 2010 Feb;9(1):97-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Synchronous gastric
adenocarcinoma
and
pancreatic
ductal
adenocarcinoma
.
BACKGROUND: The association between gastric and
pancreatic
carcinoma is a relatively rare condition.
Gastric cancer associated with
pancreatic
cancer is uncommon.
Computed tomography and magnetic resonance showed a gastric thickening in the antral and pyloric portion and a nodular mass (3 X 1.7 cm) in the uncinate portion of the
pancreas
.
Histological examination of the specimen demonstrated a moderately differentiated
adenocarcinoma of
the stomach and a poorly differentiated ductal
adenocarcinoma of
the
pancreas
.
CONCLUSIONS: Long survival is rare in patients with associated gastric and
pancreatic
cancer.
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Carcinoma,
Pancreatic
Ductal /
diagnosis
. Neoplasms, Multiple Primary /
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
. Stomach Neoplasms /
diagnosis
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20133238.001).
[ISSN]
1499-3872
[Journal-full-title]
Hepatobiliary & pancreatic diseases international : HBPD INT
[ISO-abbreviation]
HBPD INT
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
China
82.
Hussain F, Wang J, Ahmed R, Guest SK, Lam EW, Stamp G, El-Bahrawy M:
The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours.
Cytokine
; 2010 Feb;49(2):134-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The expression of IL-8 and IL-8 receptors in
pancreatic
adenocarcinomas and
pancreatic
neuroendocrine tumours.
IL-8 has been shown to have pro-angiogenic, mitogenic and motogenic effects and several studies have demonstrated the expression of IL-8 by various human
pancreatic
cancer cell lines.
METHODS: The expression of IL-8 and IL-8 receptors was studied in 52
pancreatic
adenocarcinomas and 52
pancreatic
neuroendocrine tumours using immunohistochemistry.
The expression of IL-8 and IL-8 receptors was also assessed in eight
pancreatic
adenocarcinomas and seven neuroendocrine tumours in comparison to normal
pancreatic
tissue using real time quantitative PCR (qRT-PCR).
RESULTS: Immunohistochemical analysis of the expression of IL-8, IL-8RA and IL-8RB in 52
pancreatic
adenocarcinomas demonstrated expression in 25%, 75% and 79% of
pancreatic
adenocarcinomas, respectively.
IL-8, IL-8RA and IL-8RB expression was detected in 21%, 63% and 92% of 52
pancreatic
neuroendocrine tumours.
Using qRT-PCR, the expression of each of IL-8, IL-8RA and IL-8RB mRNA was increased in 75% of
pancreatic
adenocarcinomas.
IL-8, IL-8RA and IL-8RB mRNA expression was also increased in 57%, 43% and 29% of
pancreatic
neuroendocrine tumours.
Quantitatively, there was a significant increase in expression level of IL-8 in tumours of both types in comparison to normal
pancreatic
tissue (38.5-fold in adenocarcinomas and 43.9-fold in neuroendocrine tumours).
IL-8RB was slightly increased in adenocarcinomas in comparison to normal
pancreas
(1.4-fold), but the expression was decreased in neuroendocrine tumours compared with normal
pancreas
(0.9-fold).
CONCLUSION: This is the first study to show that IL-8 and IL-8 receptors are upregulated in both
pancreatic
adenocarcinomas and neuroendocrine tumours, and indicate this signalling pathway may modulate tumour behaviour through autocrine and/or paracrine loops.
[MeSH-major]
Adenocarcinoma
/ metabolism. Interleukin-8 / metabolism. Neuroendocrine Tumors / metabolism.
Pancreatic
Neoplasms / metabolism. Receptors, Interleukin-8 / metabolism
[MeSH-minor]
Adult. Aged. Female. Humans. Male. Middle Aged.
Pancreas
/ cytology.
Pancreas
/ metabolism.
Pancreas
/ pathology. Signal Transduction / physiology. Young Adult
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Ltd. All rights reserved.
(PMID = 20005738.001).
[ISSN]
1096-0023
[Journal-full-title]
Cytokine
[ISO-abbreviation]
Cytokine
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Interleukin-8; 0 / Receptors, Interleukin-8
83.
Leiman G:
My approach to pancreatic fine needle aspiration.
J Clin Pathol
; 2007 Jan;60(1):43-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
My approach to
pancreatic
fine needle aspiration.
Pancreatic
fine needle aspiration cytopathology has earned a reputation as a rapid, safe, accurate and cost-beneficial modality of investigation of
pancreatic
mass lesion.
[MeSH-major]
Biopsy, Fine-Needle / methods.
Pancreas
/ pathology.
Pancreatic
Neoplasms / pathology
[MeSH-minor]
Adenocarcinoma
, Mucinous / pathology. Carcinoma,
Pancreatic
Ductal / pathology. Humans. Patient Selection
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2003 Oct 25;99(5):285-92
[
14579295.001
]
[Cites]
Cancer. 2003 Dec 25;99(6):372-8
[
14681946.001
]
[Cites]
Acta Cytol. 1983 Sep-Oct;27(5):500-4
[
6578648.001
]
[Cites]
Acta Cytol. 1984 Nov-Dec;28(6):733-6
[
6594886.001
]
[Cites]
Diagn Cytopathol. 1985 Apr-Jun;1(2):105-10
[
3836074.001
]
[Cites]
Diagn Cytopathol. 1986 Jan-Mar;2(1):69-71
[
3720483.001
]
[Cites]
Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5
[
3522134.001
]
[Cites]
Acta Cytol. 1986 Jul-Aug;30(4):430-4
[
3461652.001
]
[Cites]
Acta Cytol. 1988 Jan-Feb;32(1):39-42
[
3336955.001
]
[Cites]
Acta Cytol. 1988 Jan-Feb;32(1):43-8
[
2447722.001
]
[Cites]
Acta Cytol. 1988 Jul-Aug;32(4):447-51
[
3400383.001
]
[Cites]
Acta Cytol. 1992 Sep-Oct;36(5):655-60
[
1523921.001
]
[Cites]
Acta Cytol. 1992 Nov-Dec;36(6):881-6
[
1449026.001
]
[Cites]
Am J Clin Pathol. 1992 Nov;98(5):478-88
[
1283055.001
]
[Cites]
Acta Cytol. 1993 Nov-Dec;37(6):889-93
[
8249508.001
]
[Cites]
Acta Cytol. 1993 Nov-Dec;37(6):908-12
[
8249512.001
]
[Cites]
AJR Am J Roentgenol. 1988 Sep;151(3):493-4
[
3261508.001
]
[Cites]
Acta Radiol. 1988 Sep-Oct;29(5):535-9
[
3048349.001
]
[Cites]
Acta Cytol. 1996 May-Jun;40(3):585-91
[
8669201.001
]
[Cites]
Diagn Cytopathol. 1996 Jul;15(1):37-45
[
8807250.001
]
[Cites]
Diagn Cytopathol. 1995 Dec;13(5):396-410
[
8834314.001
]
[Cites]
Acta Cytol. 1996 Sep-Oct;40(5):975-9
[
8842177.001
]
[Cites]
Diagn Cytopathol. 1997 Feb;16(2):112-6
[
9067100.001
]
[Cites]
Am Surg. 1997 Aug;63(8):675-9; discussion 679-80
[
9247432.001
]
[Cites]
Am J Gastroenterol. 1998 Aug;93(8):1329-33
[
9707060.001
]
[Cites]
Diagn Cytopathol. 1998 Dec;19(6):423-7
[
9839131.001
]
[Cites]
Adv Anat Pathol. 1999 Mar;6(2):65-77
[
10331069.001
]
[Cites]
Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3
[
10367874.001
]
[Cites]
Oncol Rep. 1999 Sep-Oct;6(5):1111-5
[
10425311.001
]
[Cites]
Diagn Cytopathol. 2005 Feb;32(2):65-9
[
15637684.001
]
[Cites]
Diagn Cytopathol. 2005 Apr;32(4):204-10
[
15754366.001
]
[Cites]
Am J Clin Pathol. 2005 Nov;124(5):697-707
[
16203289.001
]
[Cites]
Gut. 2000 Feb;46(2):244-9
[
10644320.001
]
[Cites]
Am J Gastroenterol. 2000 Sep;95(9):2255-60
[
11007226.001
]
[Cites]
Diagn Cytopathol. 1988;4(4):316-22
[
3254809.001
]
[Cites]
Diagn Cytopathol. 1989;5(3):263-8
[
2551616.001
]
[Cites]
Acta Cytol. 1989 Nov-Dec;33(6):936-9
[
2686327.001
]
[Cites]
Diagn Cytopathol. 1989;5(4):388-91
[
2612315.001
]
[Cites]
Diagn Cytopathol. 1989;5(4):408-11
[
2612319.001
]
[Cites]
Am J Clin Pathol. 1990 Aug;94(2):142-9
[
2164767.001
]
[Cites]
Radiology. 1991 Jan;178(1):253-8
[
1984314.001
]
[Cites]
Am J Surg. 1991 Jan;161(1):26-9; discussion 29-30
[
1824810.001
]
[Cites]
Am J Clin Pathol. 1994 Apr;101(4):483-7
[
8160642.001
]
[Cites]
Aust N Z J Surg. 1994 Jun;64(6):444-6
[
7912067.001
]
[Cites]
Diagn Cytopathol. 1994;10(4):362-4
[
7924811.001
]
[Cites]
Acta Cytol. 1995 Jan-Feb;39(1):1-10
[
7846994.001
]
[Cites]
Acta Cytol. 1995 Jan-Feb;39(1):23-7
[
7847005.001
]
[Cites]
Gastroenterology. 1995 Apr;108(4):1230-5
[
7535275.001
]
[Cites]
Acta Cytol. 1995 May-Jun;39(3):485-8
[
7762337.001
]
[Cites]
Diagn Cytopathol. 1995 Mar;12(2):113-9
[
7774489.001
]
[Cites]
Diagn Cytopathol. 1990;6(5):336-40
[
1705496.001
]
[Cites]
Surg Gynecol Obstet. 1991 Sep;173(3):193-7
[
1925879.001
]
[Cites]
Acta Cytol. 1991 Sep-Oct;35(5):546-8
[
1927196.001
]
[Cites]
Diagn Cytopathol. 1991;7(4):341-5
[
1935510.001
]
[Cites]
Diagn Cytopathol. 1992;8(1):65-7
[
1551367.001
]
[Cites]
Acta Cytol. 1992 Jul-Aug;36(4):471-6
[
1636336.001
]
[Cites]
Surgery. 1995 Sep;118(3):472-8
[
7652681.001
]
[Cites]
Diagn Cytopathol. 1995 Aug;13(2):120-3
[
8542789.001
]
[Cites]
Diagn Cytopathol. 1995 Oct;13(3):233-46
[
8575283.001
]
[Cites]
Acta Cytol. 1996 Mar-Apr;40(2):182-90
[
8629395.001
]
[Cites]
Gastrointest Endosc. 2001 Apr;53(4):470-4
[
11275888.001
]
[Cites]
Gastrointest Endosc. 2001 Jun;53(7):722-7
[
11375578.001
]
[Cites]
Oncology. 2001;60(4):322-9
[
11408800.001
]
[Cites]
Endoscopy. 2001 Oct;33(10):824-31
[
11571676.001
]
[Cites]
Am J Surg Pathol. 2002 Apr;26(4):466-71
[
11914624.001
]
[Cites]
Ann Diagn Pathol. 2002 Apr;6(2):106-12
[
12004358.001
]
[Cites]
Cancer. 2002 Jun 25;96(3):174-80
[
12115306.001
]
[Cites]
Gastrointest Endosc. 2002 Aug;56(2):291-6
[
12145615.001
]
[Cites]
Cancer. 2002 Aug 25;96(4):232-9
[
12209665.001
]
[Cites]
Acta Cytol. 2002 Sep-Oct;46(5):813-8
[
12365212.001
]
[Cites]
Diagn Cytopathol. 2002 Dec;27(6):325-34
[
12451561.001
]
[Cites]
Cancer. 2002 Dec 25;96(6):362-9
[
12478684.001
]
[Cites]
J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8
[
12559193.001
]
[Cites]
Cancer. 2003 Feb 25;99(1):44-50
[
12589645.001
]
[Cites]
Surgery. 2003 May;133(5):459-63
[
12773972.001
]
[Cites]
Acta Cytol. 2003 May-Jun;47(3):341-8
[
12789912.001
]
[Cites]
Acta Cytol. 2003 Jul-Aug;47(4):657-62
[
12920762.001
]
[Cites]
Am J Clin Pathol. 2003 Sep;120(3):398-404
[
14502804.001
]
[Cites]
Acta Cytol. 2003 Sep-Oct;47(5):723-6
[
14526668.001
]
[Cites]
Acta Cytol. 2003 Sep-Oct;47(5):733-8
[
14526670.001
]
(PMID = 16698956.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
89
[Other-IDs]
NLM/ PMC1860594
84.
Dawelbait G, Winter C, Zhang Y, Pilarsky C, Grützmann R, Heinrich JC, Schroeder M:
Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data.
Bioinformatics
; 2007 Jul 1;23(13):i115-24
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Structural templates predict novel protein interactions and targets from
pancreas
tumour gene expression data.
MOTIVATION:
Pancreatic
ductal
adenocarcinoma
(PDAC) eludes early detection and is characterized by its aggressiveness and resistance to current therapies.
RESULTS: Here, we take such a network-centric approach to
pancreas
cancer by re-constructing networks from known interactions and by predicting novel protein interactions from structural templates.
Our analysis indicates that the alteration of the calcium pathway plays an important role in
pancreas
-specific tumorigenesis.
[MeSH-major]
Biomarkers, Tumor / metabolism. Carcinoma,
Pancreatic
Ductal / metabolism. Gene Expression Profiling / methods. Models, Biological. Neoplasm Proteins / metabolism.
Pancreatic
Neoplasms / metabolism. Signal Transduction
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17646287.001).
[ISSN]
1367-4811
[Journal-full-title]
Bioinformatics (Oxford, England)
[ISO-abbreviation]
Bioinformatics
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
85.
Gbelcová H, Lenícek M, Zelenka J, Knejzlík Z, Dvoráková G, Zadinová M, Poucková P, Kudla M, Balaz P, Ruml T, Vítek L:
Differences in antitumor effects of various statins on human pancreatic cancer.
Int J Cancer
; 2008 Mar 15;122(6):1214-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differences in antitumor effects of various statins on human
pancreatic
cancer.
The aim of the present study was to compare the effects of the individual commercially available statins on experimental
pancreatic
cancer.
The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human
pancreatic
cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines.
In summary, substantial tumor-suppressive effects of various statins on the progression of experimental
pancreatic
adenocarcinoma
were demonstrated, with marked differences among individual statins.
These results support greatly the potential of statins for the chemoadjuvant treatment of
pancreatic
cancer.
[MeSH-major]
Adenocarcinoma
/ pathology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology.
Pancreatic
Neoplasms / pathology
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Statins
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 18027870.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Primers; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
86.
Recchia F, Sica G, Candeloro G, Bisegna R, Bratta M, Bonfili P, Necozione S, Tombolini V, Rea S:
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Pancreas
; 2009 Aug;38(6):e163-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chemoradioimmunotherapy in locally advanced
pancreatic
and biliary tree
adenocarcinoma
: a multicenter phase II study.
OBJECTIVES: The antitumor activity and toxicity of a multi-step treatment were evaluated in patients with locally advanced, inoperable, or incompletely resected
pancreatic
(Pa) and biliary tree (Bt) adenocarcinomas (ADKs).
[MeSH-major]
Adenocarcinoma
/ therapy. Biliary Tract Neoplasms / therapy.
Pancreatic
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
Hazardous Substances Data Bank.
CAPECITABINE
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
13-CIS-RETINOIC ACID
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Pancreas. 2012 Jul;41(5):825. Dosage error in published abstract; MEDLINE/PubMed abstract corrected
(PMID = 19531969.001).
[ISSN]
1536-4828
[Journal-full-title]
Pancreas
[ISO-abbreviation]
Pancreas
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; EH28UP18IF / Isotretinoin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
87.
Tsutsumi K, Ohtsuka T, Oda Y, Sadakari Y, Mori Y, Aishima S, Takahata S, Nakamura M, Mizumoto K, Tanaka M:
A history of acute pancreatitis in intraductal papillary mucinous neoplasms of the pancreas is a potential predictive factor for malignant papillary subtype.
Pancreatology
; 2010;10(6):707-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A history of acute pancreatitis in intraductal papillary mucinous neoplasms of the
pancreas
is a potential predictive factor for malignant papillary subtype.
The diameter of the main
pancreatic
duct of the pancreatitis group was significantly larger than that of the nonpancreatitis group (p = 0.04).
[MeSH-major]
Adenocarcinoma
, Mucinous / pathology. Carcinoma,
Pancreatic
Ductal / pathology.
Pancreatic
Neoplasms / pathology. Pancreatitis /
diagnosis
Genetic Alliance.
consumer health - Pancreatitis
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatitis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2011 S. Karger AG, Basel.
(PMID = 21242711.001).
[ISSN]
1424-3911
[Journal-full-title]
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
[ISO-abbreviation]
Pancreatology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
88.
Adhikari RC, Tuladhar A, Shrestha S, Sharma SK:
Deep-seated thoracic and abdominal lesions: usefulness of ultrasound guided fine needle aspiration cytology, a 3 year experience.
Nepal Med Coll J
; 2010 Mar;12(1):20-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
These included liver (125 cases), lung (81 cases), abdominal and mediastinal lymph nodes (29 cases), ovary (14 cases), omentum (12 cases),
pancreas
(10 cases), kidney (10 cases), mediastinum (8 cases), gall bladder (8 cases) etc.
The aim of this study was to evaluate the overall utility of ultrasonographic guided FNAC in
the diagnosis
of abdominal and thoracic lesions.
In 264 cases (82.5%), FNAC was diagnostic with commonest
diagnosis
being malignant neoplasm (70.0%).
In liver, Metastatic
adenocarcinoma
is the commonest tumor, while in lung; the commonest lesion is non-small cell carcinoma.
[MeSH-major]
Neoplasms /
diagnosis
. Ultrasonography, Interventional
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20677604.001).
[Journal-full-title]
Nepal Medical College journal : NMCJ
[ISO-abbreviation]
Nepal Med Coll J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Nepal
89.
Newman EA, Simeone DM, Mulholland MW:
Adjuvant treatment strategies for pancreatic cancer.
J Gastrointest Surg
; 2006 Jun;10(6):916-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adjuvant treatment strategies for
pancreatic
cancer.
Pancreatic
cancer is a difficult and unsolved surgical problem.
It remains one of the top five causes of cancer-related deaths and has the lowest 5-year survival of any cancer, largely due to late
diagnosis
, low resection rates, and local recurrence.
Clinical trials examining the optimal timing and delivery of adjuvant therapies for
pancreatic
cancer have yielded controversial results.
Although most experts agree that the addition of chemotherapy has survival benefit in patients with resectable
pancreatic
cancer, there is no consensus regarding the optimal therapeutic agents, timing (neoadjuvant versus adjuvant), and the addition of radiation therapy to the treatment regimen.
Additionally, exciting progress has been made with novel chemotherapeutic combinations, and alternative treatment modalities including interferon-alpha, immunotherapy, and
pancreatic
cancer stem cells.
[MeSH-major]
Adenocarcinoma
/ surgery.
Pancreatic
Neoplasms / surgery. Pancreaticoduodenectomy
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gastrointest Endosc. 2000 Oct;52(4):578-82
[
11023593.001
]
[Cites]
Ann Surg Oncol. 2001 Mar;8(2):123-32
[
11258776.001
]
[Cites]
Hepatogastroenterology. 1997 Nov-Dec;44(18):1528-35
[
9427017.001
]
[Cites]
J Clin Oncol. 2005 Jul 10;23(20):4524-31
[
16002843.001
]
[Cites]
Int J Pancreatol. 1991 Nov-Dec;10(3-4):183-96
[
1787333.001
]
[Cites]
J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50
[
15585381.001
]
[Cites]
Mayo Clin Proc. 1992 Sep;67(9):839-45
[
1434927.001
]
[Cites]
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
[
15661684.001
]
[Cites]
Ann Intern Med. 1989 May 1;110(9):704-9
[
2930108.001
]
[Cites]
Ann Surg. 2003 Jan;237(1):74-85
[
12496533.001
]
[Cites]
Lancet. 2001 Nov 10;358(9293):1576-85
[
11716884.001
]
[Cites]
J Gastrointest Surg. 2003 Sep-Oct;7(6):766-72
[
13129554.001
]
[Cites]
Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3
[
7794076.001
]
[Cites]
Gastrointest Endosc. 2000 Sep;52(3):367-71
[
10968852.001
]
[Cites]
Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4
[
10615932.001
]
[Cites]
N Engl J Med. 1993 May 20;328(20):1433-7
[
8479461.001
]
[Cites]
Pancreas. 1993 Mar;8(2):146-50
[
8460088.001
]
[Cites]
J Clin Oncol. 2003 Sep 15;21(18):3402-8
[
12885837.001
]
[Cites]
J Gastrointest Surg. 2000 May-Jun;4(3):233-7; discussion 238-9
[
10769085.001
]
[Cites]
Cancer. 2002 Oct 15;95(8):1685-95
[
12365016.001
]
[Cites]
Am J Surg. 2003 May;185(5):476-80
[
12727570.001
]
[Cites]
Radiother Oncol. 1992 Jul;24(3):191-4
[
1357725.001
]
[Cites]
Clin Cancer Res. 2004 Apr 1;10(7):2386-92
[
15073115.001
]
[Cites]
Ann Surg. 1979 Feb;189(2):205-8
[
426553.001
]
[Cites]
Ann Surg. 1997 May;225(5):621-33; discussion 633-6
[
9193189.001
]
[Cites]
Cancer. 1995 Nov 1;76(9):1671-7
[
8635074.001
]
[Cites]
Cancer. 1998 Dec 1;83(11):2317-23
[
9840531.001
]
[Cites]
Gastrointest Endosc. 2001 Feb;53(2):182-8
[
11174289.001
]
[Cites]
Ann Oncol. 2004 Feb;15(2):224-9
[
14760113.001
]
[Cites]
Cancer Biol Ther. 2004 Nov;3(11):1081-9; discussion 1090-1
[
15467436.001
]
[Cites]
Surgery. 1999 Aug;126(2):178-83
[
10455881.001
]
[Cites]
Cancer. 2002 Aug 15;95(4 Suppl):908-11
[
12209670.001
]
[Cites]
Am J Gastroenterol. 1990 Apr;85(4):350-5
[
2183589.001
]
[Cites]
J Am Coll Surg. 1999 Jul;189(1):1-7
[
10401733.001
]
[Cites]
Nature. 2001 Nov 1;414(6859):105-11
[
11689955.001
]
[Cites]
Nat Rev Cancer. 2005 Jun;5(6):459-67
[
15905855.001
]
[Cites]
Eur J Cancer. 1993;29A(5):698-703
[
8471327.001
]
[Cites]
J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35
[
11309645.001
]
[Cites]
Cancer. 1988 Mar 15;61(6):1110-6
[
3342371.001
]
[Cites]
J Natl Cancer Inst. 1997 Mar 19;89(6):442-6
[
9091646.001
]
[Cites]
J Clin Oncol. 2002 Mar 15;20(6):1512-8
[
11896099.001
]
[Cites]
J Clin Oncol. 2001 Jan 1;19(1):145-56
[
11134207.001
]
[Cites]
J Clin Oncol. 1997 Jun;15(6):2403-13
[
9196156.001
]
[Cites]
Arch Surg. 1985 Aug;120(8):899-903
[
4015380.001
]
[Cites]
AJR Am J Roentgenol. 1999 Dec;173(6):1527-33
[
10584796.001
]
[Cites]
Hematol Oncol Clin North Am. 2002 Feb;16(1):159-97, viii
[
12063825.001
]
(PMID = 16769552.001).
[ISSN]
1091-255X
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
[Number-of-references]
53
90.
Lee SE, Jang JY, Yang SH, Kim SW:
Intraductal papillary mucinous carcinoma with atypical manifestations: report of two cases.
World J Gastroenterol
; 2007 Mar 14;13(10):1622-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Adenocarcinoma
, Mucinous /
diagnosis
. Carcinoma,
Pancreatic
Ductal /
diagnosis
. Carcinoma, Papillary /
diagnosis
.
Pancreatic
Neoplasms /
diagnosis
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hepatogastroenterology. 2000 Jul-Aug;47(34):1164-7
[
11020905.001
]
[Cites]
Pancreas. 2006 Mar;32(2):223-4
[
16552347.001
]
[Cites]
Surg Today. 2001;31(6):538-41
[
11428610.001
]
[Cites]
Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8
[
12911716.001
]
[Cites]
Eur J Surg Oncol. 2003 Oct;29(8):682-8
[
14511618.001
]
[Cites]
J Gastroenterol Hepatol. 2003 Nov;18(11):1323-4
[
14535994.001
]
[Cites]
Endoscopy. 2004 Feb;36(2):186-9
[
14765321.001
]
[Cites]
Ann Surg Oncol. 2004 Apr;11(4):393-8
[
15070599.001
]
[Cites]
Ann Surg. 2004 Mar;239(3):400-8
[
15075659.001
]
[Cites]
Pancreas. 2004 Apr;28(3):282-8
[
15084972.001
]
[Cites]
Am J Surg Pathol. 2004 Aug;28(8):977-87
[
15252303.001
]
[Cites]
Gastroenterology. 1986 Jan;90(1):202-5
[
2998918.001
]
[Cites]
J R Coll Surg Edinb. 1990 Feb;35(1):21-4
[
2342004.001
]
[Cites]
Cancer. 1990 Oct 1;66(7):1636-40
[
2208015.001
]
[Cites]
Gastroenterology. 1996 Jun;110(6):1909-18
[
8964418.001
]
[Cites]
Hum Pathol. 1997 Sep;28(9):1010-7
[
9308724.001
]
[Cites]
Pancreas. 1998 Jul;17(1):100-2
[
9667528.001
]
[Cites]
Hepatogastroenterology. 1998 Nov-Dec;45(24):2009-15
[
9951855.001
]
[Cites]
Pancreatology. 2005;5(4-5):470-4
[
15983445.001
]
[Cites]
Eur J Surg Oncol. 2001 Apr;27(3):239-43
[
11373099.001
]
(PMID = 17461460.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Other-IDs]
NLM/ PMC4146910
91.
Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM:
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Neoplasia
; 2008 Aug;10(8):782-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Progressive metaplastic and dysplastic changes in mouse
pancreas
induced by cyclooxygenase-2 overexpression.
We generated transgenic mice (BK5.COX-2) in which elevation of COX-2 and its effectors trigger a metaplasia-dysplasia sequence in exocrine
pancreas
.
By 6 to 8 months, strongly dysplastic features suggestive of
pancreatic
ductal
adenocarcinoma
emerge in the metaplastic ducts.
Alterations in biomarkers associated with human inflammatory and neoplastic
pancreatic
disease were detected using immunohistochemistry.
The abnormal
pancreatic
phenotype can be completely prevented by maintaining mice on a diet containing celecoxib, a well-characterized COX-2 inhibitor.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatitis
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CELECOXIB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neoplasia. 2007 Nov;9(11):979-86
[
18030366.001
]
[Cites]
Gastroenterology. 2007 Dec;133(6):1999-2009
[
18054571.001
]
[Cites]
Am J Clin Oncol. 2007 Oct;30(5):526-30
[
17921715.001
]
[Cites]
Carcinogenesis. 2000 Feb;21(2):139-46
[
10657949.001
]
[Cites]
Genes Dev. 2000 Sep 1;14(17):2123-33
[
10970876.001
]
[Cites]
Lancet. 2000 Dec 16;356(9247):2079-85
[
11145505.001
]
[Cites]
J Biol Chem. 2001 May 25;276(21):18563-9
[
11278747.001
]
[Cites]
Exp Biol Med (Maywood). 2001 Jul;226(7):692-700